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Tuberculosis is a major cause of increased disease burden and death among HIV 
infected HIV infected individuals in sub-Saharan Africa. In Europe vitamin D 
deficiency has been associated with increased risk of active tuberculosis. However, in 
subtropical Africa it has not been previously investigated. 
 
Aims 
The purpose of the study was to investigate association of vitamin D deficiency and 
tuberculosis in Cape Town; explore effects of smoking on vitamin D status; examine 
presence of seasonal variation of vitamin D levels and new tuberculosis case 
notifications. Determine the effects of vitamin D molecules, 25-
hydroxycholecalciferol (25(OH)D3) and 1, 25 dihydroxycholecalciferol (1,25 (OH)2D3) 
on HIV replication and M. tuberculosis growth and in addition investigate the 
influence of M. tuberculosis strain variation HIV replication. 
 
Methods 
25(OH)D3 levels were measured by liquid chromatography mass spectrometry / 
mass spectrometry in a cross-sectional study of HIV uninfected (n=251) and HIV 
infected (n=229) individuals recruited from Ubuntu clinic, Khayelitsha and GF Jooste 
hospital. HIV replication and M. tuberculosis growth was monitored by measurement 
of p24 protein and colony forming units respectively in infected pro-inflammatory 
(Mϕ-1) and anti-inflammatory (Mϕ-2) macrophages.  
 
Results 
Vitamin D deficiency (25(OH)D3 <50 nmol/L) was associated with susceptibility to 
active tuberculosis in HIV uninfected individuals (odds ratio = 5.2, 95% confidence 
interval: 2.8–9.7; p < 0.001) and HIV infected individuals (odds ratio = 5.6, 95% 
confidence interval: 2.7–11.6; p < 0.001) in comparison to latent tuberculosis 











There was no independent association between smoking and vitamin D status. The 
mean 25(OH)D3 levels varied with season with lowest levels in July to September 
and maximum levels reached in January to March inclusive (30.7 vs. 56.8 nmol/L, 
respectively; P < 0.001). The quarterly new tuberculosis case notifications for the city 
of Cape Town were higher from October to December and lower in April to June 
(5,080 vs. 4,222; P < 0.001). 
 
In Mϕ-1, 25(OH)D3 and 1,25(OH)2D3 inhibited HIV replication after 144 hrs (p<0.05 & 
p<0.001 respectively) while 1,25(OH)2D3 inhibited M. tuberculosis growth after 240 
hrs of mono-infection (p<0.05). During co-infection 25(OH)D3 and 1,25(OH)2D3 
restricted HIV replication after 72 hrs and M. tuberculosis growth after 168 hrs 
(p<0.05 in all cases). In Mϕ-2, only 25(OH)D3 inhibited HIV replication after 240 hrs 
of mono-infection (p<0.05) and vitamin D molecules had no significant effect on HIV 
replication and MTB growth during co-infection. M. tuberculosis strain variation had 
no significant effect on HIV replication in Mϕ-1 and Mϕ-2.  
 
Conclusion 
Vitamin D supplementation can be a possible safe way to enhance immunity against 
M. tuberculosis and HIV. There is need for a randomized clinical trial to explore the 























Table of Contents 
DECLARATION II 
ABSTRACT III 
LIST OF FIGURES VIII 
LIST OF TABLES X 
ACKNOWLEDGEMENTS XI 
ABBREVIATIONS XII 
CHAPTER 1: GENERAL INTRODUCTION 1 
1.1 Introduction 1 
1.1.1 HIV structure and molecular biology 2 
1.1.2 Mycobacterium tuberculosis biology 3 
1.1.3 Vitamin D physiology and metabolism 5 
1.2 Hypothesis 10 
1.3 Aims of Study 10 
1.4 Objectives 10 
1.5 Overview of thesis 11 
CHAPTER 2: MATERIALS AND METHODS 12 
2.1 Study site and participants 12 
2.1.1 Ethics approval 12 
2.1.2 Recruitment and study design 12 
2.1.3 Clinical data capturing 13 
2.1.4 Screening tests 13 
2.1.5 City of Cape Town tuberculosis notifications 13 
2.1.6 Measurement of the 25-hydroxylcholecalciferol (25(OH)D3) 13 
2.1.7 Peripheral blood mononuclear cells (PBMC) preparation, positive selection of CD14+ cells and 
generation of monocyte-derived macrophages (MDM). 15 
2.1.8 Flow cytometry analysis 16 
2.1.9 Preparation of M. tuberculosis stock 18 
2.1.10 Growth curves 19 
2.1.11 Preparation of the HIV-1 BAL 20 
2.1.12 Co-infection of MDM with HIV and M. tuberculosis strains 21 
2.1.13 HIV/TB co-infection in presence of vitamin D molecules 22 
2.1.14 Measurement of p24 in supernatants 23 
2.1.15 Statistical analysis 23 











CHAPTER 3: RECIPROCAL SEASONAL VARIATION IN VITAMIN D STATUS AND 
TUBERCULOSIS NOTIFICATIONS IN CAPE TOWN, SOUTH AFRICA. 27 
3.1 Literature review 27 
3.1.1 Vitamin D status 27 
3.1.2 Vitamin D deficiency 28 
3.1.3 Vitamin D and Tuberculosis 28 
3.1.4 Vitamin D and HIV 32 
3.2 Results 35 
3.2.1 Characteristics of study participants 35 
3.2.2 Other infections 37 
3.2.3 Categorizing vitamin D status of study participants 38 
3.2.4 Correlates of 25(OH)D3 Concentrations 42 
3.2.5 Relationship between participant 25(OH)D3 levels and season 43 
3.2.6 Correlation between serum 25(OH)D3 levels and CD4+ cells 45 
3.3 Discussion 45 
CHAPTER 4: EFFECT OF SMOKING ON VITAMIN D STATUS 52 
4.1 Literature review 52 
4.1.1 Effects of smoking on the immune system 52 
4.1.2 Effects of smoking on bone and vitamin D 53 
4.1.3 Vitamin D, smoking and respiratory disease 54 
4.2 Results 55 
4.2.1 Demographic and clinical characteristics of study participants 55 
4.2.2 Vitamin D status of study participants 58 
4.2.3 Analysis of risk factors of vitamin D status 60 
4.3 Discussion 63 
CHAPTER 5: IMMUNOPHENOTYPING OF MΦ-1 AND MΦ-2 67 
5.1 Literature review 67 
5.1.1 The mononuclear phagocyte system 67 
5.1.2 Roles for macrophages in immunity 68 
5.1.3 Macrophage polarization and activation 69 
5.1.4 In vitro generation of macrophages 72 
5.2 Results 75 
5.2.1 Morphological characteristics of Mϕ-1 and Mϕ-2 75 
5.2.2 Analysis of MDM by flow cytometry 76 
5.3 Discussion 81 
CHAPTER 6: MACROPHAGE PHENOTYPE DICTATES CELLULAR ABILITY TO CONTROL 
M. TUBERCULOSIS AND HIV-1 REPLICATION IN RESPONSE TO VITAMIN D 84 
6.1 Literature review 84 
6.1.1 Vitamin D and monocyte/macrophage biology 84 
6.1.2 Vitamin D signalling and HIV-1 long terminal repeat (LTR) 85 











6.2 Results 89 
6.2.1 The effect of vitamin D on HIV-1 replication 89 
6.2.2 The effect of vitamin D on HIV-1 replication during co-infection with M. tuberculosis. 91 
6.2.3 The effect of vitamin D on Uptake of M. tuberculosis 92 
6.2.4 The effect of vitamin D on the growth of M. tuberculosis. 93 
6.2.5 The effect of macrophage phenotype on M. tuberculosis growth 96 
6.3 Discussion 97 
CHAPTER 7: THE INFLUENCE OF MACROPHAGE PHENOTYPE ON THE DIFFERENTIAL 
GROWTH OF M. TUBERCULOSIS STRAINS AND HIV-1 REPLICATION DURING CO-
INFECTION 104 
7.1 Literature review 104 
7.1.1 Clinical outcomes associated with M. tuberculosis strain variation. 105 
7.1.2 Immunopathogenesis of HIV and M. tuberculosis co-infection 107 
7.2 Results 111 
7.2.1 Comparison of growth kinetics of M. tuberculosis strains 111 
7.2.2 The effects of M. tuberculosis strain on HIV replication 112 
7.2.3 The effect of HIV on M. tuberculosis strains growth. 116 
7.2 Discussion 123 
CHAPTER 8: GENERAL CONCLUSION 127 
8.1 Presentations and publications 129 
8.1.1 Publications 129 
8.1.2 Poster presentation 129 













List of Figures 
FIGURE 1.1. NEIGHBOR-JOINING PHYLOGENY OF M. TUBERCULOSIS COMPLEX GENOME SEQUENCES. ........... 5 
FIGURE 1.2 VITAMIN D METABOLISM. ............................................................................................... 6 
FIGURE 3.1 VITAMIN D AND THE MACROPHAGE ANTIMICROBIAL RESPONSE TO TB ................................. 33 
FIGURE 3.2 SERUM 25(OH)D3 CONCENTRATION STRATIFIED BY HIV AND TB STATUS. ........................... 39 
FIGURE 3.3 SEASONAL VARIATION IN MEAN SERUM 25(OH)D3 CONCENTRATION, ALL STUDY PARTICIPANTS.
 ........................................................................................................................................ 44 
FIGURE 3.4 NEW TB NOTIFICATIONS BY QUARTER, CITY OF CAPE TOWN, 2003 TO 2010. ....................... 44 
FIGURE 3.5 CORRELATION OF 25(OH)D3 LEVELS WITH CD4 AMONG THE HIV INFECTED PARTICIPANTS. .... 45 
FIGURE 3.6 SPECTRUM OF TUBERCULOSIS INFECTION WITH VITAMIN D ................................................. 49 
FIGURE 4.1 EFFECTS OF SMOKING IN LUNGS. .................................................................................... 53 
FIGURE 4.2 SERUM 25(OH)D3 BY STRATIFIED BY SMOKING STATUS. (A) DIVIDED INTO 3 GROUPS (B) 
DIVIDED INTO 2 GROUPS (EVER SMOKED COMPOSED OF CURRENT SMOKERS AND EX-SMOKERS). ....... 58 
FIGURE 5.1 EFFECTS OF CSFS ON DIFFERENTIATION OF MONOCYTES TO MACROPHAGES (A) MΦ-1 (B) MΦ-2
 ........................................................................................................................................ 76 
FIGURE 5.2. THE GATING STRATEGY: MACROPHAGES WERE IDENTIFIED BY STAINING FOR CD11B.  FIRST GATE 
WAS SET IN A FSC VS. SSC DOT PLOT (A) AND APPLIED TO A CD11B VS. SSC DOT PLOT (B) TO SET THE 
MACROPHAGE GATE AROUND THE CD11B POSITIVE CELLS (C). .................................................... 76 
FIGURE 5.3 FLOW CYTOMETRY DOT PLOTS OF MΦ-1 AND MΦ-2 FROM A REPRESENTATIVE DONOR. CELLS 
WERE STAINED WITH LABELLED MONOCLONAL ANTIBODIES (A) FSC VS. SSC (B) CD33 VS. TLR2 (C) 
CCR5 VS. HLADR (D) CD33 VS. CD209 (E) CD14 VS. TLR2 (F) CD16 VS. CD15 ....................... 77 
FIGURE 5.4 EXPRESSION OF CELL SURFACE RECEPTORS ON MΦ-1 AND MΦ-2. THE OPEN HISTOGRAMS 
REPRESENT CELLS STAINED WITH SPECIFIC ANTIBODY AND THE SOLID HISTOGRAMS REPRESENT NEGATIVE 
CONTROLS. ......................................................................................................................... 79 
FIGURE 5.5 QUANTITATIVE COMPARISON OF PHENOTYPIC CHARACTERISTICS OF MΦ-1 AND MΦ-2 ........... 80 
FIGURE 6.1 STRUCTURE OF THE HIV-1 5’-LTR OF HIV-1 SUBTYPE B  ................................................... 86 
FIGURE 6.2. THE EFFECT OF 1,25(OH)2D3 ON HIV-1 REPLICATION AFTER (A) 144 HRS AND (B) 240 HRS OF 
INFECTION.. ........................................................................................................................ 90 
FIGURE 6.3. EFFECT OF 25(OH)D3 AND 1,25(OH)2D3 ON HIV-1 REPLICATION 72 HRS AFTER COINFECTION 
WITH OR WITHOUT M. TUBERCULOSIS. (A) MΦ-1 AND (B) MΦ-2. ............................................. 92 
FIGURE 6.4. THE EFFECT OF VITAMIN D MOLECULES ON THE UPTAKE OF M. TUBERCULOSIS IN (A) MΦ-1 AND 
(B) MΦ-2 GROWN FOR 168 HRS IN EITHER THE PRESENCE OR ABSENCE OF HIV-1 INFECTION .. ....... 93 
FIGURE 6.5. GROWTH OF M. TUBERCULOSIS OVER 168 HRS IN THE PRESENCE OR ABSENCE OF VITAMIN D AND 
OR HIV-1 IN (A) MΦ-1 AND (B) MΦ-2.. ................................................................................ 94 
FIGURE 6.6. THE EFFECT OF VITMAIN D ON INTRACELLUAR M. TUBERCULOSIS (MTB) GROWTH AT  24 HRS (A-
B) AND 96 HRS (C-D) POST- M. TUBERCULOSIS INFECTION OF MΦ-1 (A,C) AND MΦ-2 (B,D) IN THE 
PRESENCE (HIV+MTB) OR ABSENCE (MTB) OF HIV-1 INFECTION 168 HRS PRE- M. TUBERCULOSIS 
INFECTION.. ........................................................................................................................ 95 
FIGURE 6.7. THE EFFECT OF VITAMIN D ON INTRACELLULAR M. TUBERCULOSIS (MTB) AFTER 168 HRS IN (A) 
MΦ-1 AND (B) MΦ-2 IN THE PRESENCE OR ABSENCE OF HIV-1 CO-INFECTION (HIV+MTB).. ......... 96 
FIGURE 7.1 GROWTH KINETICS OF M. TUBERCULOSIS STRAINS H37RV, LAM3 AND HN878 IN 
MIDDLEBROOK 7H9 BROTH SUPPLEMENTED WITH ADC IN TRIPLICATES.. ................................... 112 
FIGURE 7.2 THE EFFECT OF M. TUBERCULOSIS STRAIN VARIATION ON HIV-1 P24 LEVELS AT SPECIFIC TIME 
POINTS (A) 4 HRS, (B) 24 HRS, (C) 96 HRS AND (D) 168 HRS. .................................................. 113 
FIGURE 7.3 COMPARISON OF HIV REPLICATION IN MΦ-1 AND MΦ-2 AT SPECIFIC TIME POINTS (A) 4 HRS, (B) 
24 HRS, (C) 96 HRS AND (D) 168 HRS.. ................................................................................ 114 
FIGURE 7.4 EFFECT OF M. TUBERCULOSIS STRAINS ON HIV REPLICATION IN MΦ-1 AND MΦ-1 MACROPHAGES AT 
SPECIFIC TIME POINTS (A) 4 HRS, (B) 24 HRS, (C) 96 HRS AND (D) 168 HRS.. ............................. 115 











FIGURE 7.6 TWO-WAY ANOVA OF UPTAKE OF M. TUBERCULOSIS STRAINS (A) HIV UNINFECTED (B) HIV 
INFECTED.. ....................................................................................................................... 118 
FIGURE 7.7 VARIATION IN GROWTH OF THE M. TUBERCULOSIS STRAINS H37RV, LAM3 AND HN878 IN MΦ-
1 AND MΦ -2 AFTER (A) 4 HRS, (B) 24 HRS (C) 96HRS AND (D) 168HRS OF CULTURE, (N=5).. ..... 119 
FIGURE 7.8 THE GROWTH OF M. TUBERCULOSIS STRAINS IN MΦ-1 STRATIFIED BY HIV INFECTION STATUS 
AFTER (A) 24 HRS, (B) 96 HRS AND (C) 168 HRS. ................................................................... 121 
FIGURE 7.9 THE GROWTH OF M. TUBERCULOSIS STRAINS IN MΦ-2 STRATIFIED BY HIV INFECTION STATUS 
AFTER (A) 24 HRS, (B) 96 HRS AND (C) 168 HRS. ................................................................... 121 












































List of Tables 
TABLE 2.1 ANTIBODY LIST ............................................................................................................. 17 
TABLE 2.2 FLOW CYTOMETER SET UP............................................................................................... 18 
TABLE 2.3 MATERIALS AND REAGENTS USED IN METHODS DESCRIBED ABOVE ......................................... 24 
TABLE 3.1 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF HIV UN-INFECTED STUDY PARTICIPANTS. .... 36 
TABLE 3.2 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF HIV INFECTED STUDY PARTICIPANTS. .......... 37 
TABLE 3.3 NUMBER AND TYPE OF OPPORTUNISTIC INFECTIONS IN THE OI GROUP ................................... 38 
TABLE 3.4 SERUM 25(OH)D3 CONCENTRATIONS OF HIV UNINFECTED STUDY PARTICIPANTS ................... 40 
TABLE 3.5 SERUM 25(OH)D3 CONCENTRATIONS OF HIV INFECTED STUDY PARTICIPANTS ....................... 41 
TABLE 3.6 MEAN SERUM 25(OH)D3 OF HIV INFECTED AND UNINFECTED CLINICAL GROUPS .................... 42 
TABLE 3.7 CORRELATES OF VITAMIN D STATUS IN STUDY PARTICIPANTS: UNIVARIATE AND MULTIVARIATE 
ANALYSIS ............................................................................................................................ 43 
TABLE 4.1 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF STUDY PARTICIPANTS. .............................. 57 
TABLE 4.2 SERUM 25(OH)D3 CONCENTRATIONS OF STUDY PARTICIPANTS STRATIfiED BY SMOKING STATUS.
 ........................................................................................................................................ 59 
TABLE 4.3 POST HOC ANALYSIS OF VITAMIN D DEFICIENCY AND MEAN VITAMIN D LEVELS OF SMOKING 
GROUPS. ............................................................................................................................ 60 
TABLE 4.4 CORRELATES OF VITAMIN D STATUS: UNIVARIATE AND MULTIVARIATE ANALYSIS. ..................... 61 
TABLE 4.5 CORRELATES OF BMI: UNIVARIATE AND MULTIVARIATE ANALYSIS .......................................... 62 



































I wish to offer my sincere gratitude to my supervisor Professor Robert J Wilkinson for 
his assistance and support in the design and application process of the masters 
fellowship and the guidance and mentorship that he provided during the course of 
my studies. I am grateful to the guidance that I obtained from my co-supervisors Dr 
Adrian Martineau and Dr Katalin Wilkinson. I would like to acknowledge the 
assistance and laboratory guidance that I received from Dr Anna Coussens when 
carrying out the vitamin D in vitro experiments. I would like to thank Dr Maddy 
Nouserdergi for allowing me to use his laboratory for some of my experiments and 
his contribution in the design of the vitamin D experiments. 
 
I acknowledge Dr Tolu Oni, Dr Molebogeng Rangaka and Dr Suzaan Marais for their 
facilitation of the recruitment of patients. I want to thank my colleagues who all 
contributed in various ways during the course of my studies Kathryn Wood, Fadheela 
Patel, Nonzwakazi Bangani, Raylene Titus, Dr Kerryn Mathews, Ronnet Seldon, Dr 
David Lowe, and Rene Goliath. I also appreciate the contribution of the patients and 
the normal donors whom without this w rk would not have been possible. I am 
thankful to the Welcome trust for funding this work. 
 
I thank my family and friends for all their support and encouragement. I am very 
























1,25(OH)2D3   1α,25-dihydroxycholecalciferol or calcitriol 
25(OH)D3    25-hydroxycholecalciferol or calcidiol 
7H9   Middlebrook 7H9 liquid media 
ADC   albumin dextrose and catalase 
OADC   oleic acid albumin dextrose and catalase 
ANOVA   Analysis of variance 
APC   Antigen presenting cell 
ATB   Active tuberculosis 
BCG   Bacille Calmette-Guérin 
BMI   Body mass index 
BSA   Bovine serum albumin 
CD    Cluster of differentiation 
CCL2   Chemokine (C-C motif) ligand 2 
CCR5   C-C chemokine receptor 5 
CFU   colony forming units 
COPD   Chronic obstructive pulmonary disease    
CXCL   Chemokine (C-X-C motif) ligand 
CYP27B1  Cytochrome P450 27B1 
CYP27A1  Cytochrome P450 27A1 
DBP   Vitamin D-binding protein 
dosR   dormancy survival regulon 
EAST-6   6kDa early secretory antigenic target  
EHR   Enduring hypoxic response 
ELISA   Enzyme linked immunosorbent assay 
FACS   Fluorescence-activated cell sorting 
FCS   Fetal calf serum 
g   centrifugal force 
GM-CSF   Granulocyte/ Macrophage Colony Stimulating Factor 
HIV   Human immunodeficiency virus 











IGRA   Interferon gamma release assay 
IkB    Inhibitor-kB 
IKK    IkB kinase 
IL-6   Interleukin 6 
IQR   Inter quartile range 
kDa   kiloDalton 
LPS   lipopolysaccharide 
LTBI   latent tuberculosis 
LTR   long terminal repeat 
MACS   magnetic cell sorting system 
M-CSF   Macrophage-colony stimulating factor 
MDM   monocyte derived macrophages  
MDR   Multi drug resistant 
Mϕ   macrophage 
Mϕ-1   pro-inflammatory macrophages 
Mϕ-2   anti-inflammatory macrophages 
mg   milligram 
MHC   Major histocompatibility complex 
ml   milli liter 
mm   milli meter 
MOI   multiplicity of infection 
MTB   Mycobacterium tuberculosis 
ng   nanogram 
NOD   Nucleotide oligomerization domain receptors 
OD   optical density 
OI   diseases other than tuberculosis 
OR   odds ratio 
PBMC   peripheral blood mononuclear cell 
PBS   phosphate buffered saline 
PE/PPE group of gene family with the presence of N-terminal 
ProGlu/ProProGlu motifs 











PHA   phytoheamagglutinin 
PI3K   Phosphatidylinositol 3-kinase 
PPD   Purified protein derivative 
PTH   Parathyroid hormone 
RD   region of difference 
REC   Research ethics committee 
ROS   reactive oxygen species 
RNA   Ribonucleic acid 
RNI   reactive nitrogen intermediates 
rpm   rotations per minute 
SSC   side scatter 
SD   standard deviation 
T-cell   T lymphocytes 
TB   tuberculosis 
TLR   Toll like receptor 
Th1   Type 1 helper T cell 
Th2   Type 2 helper T cell 
TNF   Tumor necrosis factor 
TST   Tuberculin skin test 
UPLCMS/MS Ultrape fomance liquid chromatography mass 
spectrophotometry/ mass spectrophotometry 
UVB   ultraviolet beta radiation 
UVR   ultraviolet radiation 
UV   ultraviolet 
VDRE   Vitamin D response element 
VDR   Vitamin D receptor 
WHO   World Health Organization 
XDR   Extensively drug resistance 













Chapter 1: General Introduction 
 
1.1 Introduction 
Tuberculosis (TB) is a curable disease with the highest worldwide mortality after 
malaria. It kills one person every second which translate to approximately 4700 
people everyday, one in four of these deaths occur in Human Immunodeficiency 
Virus (HIV) infected persons according to the latest World Health Organisation 
(WHO) statistics (WHO, 2011). Africa has the highest burden of TB/HIV co-infection 
with 82% of the world’s cases.  
According to WHO statistics, (2011) South Africa is one of the top five countries with 
the highest number of incident TB cases; 490 000 (0.4–0.59 million) (WHO, 2011). 
The average incidence of tuberculosis in South Africa for 2010 was 981 cases/100 
000 and in informal settlements such as Khayelitsha Township where 70% of adults 
presenting with TB are co-infected with HIV is 1600 cases/ 100 000 (WHO, 2011, 
Garone et al., 2011). Consequently the combined burden and effect of TB and 
HIV/AIDS is immense particularly in Cape Town informal settlements, which is 
aggravated by increased rates of M. tuberculosis re-infection and multidrug resistant 
tuberculosis in HIV infected persons (Cox et al., 2010, Gupta et al., 2012). This 
demands more research into understanding of the interaction between M. 
tuberculosis and host in order to find better methods for the prevention, control and 
treatment of M. tuberculosis infection.  
During co-infection it has been observed that HIV-1 predisposes individuals to 
activation of latent tuberculosis and progression of disease on exposure whereas M. 
tuberculosis increases progression of HIV infection towards development of AIDS. 
The major causes of reactivation of M. tuberculosis are not yet fully understood, low 
CD4 count, immunosuppression due to: AIDS, corticosteroid therapy, anti-TNF-α 
therapy and rare genetic defects in IL-12 and IFN-γ have been shown to result in 
increased risk of active tuberculosis but they do not contribute much to the overall 
global burden (Corbett et al., 2003, Leandro et al., 2009, Keane et al., 2001). There is 











TB in HIV infected patients. Drug resistant TB is more common in people living with 
HIV/AIDS (Gandhi et al., 2010) and the increased incidence of TB in HIV infected 
individuals has the effect of increasing the tuberculosis burden and transmission in 
the community. In recent years there are increasing reports on the importance of 
vitamin D in enhancing immunity against M. tuberculosis infection and improved 
outcome in HIV infected individuals (Khoo et al., 2012). 
 
1.1.1 HIV structure and molecular biology 
HIV is a double stranded ribonucleic nucleic acid (RNA) retrovirus composed of a 
glycoprotein spiked membrane envelope generated from the host cell. The viral 
envelope is composed of host proteins and viral proteins gp120 and gp41, which are 
used for entry into target cells by binding to CD4 receptor in conjunction with the co-
receptors C-C chemokine receptor 5 (CCR5) or chemokine (C-X-C) receptor 4 
(CXCR4). On entry the nucleocapsid is dismantled and viral ribonucleic acid (RNA) is 
transcribed into complementary deoxyribonucleic acid (DNA) by the reverse 
transcriptase that is integrated into host DNA by the integrase enzyme (Krogstad, 
2003).  
 
The virus can remain in host cell latently and activation of the host cell stimulates 
viral DNA transcription followed by generation of viral proteins. HIV genome is 
composed of 9 kilobase pairs carrying 9 genes gag, polymerase (pol), envelope 
protein (env), viral infectivity factor (vif), viral protein U (vpu), transcriptional 
activator (tat), viral protein R (vpr), negative effector (nef) and regulator of viral gene 
expression (rev) genes that are flanked by the long terminal repeats on the 5’ and 3’ 














1.1.2 Mycobacterium tuberculosis biology 
Infection with Mycobacterium tuberculosis occurs through the respiratory tract and 
inhalation of 1-5 bacilli can result in infection. The innate immune cells such as 
epithelial cells, alveolar macrophages and neutrophils are involved in early control of 
M. tuberculosis (Rivas-Santiago et al., 2008). Detection of inhaled M. tuberculosis by 
alveolar macrophage’s complement receptor 3, mannose receptors, scavenger 
receptors, nucleotide oligomerization domain like (NOD-like) receptors and Toll like 
receptors (TLR) stimulates its phagocytosis and secretion of pro-inflammatory 
cytokines; tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), IL-1β, interferon 
gamma (IFN-γ) and chemokines: chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL7, 
Chemokine (C-X-C motif) ligand 2 (CXCL2) and CXCL10 (Ferrero et al., 2003). Fusion 
of the M. tuberculosis phagosome with lysosomes results in its destruction by 
reactive oxygen species (ROS), reactive nitrogen intermediates (RNI) and 
antimicrobial peptides (Sundaramurthy and Pieters, 2007). However in most cases 
M. tuberculosis inhibits fusion of its phagosome with lysosomes (Hmama et al., 
2004). This allows the bacilli to replicate inside the macrophages and be transported 
to other tissues. 
 
The local inflammatory response generated by the macrophages and neutrophils 
results in the recruitment of T cells to the site of infection which walls off the 
infection foci resulting in granuloma formation (Houben et al., 2006). Granulomas 
are composed of the bacilli in a caseous phase at the centre surrounded by layers of 
macrophages, epithelial cells and T cells. M. tuberculosis goes into latency a dynamic 
state where the bacilli activate the dormancy survival regulator (DosR) regulated and 
enduring hypoxic response (EHR) genes. It replicates at a very slow rate and is kept 
at bay by the macrophages and T cells that are constantly mounting an immune 
response against it and the immune cells in the granuloma are constantly being 
renewed (Barry et al., 2009).The infection can remain controlled (latent) for many 
years or it can be activated into active infection by immunodeficiency caused by 












 1.1.2.1 Mycobacterium tuberculosis evolution and genetic variation 
Mycobacterium tuberculosis belongs to the genus Mycobacteria, which is composed 
of many strains and most of which are non-pathogenic. M. tuberculosis is thought to 
have originated from Africa and then spread to the rest of the world (Gagneux and 
Small, 2007). M. tuberculosis strains have a high degree of evolutionary conservancy 
with similar DNA sequences and identical 16s RNA gene sequences with the other 
strains in the Mycobacterium tuberculosis complex (Brosch et al., 2002).   
 
The M. tuberculosis specific deletion 1 (TbD 1) is used to classify M. tuberculosis into 
“ancient” and “modern” strains, where the “modern” strains lack the TbD1 (Brosch 
et al., 2002). Various molecular techniques are used to study the M. tuberculosis 
lineages and strains these include: large sequence polymorphism (LSP), single 
nucleotide polymorphism (SNP), restriction fragment length polymorphism of the 
IS6110, spoligotyping to identify unique spacers with clustered regulatory short 
palindromic repeats (CRISPR) or direct repeat region (DR) and the identification of 
variable number of tandem repeats -mycobacterial interspersed repetitive units 
(MIRU-VNTR) (Mathema et al., 2006). Based on the LSP molecular method M. 
tuberculosis strains are divided into six phylogeographical lineages (Figure 1.1) 
(Gagneux and Small, 2007). The genetic variability of clinical strains of M. 
tuberculosis can result in phenotypic differences like transmissibility, virulence and 
pathogenicity that can have an impact on the clinical outcome of disease (Nicol and 













Figure 1.1. Neighbor-joining phylogeny of M. tuberculosis complex genome 
sequences (Comas et al., 2010). 
 
1.1.3 Vitamin D physiology and metabolism 
Vitamin D has important biological and physiological functions in the body. There are 
2 main types: cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2)  
(Figure 1.2). Vitamin D3 is obtained by use of ultraviolet B radiation (UVB) 
photosynthesis in the skin and through ingestion from the diet. Exposure to UVB in 
sunlight with wavelength 290-315 nm results in synthesis of vitamin D3 from 7-
dehydrocholesterol (7-DHC) in the epidermis (Holick, 2007).  
 
The skin is able to synthesize up to 3 000 IU of vitamin D3 when exposed to UVB for 
5-10 minutes and it is self-limiting as the same UV starts to break it down when in 
excess (Holick, 2007). Continual exposure to ultraviolet radiation (UVR) results in the 
pre-vitamin D3 intermediates being converted to non-toxic lumisterol and 
tachysterol, which can be reversibly converted back to pre-vitamin D3 when 












Figure 1.2 Vitamin D metabolism (Holick, 2007). 
 
Dietary sources of vitamin D2 include yeasts, fungi and mushrooms, whereas vitamin 
D3 comes from cod liver oil, oily fish, eggs, salmon, and mackerel.  Vitamin D3 can be 
made synthetically from lanolin extracted from sheep wool fat through purification 
and extraction (Holick, 2007). The dietary sources of vitamin D are quite expensive. 
Although sunlight remains the cheapest source, it is not fully utilised because of 
changes in lifestyles. Fortification of foods and taking supplements are the possible 












Factors which affect vitamin D synthesis from sunlight are latitude, skin 
pigmentation, amount of clothing, time of day, season, diet, age, obesity, 
malabsorption, sunscreen use, liver and kidney disease. Melanin absorbs UVB in 
sunlight needed for vitamin D synthesis in the epidermis and in black Africans 
melanin has been associated with decreased vitamin D synthesis (Clemens et al., 
1982). 
 
Dietary vitamin D3 or D2 is absorbed in the small intestines and is transported into 
circulation bound to vitamin D binding proteins and albumin. In the liver it is 25-
hydroxylated to 25 hydroxycholecalciferol (25(OH)D3) by the microsomal and 
mitochondrial 25 hydroxylase enzymes such as CYP27A1 and CYP2R1.The 25(OH)D3 
is transported to kidneys where it is hydroxylated to 1,25 dihydroxycholecalciferol 
(1,25(OH)2D3) which is the active hormone (Holick, 2007). 1,25(OH)2D3 synthesis is 
not only limited to kidneys, paracrine synthesis occurs in many extra-renal tissues 
which express CYP27B1: immune cells, brain tissue, osteoblasts, testis, pancreas, 
eyes and colon tissues (Hewison et al., 2007). 
 
Vitamin D actions are mediated via the vitamin D receptor (VDR) and through non-
genomic and genomic signalling. In non-genomic signalling 1,25(OH)2D3 binds to the 
membrane VDR which activates rapid signalling transduction pathways that induce 
intracellular physiological processes such as secretion of insulin, absorption of 
calcium, exocytosis and opening of voltage gated calcium, chloride channels and 
production of ROS (Norman et al., 2004). The non-genomic effects take seconds to 
hours to occur whereas as those for genomic signalling take hours to days for their 
effects to manifest. Genomic signalling involves the binding of 1,25(OH)2D3  to 
nuclear VDR which heterodimerises with retinoid X receptors resulting inactivation 
or suppression of target genes in the presence of co activators or co-repressor 
molecules (Rachez and Freedman, 2000).  
 
The main classic functions of kidney produced 1,25(OH)2D3 are bone growth and 
mineral metabolism (Figure 1.2). 1,25(OH)2D3 synthesis increases the adsorption of 











Vitamin D deficiency causes inadequate calcification of bones, resulting in rickets, 
osteoporosis and fractures (Holick, 2007). Extra renally synthesized 1,25(OH)2D3 has 
autocrine, paracrine and intracrine functions in different tissues and cells. It controls 
many genes, some of which are involved in angiogenesis, apoptosis, cell proliferation 
and differentiation. 1,25(OH)2D3 has been implicated as important for a number of 
immunomodulatory activities on innate and adaptive immune system, such as 
antimicrobial activities against infectious diseases like tuberculosis and influenza. In 
non-communicable diseases, 1,25(OH)2D3 has been reported to mediate activities 
against cancer, cardiovascular disease, autoimmune disorders, hypertension, and 
diabetes mellitus (Heaney, 2008).  
 
In the pre-antibiotic era vitamin D was used for the treatment of tuberculosis 
through sunbathing in sanatoriums, use of UV light lamps and consumption of cod 
liver oil. There is a high prevalence of vitamin D deficiency in different populations 
worldwide. A large amount of literature points towards a role of vitamin D in the 
control of HIV and drug sensitive and resistant tuberculosis infection (Martineau et 
al., 2007a, Mehta et al., 2011, Rathored et al., 2012), through in vivo, ex vivo and in 
vitro studies that demonstrated the immunomodulatory effects of vitamin D 
(Martineau et al., 2007c, Coussens et al., 2012, Fabri et al., 2011, Campbell and 
Spector, 2012). Therefore vitamin D can possibly be used as adjunctive 
immunotherapy against M. tuberculosis. Vitamin D deficiency is common among HIV 
infected individuals and it has been associated with increased disease progression 
(Mehta et al., 2011).  
 
However, there have been no studies to evaluate prevalence of vitamin D deficiency 
among tuberculosis and HIV infected persons in Cape Town, South Africa. Cape Town 
townships have some of the highest prevalence and incidence of tuberculosis due to 
biological, social and economic problems. The need to evaluate the prevalence of 
vitamin D deficiency in these high burden settings is great considering the possible 












The high prevalence of tuberculosis in Cape Town might potentially be related to 
vitamin D deficiency because Pettifor et al demonstrated that in vitro synthesis of 
vitamin D3 from 7-dehydrocholesterol was low in winter, it was one third of that in 
Johannesburg (Pettifor et al., 1996).  
 
Furthermore use of nucleoside reverse transcriptase and protease inhibitors of HIV 
have been shown to have adverse effects on vitamin D metabolism as well as 
rifampicin and isoniazid (Cozzolino et al., 2003, Bout-Van Den Beukel et al., 2008, 
Brodie et al., 1982). Hence all these factors support the need for determination of 
vitamin D levels in this population. Previously smoking has been associated with 
vitamin D deficiency and Cape Town has the highest number of smokers in South 
Africa (Brot et al., 1999, Chopra M et al., 2007). Therefore investigation of the effect 
of smoking on the vitamin D levels of the study participants was also carried out. 
 
Vitamin D can be used for targeted or mass supplementation as in vivo studies have 
shown it to be safe in HIV infected and un-infected individuals with latent and active 
tuberculosis (Arpadi et al., 2009, Martineau et al., 2009b). However there are 
conflicting reports on the effect of vitamin D on HIV replication. In light of in vitro 
studies which report increased HIV replication by vitamin D there is need to 
investigate the safety and effectiveness of vitamin D supplementation in HIV 
infected individuals. Therefore the study investigated the effect of vitamin D 
molecules 25(OH)D3 and 1,25(OH)2D3 on HIV replication in macrophages.  
 
Macrophages are the major target of M. tuberculosis infection as well as being 
reservoirs of HIV infection. In vivo macrophages occur as a spectrum of activation 
phenotypes depending on their microenvironment in the body. Therefore it is 
necessary to carry out the experiments in the two extremes of macrophage 
activation pro-inflammatory (Mϕ-1) and anti-inflammatory (Mϕ-2) macrophages 
(Verreck et al., 2004). Moreover in light of recent reports of differential immune 
responses as a result of genetic variation of M. tuberculosis strains in peripheral 
blood mononuclear cells (Ranjbar et al., 2009a), I sought to further investigate the 












1. Vitamin D deficiency is associated with tuberculosis in Cape Town, South 
Africa. 
2. Vitamin D deficiency is associated with smoking. 
3. Vitamin D does not enhance HIV replication. 
4. HIV replication is differentially influenced by M. tuberculosis strain variation. 
 
1.3 Aims of Study 
1. The primary goal of the thesis was to determine the prevalence of vitamin D 
deficiency in HIV infected and uninfected patients with tuberculosis in Cape 
Town, South Africa.  
2. To investigate the relationship between seasonal variation of vitamin D levels 
of study participants and new tuberculosis case notifications of the city of Cape 
Town from 2003 to 2010.   
3. To investigate the influence of vitamin D molecules and M. tuberculosis strain 
variation on HIV replication and M. tuberculosis growth. 
 
1.4 Objectives 
1. To determine total 25 hydroxycholecalciferol levels in patients with M. 
tuberculosis and appropriate controls. 
2. To examine the 25(OH)D3 levels of smokers, ex-smokers and non-smokers. 
3. To investigate the effect of 25(OH)D3 and 1,25(OH)2D3 on HIV replication in 
GM-CSF macrophages (Mϕ-1) and M-CSF macrophages (Mϕ-2). 
4. To establish the effect of 25(OH)D3 and 1,25(OH)2D3 on M. tuberculosis 
growth in Mϕ-1 and Mϕ-2. 
5. To investigate the effect of M. tuberculosis strains H37Rv, LAM3 and HN878 
on HIV replication in Mϕ-1 and Mϕ-2. 













1.5 Overview of thesis 
Chapter 1 is a general introduction to the thesis. 
Chapter 2 describes the materials and methods that were used in the investigations.  
Chapter 3 describes the investigation of the association of vitamin D deficiency and 
Tuberculosis in Cape Town South Africa. 
Chapter 4 examines the effect of smoking on vitamin D levels. 
Chapter 5 describes the immunophenotype of the Mϕ-1 and Mϕ-2 used in the HIV 
and M. tuberculosis co-infection model. 
Chapter 6 describes the in vitro effects of vitamin D molecules on HIV replication and 
M. tuberculosis growth in Mϕ-1 and Mϕ-2. 
Chapter 7 describes the reciprocal effect of M. tuberculosis strains and HIV on each 
other’s growth during co-infection in Mϕ-1 and Mϕ-2. 











Chapter 2: Materials and Methods 
 
2.1 Study site and participants 
2.1.1 Ethics approval 
Ethical approval for the studies was obtained from the University of Cape Town 
Ethics committee: 
1. Cross sectional study for vitamin D and tuberculosis in Cape Town REC REF 
030/2010. 
2. Recruitment and collection of blood from healthy normal donors for in vitro 
studies REC REF 261/2008. 
 
2.1.2 Recruitment and study design 
The study design used for the Vitamin D and tuberculosis study was cross sectional. 
Participants were recruited from the Ubuntu clinic at Khayelitsha site B and the GF 
Jooste hospital in Mannenberg, Cape Town, between April 2005 and January 2010. 
The study recruited 480 participants that were composed of 208 males and 272 
females. The inclusion criterion included HIV infected and un-infected adults over 
the age of 18 years and met the clinical criteria as detailed below. Patients were 
recruited before initiation of either anti mycobacterial or highly active antiretroviral 
therapy. The nature of the study procedures, potential risks, benefits of the study, 
maintenance of confidentiality and voluntary nature of participation was explained 
to all the study participants before written informed consent was obtained. The 
individuals who met the full clinical criteria for their final study group were included 














2.1.3 Clinical data capturing  
The participants were screened for common symptoms of tuberculosis such as 
cough, weight loss, fever, loss of appetite and night sweats. Clinical and demographic 
data which was captured included HIV status, age, history of TB, BCG scar, CD4 cell 
count, gender, body mass index (BMI), employment status, smoking status, level of 
education and presence of any other infection or disease other than M. tuberculosis.  
 
2.1.4 Screening tests 
Blood samples were collected into heparin anti-coagulated and plain tubes from the 
study participants by venepuncture. HIV was diagnosed at the clinic using the 
Determine HIV 1/2 test (Abbott) and the confirmatory enzyme linked 
immunosorbent assay (ELISA) was performed at the reference National Health 
Laboratory Service (NHLS). Sputum samples were collected and sent to the NHLS 
where M. tuberculosis infection was diagnosed by smear microscopy or culture in 
the mycobacterial growth indicator tube (MGIT) system. Latent tuberculosis was 
diagnosed in individuals with no clinical symptoms of tuberculosis and negative 
sputum smear and culture for M. tuberculosis by a positive tuberculin test (TST) and 
in-house interferon gamma release assay (IGRA) (Oni et al., 2012). 
 
2.1.5 City of Cape Town tuberculosis notifications 
The new tuberculosis case notifications for the City of Cape Town for the period 
2003 to 2010 inclusive were obtained from the City Department of Health database.  
 
2.1.6 Measurement of the 25-hydroxylcholecalciferol (25(OH)D3) 
The 25-hydroxylcholecalciferol quantification was performed at Homerton Hospital 
laboratory, which is enrolled in the Charing Cross External Quality Control Schemes 












25 hydroxycholecalciferol was measured using the Waters ACQUITY UPLC XEVO 
Tandem quadrupole mass spectrometer (TQ MS) (Waters corp Milford MA), which 
uses the Ultraperfomance liquid chromatography mass spectrophotometry/mass 
spectrophotometry (UPLCMS/MS) method. The manufacturers instructions were 
followed during the analysis. The Waters UPLC system consisted of a binary pump, 
binary solvent manager, auto sampler manager, column heater, Mass Lynx & 
Quanlynx software, vortex mixer Millipore 1L quick fit vacuum filter system, Varian 
Captiva 96 well 0.2 μm filter plate, Varian Captiva 96 well, 1mL collection plate, 
Varian vacuum manifold and pump for Captiva filter and photodiode array detector 
with a tandem quadrupole mass spectrometer equipped with an electrospray 
ionisation (ESI) source (MS/MS detector).  
 
150 μl of calibrator, quality control samples and study specimens were added into a 
multiwell plate. 20 μl of internal standard containing 25(OH)D3 and 25(OH)D2 
labelled with hexa-deuterated hydrogen (Synthetica) was added to each sample to 
correct for analytical loss of vitamin D molecules. The proteins in the samples were 
extracted by mixing with 150 μl 0.2M zinc sulphate (Sigma Aldrich) and 300 μl 80% 
methanol (Sigma Aldrich) and vortex mixing for 2 minutes. Vitamin D molecules were 
extracted by addition of 750 μl of hexane (Sigma Aldrich) followed by mixing and 
centrifugation for 5 minutes at 1500 relative centrifugal force (g). The layer of 
hexane was aspirated and dried by evaporation in a new microtitre plate.  
 
The residue was re-dissolved in 200 μl of 80% methanol buffer and loaded into the 
Acquity UPLC where the analytes were separated in an ultra pressure liquid 
chromatography column. The eluate was loaded onto the LCMS/MS where it was 
ionised with ESI and ionised molecules produced were separated according to their 
mass charge ratio (m/z) in the first quadrupole. Entry into the collision cell resulted 
in collision-induced dissociation of the 25(OH)D3 molecules facilitated by argon and 
collision energy to produce characteristic 25(OH)D3 daughter ions that were 
detected in the third quadrupole. The third quadrupole allows ions with a specific 











The 25(OH)D3 daughter ions were expressed as a ratio of the internal standard 
25(OH)D3 or 25(OH)D2 which was directly proportional to the concentration of the 
25(OH)D3 in the sample. 
 
2.1.7 Peripheral blood mononuclear cells (PBMC) preparation, positive selection of 
CD14+ cells and generation of monocyte-derived macrophages (MDM). 
A volume of 150 ml whole blood was collected from normal healthy donors in 
heparinised (Biochrome) 50ml syringes after obtaining written informed consent. 
The blood was diluted 1:3 with phosphate buffered saline without calcium (Sigma 
Aldrich) and overlayed on a density gradient of lymphoprep (Axis-Shield) for 
centrifugation to extract peripheral blood mononuclear cells. Monocytes were 
extracted from PBMCs by positive selection using CD14 magnetic cell sorting (MACS) 
system (Miltenyi biotec) according to the manufacturer’s instructions. This involved 
mixing the PBMC with magnetic microbeads coated with anti-CD14 (Miltenyi biotec) 
at a ratio of 1:5 (beads: cells) and incubation at 4°C for 15 minutes. The cells were 
washed twice to remove unbound beads and loaded into LS MACS column (Miltenyi 
biotec) that was placed in a MidiMACS separator magnetic field (Miltenyi biotec). 
CD14 positive cells (+) were retained in the column while the unlabelled cells passed 
through the column and were collected in tubes. The retained CD14+ monocytes 
where eluted into new tub s after rinsing of the column with MACS buffer.      
 
The CD14+ monocytes where differentiated and matured into pro-inflammatory GM-
CSF  (Mϕ-1) and anti-inflammatory M-CSF macrophages (Mϕ-2) as described in 
(Verreck et al., 2004). The monocytes were suspended in RPMI 1640 (Invitrogen) 
containing 10% heat inactivated autologous serum and 5 ng/ml of GM-CSF (Miltenyi 
biotech) for pro-inflammatory MDM or 20 ng/ml M-CSF (Miltenyi biotec) for anti-
inflammatory MDM. The cells were plated into 6-well microtitre plates (Corning) at a 
concentration of 1 X 106 cells/ml and incubated at 37°C in 5% carbon dioxide for 6 
days. On day 6 adherent MDM were gently removed using 0.25% Trypsin-EDTA 












2.1.8 Flow cytometry analysis 
Immunophenotyping of the Mϕ-1 and Mϕ-2 was performed using the 4 colour FACS 
Calibur (Becton Dickinson).  Mϕ-1 and Mϕ-2 surface receptors were identified by use 
of flurochrome labelled monoclonal antibodies. 200 μl of the cell suspension 
containing 2 x 105 MDM in phosphate buffered saline (PBS) containing 5% Foetal calf 
serum (FCS) (5% FCS/PBS) were plated per well into 96 well round bottom microtitre 
plates (Corning). The microtitre plate was centrifuged at 400g for 5 min and the 
supernatant was discarded. 50 μl of 5% FCS/ PBS containing optimal volume of each 
appropriate antibody was added to the cell pellets and incubated for 15 minutes at 
4°C in the dark (Table 1). Thereafter the cells were washed three times with 5% 
FCS/PBS to remove unbound antibody and then fixed for 20 minutes at 4°C with 100 
μl of cytofix buffer (BD Pharmingen). Excess cytofix buffer was washed from the cells 
with 200 μl of 5% FCS/PBS and finally the cells were suspended in 200 μl 5% FCS/PBS 
that was transferred to 5 ml FACS tubes (BD Pharmingen) for acquisition on the flow 
cytometer. Data analysis was performed using Flowjo version 9.5.3 (Tree star). 
 
2.1.8.1 Determination of optimal antibody concentration  
The optimal antibody concentration required for each antibody was titrated in order 
to determine the antibody volume needed for maximal staining of the monocyte 
derived macrophages with minimum background staining under the conditions of 
the experiment. Serial titrations of each antibody were used to stain the MDM as 
described in section 2.1.7.1. The samples were analysed by flow cytometry to 
determine the concentration at which the sample is near, but not above, the 

















Table 2.1 Antibody List 
 
Instrument : BD FACS CALIBUR BD Pharmingen/557742/M5E2 
Antibody Flourochrome Optimal 
Volume  
Vendor/Cat number/clone 
CD14  PE-CY7  5ul BD Pharmingen /557742/M5E2 
CD1a PE 5ul BD Pharmingen /333167/SK9 
CD282 (TLR2) ALEXA 488  10ul BD Pharmingen /558318/11G7 
CCR5 PE CY7 5ul BD Pharmingen /557752/207/CCR5 
CD4 PE 5ul BD Pharmingen /345769/SK3 
CD15 FITC 5ul BD Pharmingen /332778/MMA 
CD16 PE 5ul BD Pharmingen /555407/3G8 
CD209 FITC  5ul BD Pharmingen /551264/DCN46 
CD11b PE 5ul BD Pharmingen /333142/D12 
HLA-DR FITC 5ul BD Pharmingen /347400/L243 
CD33 PE-Cy7 5ul BD Pharmingen /333952/P67.6 
IgG1 isotype control  ALEXA488 5ul BD Pharmingen/ 557702 
IgG2a isotype control PE-CY7 5ul BD Pharmingen/ 557907 
IgG1 isotype control  PE 5ul BD Pharmingen/ 555749 
IgG2b isotype control FITC 5ul BD Pharmingen/ 555742 
 
2.1.8.2 Calibration of the flow cytometer 
The flow cytometer instrument settings, sensitivity and fluorescent compensation 
was optimised and monitored using the BD CALIBRITE beads and the FACSComp 
version 5.2.1 software before acquisition of samples according to the manufacturers 
instructions. Briefly it involved the analysis of FITC, PE, PERCP, APC and unlabelled 
beads. These adjusted the photomultiplier tube (PMT) voltages, compensation and 













Table 2.2 Flow cytometer set up 
Instrument  BD FACS CALIBUR 
Laser lines 488nm Blue laser 635nm 
Red laser  
Emission filters 530/30 
 





PE PE-CY7 682/33 APC 
 
2.1.8.3 MDM controls 
Mϕ-1 and Mϕ-2 single stained with TLR-2 Alexa flour 488, CD11b PE, CD33-CY7, and 
CD4-APC and were used for compensation and analysis of the MDM. The unstained 
MDM were used to optimise the resolution of the MDM and evaluate 
autofluorescence and confirm the region or channel in which the unstained 
monocyte derived macrophages were placed. Isotype matched controls were used 
for the evaluation of non-specific staining and to set the negative and positive 
analysis regions of the cell populations using quadrant markers.  
 
2.1.8.4 Acquisition of data 
The BD cell quest ™ Pro software version 5.2.1 was used for creation of the 
acquisition template with the scatter plots forward scatter (FSC) vs. side scatter 
(SSC), FL1 vs. FL2, FL2 vs. FL3 and FL3 vs. FL4. The MDM were located using FSC and 
SSC and gated accordingly. The gating strategies used to analyse the subsets of the 
MDM are shown in the results section of chapter 5.2.2.1. 
 
2.1.9 Preparation of M. tuberculosis stock 
The following frozen glycerol stocks of M. tuberculosis strains were used: H37Rv, 
LAM3 and HN878 and the stock of each strain was prepared by adding 100 μl of each 
M. tuberculosis strain into 10 ml of Middlebrook 7H9 broth (BD Pharmingen) 
supplemented with 0.2% glycerol, 10% albumin dextrose and catalase (ADC) (BD 











Thereafter 1ml of the culture was subculture in 100 ml Middlebrook 7H9 broth 
supplemented with 0.2% glycerol and 10% ADC. After 10 days, single cell stock of 
each specific M. tuberculosis strain was prepared through first sedimenting the M. 
tuberculosis cell suspension by centrifugation for 5 minutes at 2500 revolutions per 
minute (rpm) and discarding the supernatant. The bacterial cells were separated into 
single cells by shaking vigorously with 3 mm glass beads (Sigma-Aldrich) followed by 
mixing with 6 ml of PBS. After leaving the tube to stand for 5-10 minutes, the upper 
5 ml of suspension was harvested and spun for 10 minutes at 1400g. This was 
followed by harvesting of the upper 4.5ml into a tube containing 500 μl of 50% 
glycerol and mixed. The single cell stocks was then aliquoted into 2 ml cryol tubes 
and stored at -80°C. To determine the titer of each strain stock, ten fold serial 
dilutions of each strain were prepared using PBS containing 0.01% tween 80 and 
colony forming units (CFU) were determined by plating the serial dilutions in 
multiple replicates on Middlebrook 7H11 agar supplemented with 10% oleic acid, 
albumin, dextrose and catalase (OADC) and 0.5% glycerol. The culture plates were 
incubated at 37°C for 3-4 weeks. 
 
2.1.10 Growth curves 
The growth curves of the M. tuberculosis strains H37Rv, LAM3 and HN878 were 
determined by inoculation of 100 μl of each M. tuberculosis strain stock in 10 mls of 
Middlebrook 7H9 broth supplemented with 10% ADC and 0.05% tween 80. This was 
incubated at 37°C and optical density was measured using a Novaspec II 
spectrophotometer (Biochrom Ltd) at 600 nm everyday until a OD600 of between 0.6 
to 0.8 was reached when the bacteria are in the log phase of growth. The M. 
tuberculosis culture was then sub-cultured into 100 ml of Middlebrook 7H9 
supplemented with 0.2% glycerol, 10% ADC and 0.05% Tween 80 at an OD600 of 0.01. 
The OD600 was monitored daily up to an OD600 of 0.4 to 0.5 and an aliquot was taken 













The OD600 0.4 culture was then sub-cultured at an OD600 of 0.01 in triplicates of 100 
ml of Middlebrook 7H9 broth supplemented with 0.2% glycerol, 10% ADC and 0.05% 
Tween 80. The OD600 was measured daily at the same time for up to 3 weeks and the 
growth curve was drawn using the absorbance and number of days in culture. 
 
 2.1.11 Preparation of the HIV-1 BAL 
The CCR5 tropic HIV-1 BAL was prepared by propagation in CD14 negative peripheral 
blood lymphocytes left over after separation of CD14+ monocytes. The peripheral 
blood lymphocytes were activated by culturing them for 3 days in RPMI 1640 
containing 20% Foetal calf serum (FCS) (Sigma Aldrich) and 0.5 μg/ul 
phytoheamagglutinin (PHA) (Sigma-Aldrich). These were infected with HIV-1 BAL at 
multiplicity of infection (MOI) of 1:1 and cultured in RPMI 1640 with 20% FCS and 
20U/mL of IL-2 (Peprotech). Cell culture supernatants were harvested every third 
day, leaving 1 ml in culture, and were filtered through a 0.45 μm Millipore filter 
(Corning). Additional PHA activated peripheral blood lymphocytes were added to 
keep the cell density at 1 X 106 cell/ml. The harvested cell culture supernatants were 
used to infect 6 day MDM cultures MOI f 1:1 and the media refreshed after 16 hrs. 
Every week supernatants from the infected MDM were harvested and centrifuged at 
400g for 5 minutes and filtered through a 0.45 μm Millipore filter to remove cellular 
debris and stored at -80 °C. The virus suspensions were ultracentrifuged through 
20% sucrose buffer and resuspended in RPMI 1640 with 5% AB normal human serum 
and stored at -80°C for subsequent infection of MDM. 
 
The titre of the virus suspension was determined through titration on neural 
pentraxin 2 (NP2) cells transfected with CD4 and CCR5 or CXCR4. The NP2 cells were 
cultured in Dulbecco’s modified eagle medium (GIBCO Invitrogen) with 5% FCS, 1 
μg/ml puromycin (Sigma-Aldrich) and 2.5 mg/ml G418 (sigma Aldrich). The cells were 
infected with serial log fold dilutions of viral stocks and incubated for 2 hrs at 37°C in 
5% CO2 before removing the inoculum and replacing the media. The immunostaining 












2.1.11.1 Intracellular p24 staining 
Media was removed and the cell layer was covered with ice-cold methanol: acetone 
at ratio of 1:1 vol:vol for 5 minutes and washed 3 times with PBS. The NP2 cells were 
incubated with mouse anti-HIV gag (p24) monoclonal antibodies (E365/366) 
(National Institute of Biological Standards and Control UK) for 2 hrs at room 
temperature. This was followed by incubation with goat anti-mouse immunoglobulin 
conjugated to galactosidase (gal) (Southern Biotechnology Associates) for 1 hr at 
room temperature. The gal substrate solution was then added and incubated 
overnight at 37°C to develop a blue coloured solution. The virus titre was calculated 
by counting the number and proportion of positively stained cells under the 
microscope (forming units/ml). 
 
 2.1.12 Co-infection of MDM with HIV and M. tuberculosis strains 
For the investigation of the effect of HIV/TB co-infection on growth M. tuberculosis 
strains and HIV replication, MDM were generated from blood from 5 normal healthy 
donors at the Institute of Infectious Diseases and Molecular Medicine, University of 
Cape Town. The MDM were plated into flat bottom 96 well microtitre plates 
(Corning) at a concentration of 8 X 105 cells per well. They were then infected with 
HIV-1 BAL at a multiplicity of infection MOI 1:3 in triplicates and the plates were 
incubated at 37°C in 5% carbon dioxide for 7 days with refreshment of the media 
every 3 days.  On day 7, the MDM were infected with M. tuberculosis strains H37Rv, 
LAM3 and HN878 at MOI 1 in triplicates. The culture plates were incubated at 37°C 
in 5% carbon dioxide for 7 days and supernatants were collected after 4 hrs, 24 hrs, 
96 hrs and 168 hrs for p24 measurement and stored at -80°C. After 4 hrs, 24 hrs, 96 
hrs and 168 hrs, extracellular bacteria were removed form adherent cells by washing 
and the cells were then lysed with deionised water containing 0.05% tween 80 
(Sigma-Aldrich). The suspension was serially diluted, and the highest 3 dilutions were 
plated in triplicate on Middlebrook 7H11 agar (BD Pharmingen) supplemented with 
0.5% glycerol (Sigma-Aldrich) and 10% OADC (BD Pharmingen). The plates were 












 2.1.13 HIV/TB co-infection in presence of vitamin D molecules 
For the determination of the effect of vitamin D molecules on HIV replication in the 
presence and absence of M. tuberculosis 12 healthy donors were used and 6 healthy 
donors were used for determination of effect of vitamin D molecules on M. 
tuberculosis growth.  
 
For the investigation of effect of vitamin D molecules on HIV replication and M. 
tuberculosis growth, CD14+ monocytes were differentiated into Mϕ-1 in RPMI 1640 
containing 5ng/ml GM-CSF and either 100nm 1,25 dihydroxycholecalciferol 
(1,25(OH)2D3) (Sigma-Aldrich) or 100nm 25-hydroxycholecalciferol (Sigma- Aldrich) 
and 0.01% ethanol (Sigma-Aldrich) as vehicle. Mϕ-2 were differentiated in RPMI 
1640 containing 20 ng/ml M-CSF and either 100 nm 1,25 dihydroxycholecalciferol 
(1,25(OH)2D3) or 100 nm 25-hydroxycholecalciferol and 0.01% ethanol as vehicle. 
The monocytes under each condition were plated in triplicates at a concentration of 
1 X 106 cells/ml in a 6 well microplate and incubated at 37°C in 5% carbon dioxide for 
6 days. 
 
On day 6 adherent MDM were removed gently using 0.25% Trypsin-EDTA-and a cell 
scraper. MDM were counted and plated into flat bottom 96 well microtitre plates 
(Corning) at a concentration of 8 X 105 cells in RPMI 1640 containing 5% AB serum 
(Biowest) and supplemented with the appropriate corresponding vitamin D 
molecules followed by infection with HIV-1 BAL at MOI 1:3 in triplicate. The plates 
were incubated at 37°C in 5% carbon dioxide for 7 days with media refreshment by 
removal of the supernatants and addition of the new RPMI media containing vitamin 
D molecules every 3 days. The 72 hrs and day 6 supernatants were stored at -80 °C. 
On day 7 the MDM were infected with M. tuberculosis strain, H37Rv at a MOI of 1:1. 
The culture plates were incubated at 37°C in 5% carbon dioxide for 7 days. 
Supernatants were collected after 72 hrs and day 6 and were stored at -80°C for p24 
measurement. Extracellular bacteria were removed from adherent cells by washing 












The suspension was diluted and plated on Middlebrook 7H11 agar supplemented 
with 0.5% glycerol and 10% OADC after 4 hrs, 24 hrs, 96 hrs and 168 hrs for 
determination of M. tuberculosis CFU. The plates were incubated at 37°C for 3-4 
weeks after which CFUs were enumerated.  
 
 2.1.14 Measurement of p24 in supernatants 
Supernatants were incubated with 100 μl of 10% Triton X (Sigma-Aldrich) at 37°C for 
2 hrs to lyse the HIV. Supernatants were then filtered twice through Millipore 0.22 
μm durapore 96 well filter plates (Corning) to remove any M. tuberculosis. The p24 
levels in the supernatants were measured using the HIV-1 p24CA antigen capture 
assay kit (SAIC Frederick) following the manufacturers instructions. Briefly, 100 μl of 
samples and 1:2 serial dilutions of standards, were added to 96 well plates coated 
with monoclonal antibody to HIV-1 p24, and blocked with 0.5% casein solution. After 
2 hrs incubation at 37°C, the plates were washed and incubated with 100 μl of 1:200 
dilution of primary rabbit anti-HIV-1 p24 antibody at 37°C for 1 hr. The plates were 
washed and incubated with 100 μl of 1:100 dilution of secondary goat anti-rabbit IgG 
conjugated with horseradish peroxidase (SAIC Frederick) for 1 hr at 37°C. After the 
plates were washed TMB substrate (KPL) solution was added and caused an 
enzymatic reaction with production of a coloured soluble product. The reaction was 
stopped by addition of 1N HCL (Sigma-Aldrich) and the absorbance of coloured 
product was measured with plate reader at a wavelength of 450 nm with a reference 
filter of 650nm. The colour that developed was directly proportional to the quantity 
of p24. Concentration of p24 in supernatants was calculated from the standard 
curve. 
 
 2.1.15 Statistical analysis  
Data for the vitamin D and tuberculosis cross-sectional study was analysed using the 
SPSS version 20 (SPSS Inc.) and GraphPad Prism version 5 (GraphPad) software 
packages. Contingency tables were analysed using the Chi-squared test and Fisher’s 











The Mann-Whitney test was used to compare median values while the unpaired t-
test was used to compare means. The Bonferroni test was used for multiple 
comparisons. Spearman’s R was used for the calculation of correlation between age, 
BMI, CD4 and serum 25(OH)D3. Multivariate analysis of correlates of serum 
25(OH)D3 contrasts were conducted using multiple linear regression and p-values 
less than 0.05 were considered to be significant. 
 
For the in vitro HIV/TB macrophage co-infection experiments GraphPad Prism 
version 5 was used for statistical analysis of the results. One-way ANOVA was used 
for the analysis of independent variables with more than two conditions. The effects 
of two or more independent variables with multiple conditions were analysed by 
two-way repeated measure ANOVA. The Bonferroni test and Dunn’s test with 
correction for multiple comparisons were used for post hoc pairwise comparisons to 




Table 2.3 Materials and reagents used in methods described above 
 
Reagents and materials Supplier and product number 
BD FalconTM Polystyrene round 
bottomed tubes, 5 ml, 12x75 mm style 
Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA#352054 
FACS flow Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA 
FACS clean Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA 
FACS rinse Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA 
BD cytofix/CytopermTM Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA #51-2090KZ 
Small 25 cm cell scraper  Corning, NY 14831, USA CLS3010 
RPMI I640 Sigma-Aldrich, South Africa #R8758 
Trypsin EDTA (0.25% 1X) BioWest, France L0931-100 
Human serum AB male  Biowest, France 54190-100 
Round bottom 96 well microtitre plates Corning, NY 14831, USA #14831 












Reagents and materials Supplier and product number 
PBS without Ca2+ Sigma-Aldrich, South Africa 
# D8537 
Middlebrook 7H9 broth Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA 
Middlebrook ADC enrichment 
 
Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA 211886 
Middlebrook OADC enrichment 
 
Becton Dickson Biosciences, Pharmingen, 




ATCC strain from IIDMM university of 
Cape Town 
HN878 strain Donation form the National Institute of 
Medical Research (UK) 
LAM3 strain Clinical strain from patient from 
Khayelitsha Clinic 
Tween 80 Sigma-Aldrich, South Africa 
# P1754 
Millex syringe filter 0.22 μM Durapore 
PVDF 
Sigma-Aldrich, South Africa 
# F7648-50 
Glycerol Sigma-Aldrich, South Africa 
# G5516-1L 
Millex syringe filter 0.45 μM Durapore 
PVDF 
Sigma-Aldrich, South Africa # Z355518-50 
Solid-glass beads borosilicate, diameter 3 
mm 
Sigma-Aldrich, South Africa # Z143928 
1L polystyrene bottles Corning, NY 14831, USA # 430518 
250ml polystyrene bottles Corning, NY 14831, USA  # 430281 
Biolite 175 cm2 Flask Thermo Fisher Scientific, USA 
 # 130190 
Biolite 175 cm2 Flask Thermo Fisher Scientific, USA 
 # 130190 
50ml Falcon tubes Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA 
#352070 
Tuberculin Purified Protein Derivative 
(PPD) 
Statens Serum Institute, DK-2300, 
Copenhagen S, Denmark #2391 
BD CaliBRITETM 3 three-color-kit Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA #340486 
  
Reagents and materials Supplier and product number 
BD CaliBRITETM APC Beads Becton Dickson Biosciences, Pharmingen, 
San Diego, CA, USA #340487 
Trypan blue 0.4% Sigma-Aldrich, South Africa #T8154 
Middlebrook 7H11 agar 
 
Becton Dickson Biosciences, Pharmingen, 











Reagents and materials Supplier and product number 
L-shaped spreaders Sigma-Aldrich, South Africa # Z376779 
Triton X 100 Sigma-Aldrich, South Africa # X100 
96 well filter plates 0.2 μm PVDF 
hybrophilic membrane 
Sigma-Aldrich, South Africa # CLS3505 
Fetal calf serum, endotoxin free 
 
Delta Bioproducts, Highveld Biological, 
Lyndhurst, South Africa #14-501-BI 
Fugene 6 transfection reagent Roche Applied Science # 11 815 091 001 
Optimem media (without additives) Life Technologies, UK # 11058-021 
Sucrose Sigma-Aldrich, South Africa # S0389 
70% Ethanol Sigma-Aldrich, South Africa # E7023 
LymphoprepTM Axis-Shield, Oslo Norway # 1114547 
Heparin (5000 U/ml)  Biochrom AG Berlin # L6510 
Bovine serum Albumin Sigma-Aldrich, South Africa # A7906 
Sodium Pyruvate 100 mM Life Technologies, South Africa #11360-
039 
Disodium EDTA 18.61g Sigma-Aldrich, South Africa # E5134 
NaOH  Sigma-Aldrich, South Africa # S5881 
MidiMACS separator Miltenyi Biotec # 130-042-302 
LS MACS separation columns Miltenyi Biotec # 130-042-302 
Human GM-CSF premium grade (100 μg) Miltenyi Biotec # 130-093-866 
Human M-CSF premium grade (100 μg) Miltenyi Biotec # 130-096-492 
HIV-1 p24 Antigen Capture Assay Kit SAIC Frederick, USA 
20X Wash concentrate Buffer KPL, Washington DC, USA 50-63-01 
Tween 20 Sigma-Aldrich, South Africa # P1379 
Normal mouse serum (NMS) Sigma-Aldrich, South Africa # M5905 
Normal goat serum (NGS), GIBCO Life Technologies, South Africa, 
#16210064 
SureBlue TMB Microwell Peroxidase 
substrate solution. 
KPL, Washington DC, USA # 52-00-02 
Hydrochloric Acid Sigma-Aldrich, South Africa # H1758 
Analytical UPLC column- Waters Acquity 
UPLC – BEH C18, 1.7 μm, 2.1 x 50 mm. 
Waters, USA - # 186002350 
Methanol Hypersolve grade.  VWR, Radnor, USA #152507P 
Ammonium Acetate  Sigma-Aldrich, South Africa # 09689 
Formic Acid  Sigma-Aldrich, South Africa # 33015 
Deuterated 25 Hydroxyvitamin D3 (5 mg) Synthetica, Oslo, Norway 
25 Hydroxyvitamin D2 & D3 calibrator Chromsystems, Munich Germany # 
38033 
25 Hydroxyvitamin Vitamin D3 bi-level 
control (I+II) 











Chapter 3: Reciprocal Seasonal Variation In Vitamin D Status And 
Tuberculosis Notifications In Cape Town, South Africa. 
 
3.1 Literature review 
3.1.1 Vitamin D status 
Vitamin D nutritional status is determined by measurement of circulating 25(OH)D3 
and 25(OH)D2 levels in plasma or serum. These metabolites are suitable, because of 
their stability and longer half-life, the plasma half-life of 25(OH)D3 is 15 days while 
that of 1,25(OH)2D3 is of 10-20 hours (Jones, 2008). The active metabolite 
1,25(OH)2D3 is not a good measure of vitamin D status as it is tightly regulated 
throughout a wide range of 25(OH)D3 concentration. There is some debate about 
25(OH)D3 levels which signify vitamin D deficiency and sufficiency since 
recommendations for higher cut-off values are based  on observational 
epidemiological studies, which might be confounded rather than on clinical trials. 
The general consensus among experts is that vitamin D deficiency is defined as 
25(OH)D3 levels less than 50 nmol/L, vitamin D insufficiency levels from 51 nmol/L to 
74nmol/L and vitamin D sufficiency levels above 75 nmol/L. Vitamin D intoxication 
occurs when the 25(OH)D3 levels are above 375 nmol/L (Holick, 2007). 
 
Competitive immunoassays and chromatographic direct detection methods are the 
two main methods used for 25(OH)D3 and 25(OH)D2 quantification. The 
chromatographic methods such as liquid chromatography tandem mass 
spectrophotometry (LC-MS/MS) are more accurate and precise. They begin with the 
deproteinisation, lipid extraction and chromatographic separation of the 25(OH)D3 
and 25(OH)D2 in serum samples. Quantification in LC-MS/MS involves atmospheric 
pressure ionisation of 25(OH)D3 molecules and measurement by mass detection. 
Their major disadvantage is that they require expensive equipment and technical 













3.1.2 Vitamin D deficiency 
Globally it has been noted that there is an increasing prevalence of vitamin D 
deficiency, which is due to a variety of causes, mainly related to lifestyle changes in 
most populations. The vitamin D status of populations is dependent on availability of 
sunlight, nutritional provision and the underlying disease states. Sunlight is generally 
the main source of vitamin D rather than diet. As the latitude increases to above 
30 N or 30 S the need for dietary vitamin D supplementation increases especially in 
winter (Holick, 2007). The high prevalence of vitamin D deficiency has been found to 
be associated with increased economic burden of disease in Europe (Grant et al., 
2009).The common assumption that vitamin D deficiency is not prevalent in Africa 
due to the high availability of sunlight might have contributed to very few studies on 
vitamin D being performed in Africa .The available data show that the vitamin D 
status of African populations are variable depending on region. According to the 
current acceptable limits of vitamin D sufficiency, there is wide spread vitamin D 
deficiency and insufficiency in different population groups in Africa, which range 
from healthy adults to pregnant women (Prentice et al., 2009).  
 
Factors that influence vitamin D status in Africa are low calcium intake, malnutrition, 
fluorosis, tropical enteropathy, tuberculosis, Human Immunodeficiency Virus 
infection (HIV), malaria, non-communicable diseases and vitamin D inadequate diet 
(Prentice et al., 2009). More recently vitamin D deficiency has been shown to result 
in increased risk and susceptibility to infectious diseases and non-communicable 
diseases (Heaney, 2008).  
 
3.1.3 Vitamin D and Tuberculosis 
From the early 1700s, vitamin D was used for the treatment of tuberculosis in 
Europe. Various sanatoria were set up in various parts of the world, some in the 
mountains where patients were exposed to fresh air and sunlight for vitamin D 
treatment. Later on Cod liver oil, which contains high vitamin D levels, was used for 
treatment of tuberculosis. Vitamin D and UV light lamps have been successfully used 











The discovery of antibiotic drugs for treatment of tuberculosis resulted in the use of 
vitamin D treatment being less preferable. 
 
In vitro experiments by Rook et al in the early 80s demonstrated that infection of 
macrophages with M. tuberculosis in the presence of 1,25(OH)2D3 resulted in growth 
restriction of M. tuberculosis (Rook et al., 1986). The same results were corroborated 
by Crowle and colleagues, who also showed that supplementation of macrophages 
with 1,25(OH)2D3 increased their ability to inhibit growth of M. tuberculosis (Crowle 
et al., 1987). In 2006 Liu and colleagues were able to demonstrate that the ability of 
1,25(OH)2D3 to kill Mycobacterium tuberculosis was mediated through its 
stimulation of secretion of the antimicrobial peptide cathelicidin (Liu et al., 2006).  
 
More in vitro studies using monocytes and macrophages demonstrated that binding 
of M. tuberculosis antigens on macrophage TLR2/1 results in increased expression of 
VDR and CYP27B1 which causes increased synthesis of 1,25(OH)2D3 and induces the 
antimicrobial activities against M. tuberculosis (Fabri et al., 2011). Apart from the 
direct effects of antimicrobial peptides, 1,25(OH)2D3 mediates inhibition of M. 
tuberculosis growth by autophagy and production of reactive oxygen species and 
reactive nitrogen intermediates (Yuk et al., 2009, Sly et al., 2001, Thoma-Uszynski et 
al., 2001). Furthermore, 1,25(OH)2D3 has been shown to modulate the immune 
response by inhibiting expression and secretion of pro-inflammatory cytokines such 
TNF-α , IL-12 and IL-17 (Ikeda et al., 2010, Daniel et al., 2008, Sigmundsdottir et al., 
2007, Jeffery et al., 2009) and matrix metalloproteinases (MMP) 7, 9 and 10 during 
M. tuberculosis infection (Coussens et al., 2009). This might be important in the 
reduction of tissue damage during tuberculosis. 
 
A number of studies in different geographic areas have shown association between 
vitamin D deficiency and tuberculosis. Early studies in London showed an association 
between vitamin D deficiency and tuberculosis among Gujarati Indians (Wilkinson et 
al., 2000). In the African setting, studies in Guinea-Bissau, Malawi and Uganda have 
shown increased prevalence of vitamin D deficiency in tuberculosis patients 











in Indonesia and South Korea, found no significant difference between vitamin D 
levels of tuberculosis patients and controls (Grange et al., 1985, Koo et al., 2012). 
Nevertheless, a recent meta-analysis by Nnoaham and Clarke, concluded that low 
vitamin D levels were associated with a higher risk of developing active tuberculosis 
(Nnoaham and Clarke, 2008). Moreover patients with vitamin D deficiency have 
been shown to be at increased risk of autoimmunity in M. tuberculosis infected 
individuals (Li et al., 2012). 
 
Apart from the association between 25(OH)D3 deficiency and active tuberculosis, 
sufficient 25(OH)D3 levels have been shown to protect against progression and 
development of active tuberculosis. Serum 25(OH)D3 concentration has been 
associated with increased risk for latent TB infection among African immigrants. The 
study showed that patients with latent TB who were vitamin D deficient were at high 
risk of developing active tuberculosis (Gibney et al., 2008). A 4-year longitudinal 
cohort study in Pakistan demonstrated that vitamin D deficiency in household 
contacts of patients with tuberculosis was associated with 5 fold-increased risk of 
progression to active tuberculosis. The limitations of this study were small sample 
size, and there was a lack of information on BMI, diet and exposure to sunlight (Talat 
et al., 2010). 
 
In addition sufficient 25(OH)D3 (≥75 nmol/L) was associated with protection against 
tuberculin skin test (TST) conversion (Arnedo-Pena et al., 2011). There was also a 
reduced risk of TST conversion in children whose serum 25(OH)D3 levels increased to 
more than 20 ng/ml after supplementation (Ganmaa et al., 2012). Furthermore 
Martineau and colleagues were able to demonstrate that whole blood from TB 
contacts that had received vitamin D supplementation was able to restrict growth of 
Bacille Calmette-Guerin (BCG) (Martineau et al., 2007c).  
 
VDR polymorphism has been associated with susceptibility to active tuberculosis and 












The Taq1 and Fok1 restriction fragment length polymorphisms (RFLP) have been 
associated with susceptibility to active tuberculosis and early microbiologic 
clearance of pulmonary tuberculosis during treatment (Wilkinson et al., 2000, Roth 
et al., 2004, Martineau et al., 2011).  The taq1 tt genotype was associated with 
resistance to M. tuberculosis infection among West Africans (Bellamy et al., 1999). A 
systematic review and meta-analysis by Gao et al, points to a possible role of VDR 
polymorphism as a risk factor in the development of tuberculosis (Gao et al., 2010). 
The vitamin D binding protein (DBP) polymorphisms play a role in bioavailability of 
vitamin D. The DBP variants Gc2-1S and Gc2-2 have low affinity to vitamin D 
compared to Gc1F-1F (Chun et al., 2010). The Gc2-2 genotype is associated with 
increased susceptibility to active TB among Gujarati Indians due to its inability to 
transport sufficient amounts of vitamin D to target tissues (Martineau et al., 2009a). 
In addition CYP27B1 polymorphism might have a role in immunity to tuberculosis, as 
it has been associated with Vitamin D deficiency in other infectious diseases such as 
Hepatitis C (Lange et al., 2011). 
 
Vitamin D supplementation studies have not always produced the expected results 
due to a number of reasons related to their study designs.  Supplementation of 
0.25mg vitamin D/day for 6 weeks in TB patients receiving conventional therapy 
resulted in higher rates of sputum smear conversion in the treatment group 
compared to the placebo group (p=0.002) (Nursyam et al., 2006). Morcos et al, also 
reported faster resolution of TB symptoms in children treated with 1,000 IU of 
vitamin D daily as an adjunct to standard TB therapy (Morcos et al., 1998). Both 
studies did not report baseline and follow up vitamin D levels in order to determine 
the adequacy of the supplementation. In contrast, a randomized double-blind 
placebo trial by Wejse et al, (2009) in Guinea-Bissau, showed no effect of 
supplementation on clinical outcomes or mortality amongst TB patients, the 2 doses 
of 100000 IU vitamin D3 which were administered was low since there was no 
significant increase in serum 25(OH)D3 levels suggestive of insufficient 












In a recent multicentre, randomized, double-blind, controlled trial Martineau et al, 
(2011) reported that only patients with the tt genotype of the taq1 VDR 
polymorphism had faster sputum culture conversion after receiving standard 
tuberculosis treatment and vitamin D. There was no significant difference in rate of 
sputum culture conversion between the treated group and the placebo group 
(Martineau et al., 2011). Nevertheless, vitamin D3 adjunctive therapy enhanced the 
clearance of the pro-inflammatory responses in tuberculosis patients by inhibiting 
the secretion of pro-inflammatory cytokines and chemokines, and reduced the 
immunosuppressive effect of tuberculosis antimicrobial therapy and which could be 
important in the prevention of severe tissue damage. On the other hand, it also 
enhanced the clearance of monocytosis, lymphopenia, hyperchemokinaemia and 
hyperkalaemia (Coussens et al., 2012). Furthermore vitamin D supplementation has 
been associated with low risk of all cause mortality in a meta-analysis of vitamin D 
randomized controlled trials (Autier and Gandini, 2007).  
 
3.1.4 Vitamin D and HIV 
A high prevalence of vitamin D deficiency has been reported in HIV infected patients. 
Comparison of levels of vitamin D metabolites in HIV-infected individuals and 
appropriate control patients has shown that HIV infected patients have lower mean 
levels of 1,25(OH)2D3 and 25(OH)D3 which has been related to the increased 
occurrence of hypocalcaemia attributed to increased bone turnover during HIV 
progression (Teichmann et al., 2003, Kuehn et al., 1999, Teichmann et al., 2000). The 
severity of vitamin D deficiency increases as HIV infection advances to acquired 
immunodeficiency syndrome (AIDS) (Haug et al., 1998a). 
 
Increased prevalence of vitamin D deficiency in HIV infected individuals has been 
associated with use of antiretroviral drugs and effects of HIV on bone health (Childs 
et al., 2012). HIV positive individuals have higher propensity to developing 
osteoporosis and osteopenia, conditions commonly associated with vitamin D 











This is because HIV proteins increase osteoclastic activity (Fakruddin and Laurence, 
2005) and decrease bone formation by promoting osteoblastic apoptosis (Gibellini et 
al., 2008).  
 
Factors that lead to vitamin D deficiency during HIV infection include increases in 
chronic inflammation, immune activation, secretion of pro-inflammatory cytokines 
like TNF-α and IL-6 (Haug et al., 1998a) and increased utilisation of vitamin D by 
macrophages and lymphocytes as disease progresses (Villamor, 2006). The over 
activation of TNF-α in HIV infected persons inhibits the stimulatory effect of PTH on 
1α-hydroxylase (Villamor, 2006, Haug et al., 1994). In addition malabsorption of 
dietary vitamin D, reduced exposure to sunlight, and use of ARVs NNRTIs and PIs also 
contribute to vitamin D deficiency during the course of HIV infection (Cozzolino et 
al., 2003, Bout-Van Den Beukel et al., 2008). Vitamin D deficiency in HIV infected 




Figure 3.1 Vitamin D and the macrophage antimicrobial response to TB  
(Realegeno and Modlin, 2011). 
 
 Sufficient 25(OH)D3 levels(>32 ng/ml) have been shown to result in better 
outcomes in HIV infected women (Mehta et al., 2010). Studies on the role of vitamin 
D on HIV replication are inconclusive. Some studies have shown that vitamin D 
increases HIV replication while others have shown that it inhibits HIV replication 













Cathelicidin (LL-37) an antimicrobial peptide secreted in response to vitamin D stimulation 
of cells has been shown to have immunomodulatory effects on HIV. It has been 
demonstrated to inhibit HIV replication in primary PBMC and CD4 T cells, through its effects 
on the target cells not the HIV (Bergmana et al., 2007). Defensins have inhibitory effects on 
HIV replication, for example β-defensins inhibit HIV-1 infection by directly binding to HIV-1 
virus and by down regulation of HIV fusion receptor CXCR4 (Quinones-Mateu et al., 2003) 
and inhibition of intracellular replication (Sun et al., 2005).  
There are few studies on vitamin D supplementation in HIV infected individuals. Most of the 
studies focus on its importance on bone health in the HIV infected. Bimonthly 
administration of 100 000 IU of cholecalciferol and 1g calcium daily resulted in increased 
25(OH)D3 levels >30ng/L in most of the patients and did not affect CD4 or viral load in the 
12 months of the study. In addition supplementation did not have any adverse effects on 
the HIV infected participants (Arpadi et al., 2009).  
 
Vitamin D deficiency has been shown to be a major risk factor in progression of 
latent tuberculosis to active tuberculosis. In the case of HIV, vitamin D is proving to 
be more important as more studies are pointing towards its role towards prevention 
of disease progression to AIDS. Few studies have been done to investigate the role of 
vitamin D deficiency during HIV/TB co-infection in high disease burden settings like 
Cape Town South Africa. Although Cape Town is sunny and close to the sea with a lot 
of fish, there might be a high prevalence of vitamin D deficiency because of high 
disease burden due to HIV and tuberculosis (TB) and changes in life style as well as 
the fact that antiretroviral drugs (ARVs) and tuberculosis drugs interfere with vitamin 
D metabolism (Brodie et al., 1982, Childs et al., 2012).  
 
Seasonal variation in rates of tuberculosis incidence has been noted in Cape Town. 
There are reports of increases in new cases, worsening of conditions of TB patients 
and reactivation of latent TB during late winter and early spring in the Western Cape. 
Previous studies have noted increased cases of tuberculosis in early spring after 
winter in children (Schaaf et al., 1996). Pettifor et al, 1996 demonstrated a decrease 











The Vitamin D synthesis from sunlight in Cape Town was reported to be 3 times less 
than that in Johannesburg during the same period (Pettifor et al., 1996). The high 
prevalence of tuberculosis transmission and disease might be due to deficient innate 
immunity for surveillance of M. tuberculosis due to vitamin D deficiency. Therefore 
we sought to determine the prevalence of vitamin D deficiency in HIV infected and 
uninfected patients with tuberculosis in Cape Town, South Africa. This is the first 
study to investigate the association of vitamin D deficiency with tuberculosis in this 
population and settings.  
3.2 Results 
3.2.1 Characteristics of study participants 
A total of 480 participants were recruited; 251 were HIV uninfected and 229 were 
HIV infected. The patients were further stratified into three clinical groups; 192 
active tuberculosis (ATB), 178 latent tuberculosis infection (LTBI) and 110 diseases 
other than tuberculosis groups (OI). The demographic and clinical characteristics of 
the HIV uninfected study participants stratified by tuberculosis status are shown in 
Table 3.1. 
 
In the HIV uninfected the comparison of ATB vs. OI revealed that diagnosis of active 
tuberculosis was associated with younger age (p=0.01), lower BMI (p=0.02), male sex 
(p=0.001), black race (p<0.001) and sampling between October to March (p=0.02).  
The latent TB vs. active TB comparison indicated that a diagnosis of active 
tuberculosis was associated with older age (p<0.001), low BMI (p<0.001), fewer 
years of education  (p<0.001) and being a male  (p<0.001). The ethnic group of 3 














Table 3.1 Demographic and clinical characteristics of HIV un-infected study 
participants (n=251). 
 
HIV uninfected n=251 
Variables 
 
OI (n=55) LTBI (n=103) ATB (n=93) 
 
p-values 




(28.9 to 52.2) 
22.65 
(19.65 to 26.0) 
 
31.7 






(18.7 to 25.1) 
 
23.0 
(21.4 to 29.0) 
 
20.1 





9 (7 to 11) 11 (10 to 12) 10 (7 to 11) 0.41 <0.001 
Sex, n (%)      
Male 22(40) 42(40.8) 64(68.8) 0.001 <0.001 
Females 33(60) 61(59.2) 29(31.2)   
Ethnic group      
   Black 23 103 89 <0.001 0.05 
  ‘Coloured’ 32 0 4   
Sampling      
Apr - Sept 34 39 39 0.02 0.52 
Oct - Mar 21 64 53   
 
 
Table 3.2 shows the demographic and clinical characteristics of the HIV infected 
participants stratified according to tuberculosis status. The demographics and clinical 
characteristics were equally distributed for the OI and active TB groups. In the 
comparison of the latent TB vs. active TB diagnosis; active TB was associated with 

















3.2.2 Other infections 
Table 3.3 shows the distribution of the other diseases stratified by HIV status among 
the OI groups. The most common OIs among the HIV uninfected individuals were 
cancer (40%), genitourinary disease (28%) and lower respiratory tract infection 
(16%). Among the HIV infected participants the most common OIs was lower 
respiratory tract infections (47.3%), Kaposi sarcoma (12.7 %) and   gastrointestinal 
infection (10.9%).  
 
HIV infected (n=229) 
Variables OI (n=55) LTBI (n=75) ATB (n=99) 
 
p-values 
ATB vs. OI LTBI vs. ATB 
Median age, years 
(IQR) 
33  
(28 to 36.5) 
30.0  
(27.0 to 35.1) 
32.0  





(20.0 to 24.4) 
 
24.8 
(21.3 to 30.1) 
 
21.1 





(9 to 12) 
 
10.5  
(8 to 12) 
10  
(8.5 to 11.5) 
0.25 0.78 





(262 to 548) 
167  
(57 to 292) 
0.075 <0.001 
Sex, n (%)      
Male 21 19 40 0.79 0.04 
Females 34 56 59   
Ethnic group      
Black 54 72 98 1.0 0.58 
‘Coloured’ 1 2 1   
Sampling      
Apr- Sept 31 50 61 0.30 0.81 











Table 3.3 Number and type of opportunistic infections in the OI group 
 







Opportunistic infection n % n % n % 
Lower respiratory tract 
infections (not 
tuberculosis) 
8 16 26 47.3 34 30.9 
Meningitis 0 0 5 9.1 5 4.5 
Kaposi sarcoma 3 6 7 12.7 10 9.1 
Liver disease 3 6 3 5.5 6 5.5 
Gastrointestinal infection 1 2 6 10.9 7 6.4 
Genitourinary infection 14 28 3 5.5 17 15.5 
Gallstones 4 8 5 9.1 9 8.2 
Cancer 22 40 0 0 22 20.0 
 
 
3.2.3 Categorizing vitamin D status of study participants 
Figure 3.2 shows the distribution of the vitamin D levels of the study participants. 
Vitamin D deficiency was highly prevalent in all the patient groups with 316 (65.8%) 
of the participants having 25(OH)D3 less that 50 nmol/L while 116 (23.5%) of the 
participants had vitamin D insufficiency (25 nmol/L <25(OH)D3<75 nmol/L) and 75 













Figure 3.2 Serum 25(OH)D3 concentration stratified by HIV and TB status.  Bars 
represent means. Blue dashed line represents limit of detection (10 nmol/L) and red 
dashed lines represent (50 nmol/L) and (75 nmol/L) thresholds. 
 
Table 3.4 shows the 25(OH)D3 levels comparisons of the HIV uninfected participants. 
Among the HIV uninfected the comparison of ATB vs. OI shows that having an OI is 
associated with vitamin D levels less than 20 nmol/L (odds ratio (OR)=0.4, 95% 
confidence interval (95% CI): 0.2 to 0.8, p=0.017). In this case vitamin D deficiency 
was neither associated with OI nor active TB among the HIV uninfected. A diagnosis 
of active TB was associated with 25(OH)D3 levels below the 20 nmol/L threshold 
(OR=13.7, 95% CI: 1.7 to 108.2, p<0.002) and below the 50 nmol/L threshold (OR 5.2, 



















Table 3.4 Serum 25(OH)D3 concentrations of HIV uninfected study participants 
 










ATB vs. OI 
p-value 
 (Odds Ratio) 
LTBI vs. ATB 
p value 
(Odds Ratio) 
<20 nmol/L, n (%) 15 
(27.3) 




<50 nmol/L, n (%) 48 
(87.3) 


































Table 3.5 shows the 25(OH)D3 comparisons for the HIV infected participants. In the 
contrast of ATB with OI, diagnosis of active tuberculosis was associated with Vitamin 
D levels below the 20 nmol/L (OR=3.5, 95% CI: 1.5 to 8.2, p=0.003) and below the 50 
nmol/L (OR=3.2, 95% CI: 1.45 to 7.1, p=0.003) thresholds. The assessment of LTBI vs. 
ATB revealed that active tuberculosis was associated with vitamin D levels beneath 
the 20 nmol/L (OR=14.3, 95% CI: 4.2 to 48.8, p<0.001), the 50 nmol/L  (OR=5.6, 95% 
CI: 2.7 to 11.6, p<0.001), and beneath the 75 nmol/L (OR=7.3, 95% CI: 2.0 to 26.6, 
p=0.001) thresholds. 
 
The serum 25(OH)D3 concentrations of the 480 study participants stratified by HIV 
and TB status are shown in Figure 3.2. For the HIV uninfected participants OI was 
associated with lower mean 25(OH)D3 in the comparison with ATB (mean difference 
10.8 nmol/L, 95% CI: 4.3 to 17.2, p =0.001).  Active tuberculosis was associated with 
lower mean 25(OH)D3 in the comparison with latent TB (mean difference 14.7 












Table 3.5 Serum 25(OH)D3 concentrations of HIV infected study participants 
 










ATB vs. OI 
p-value 
(Odds Ratio) 
LTBI vs. ATB 
p-value 
 (Odds Ratio) 
<20 nmol/L, n 
(%) 




<50 nmol/L, n 
(%) 




<75 nmol/L, n 
(%) 





nmol/L, n (%) 




















In the presence of HIV infection, active TB was associated with lower mean 
25(OH)D3 by comparison with either  OI  (mean difference 14.3 nmol/L, 95% C.I: 7.6 
to 20.9, p <0.001) or LTBI (mean difference 26.0 nmol/L, 95% CI:19.1 to 33.0,  
p <0.001).  
 
When comparing patient groups by HIV status, HIV infection was associated with low 
25(OH)D3 levels among the participants with ATB (mean difference 11.9, 95% CI: 6.2 
to 17.6, p<0.001). As for the participants with OI low 25(OH)D3 levels were 
associated with absence of HIV infection (mean difference 13.2, 95% CI: -20.4 to -6.0, 
p<0.001). There was no significant difference of mean vitamin D levels between HIV 
infected and uninfected LTBI individuals (mean difference 0.51, 95%CI: -6.4 to 7.4, 




























ATB 40.5 (20.8) 28.7 (19.1) 11.9 (6.2 to 17.6)  <0.001 
LTBI 55.2 (19.4) 54.7 (27.4) 0.51(-6.4 to 7.4) 0.89 
OI 29.7 (15.8) 43.0 (21.7) -13.2 (-20.4 to -6.0) <0.001 
 
3.2.4 Correlates of 25(OH)D3 Concentrations 
Univariate analysis of the categorical correlates of vitamin D status showed that low 
vitamin D status was associated with active TB (p<0.001), HIV infection (p=0.001) 
and sampling between April to September inclusive (p<0.001). The co tinuous 
correlates showed that age and BMI were associated with vitamin D status (p<0.001) 
in both cases. There was no significant association between sex and vitamin D status 
as shown in Table 3.7. 
 
There was unequal distribution of potential correlates of vitamin D deficiency such 
as sampling season between study groups. Therefore multivariate analysis was 
performed to determine potential determinants of vitamin D status independently 
associated with lower serum 25(OH)D3 (Table 3.7). The OI group was excluded 
because of its heterogeneity in the univariate and multivariate analysis models. 
 
Lower vitamin D status was independently associated with the presence of active 
tuberculosis (mean difference in 25(OH)D3 concentration 28.9 nmol/L, 95% CI: 18.2 
to 39.7 nmol/L, p < 0.001) sampling from April to September inclusive (mean 
difference in 25(OH)D3 concentration 10.3 nmol/L, 95% CI: 0.4 to 20.1 nmol/L, 
p=0.04) and lower BMI (mean difference in 25(OH)D3 concentration 0.50 nmol/L per 
unit of BMI, 95% CI: 0.06 to 0.93 nmol/L, p=0.03). The effect of HIV and age was lost 
in the multivariate model p=0.08 and p=0.052 respectively. The difference in vitamin 
D status between participants with and without active tuberculosis was greater in 












Table 3.7 Correlates of vitamin D status in study participants (n = 370): univariate 
and multivariate analysis 
 
n=370 Univariate analysis Multivariate analysis 
Categorical 
correlates 
Mean serum 25(OH) 
D3, nmol/L (s.d) 









(-39.74 to -18.24) 
 
<0.001 
Latent 55.0 (23.0)  Ref  
     








(-17.7 to 1.10) 
 
0.08 
No 48.3 (21.3)  Ref  








Female 46.5 (23.3)    

















Oct - Mar 55.3 (24.1)  Ref  
     
Continuous 
correlates 
Spearman’s r (95% CI) p-value β (95% CI) p-value 
Age, years 0.30 (-0.38 to -0.20) <0.001 -0.25 (-0.50 to -
0.00) 
0.052 
BMI, kg/m2 0.21 (0.10 to 0.31) <0.001 -0.50 (0.06 to 0.93) 0.03 
 
 
3.2.5 Relationship between participant 25(OH)D3 levels and season 
The seasonal variation of 25(OH)D3 levels was shown by the sinusoidal pattern of 
the mean 25(OH)D3 levels by month (Figure 3.3). The highest 25(OH)D3 levels were 
in March (mean =57.4 nmol/L, SD = 22.8)  and lowest in July (mean =22.9 nmol/L, 
SD=18.5). Analysis by quarter showed that higher mean 25(OH)D3 levels were 
reached from January to March and lower from July to September inclusive (56.8 vs. 





















































Figure 3.3 Seasonal variation in mean serum 25(OH)D3 concentration, all study 
participants (n = 370). Error bars indicate SD. 
 
In addition analysis of the mean number of new tuberculosis notifications for the 
City of Cape Town showed consistent decrease in notifications in second quarter 
(April to June) of every year from 2003 to 2010 inclusive (Figure 3.4). The quarterly 
mean number of new tuberculosis notifications over this period was lowest in April-
June and highest in October-December (4222 vs. 5080 notifications per quarter; 95% 
CI for difference, 642 to 1075 notifications per quarter, p<0.001). 
 
 








































3.2.6 Correlation between serum 25(OH)D3 levels and CD4+ cells 
The determination of a relationship between serum 25(OH)D3 and CD4 count 
showed that there was a  statistically significant weak positive correlation between 
serum 25(OH)D3 and CD4 cell counts among the HIV infected patients. (Spearman’s 
correlation coefficient r=0.24, 95% CI 0.15 to 0.44, p=0.002) as shown in Figure 3.5. 
 




















Figure 3.5 Correlation of 25(OH)D3 levels with CD4 among the HIV infected 




In this cross-sectional study the association between vitamin D deficiency and 
tuberculosis among township dwellers was determined in Cape Town, South Africa. 
Vitamin D deficiency was associated with active tuberculosis in both HIV infected 
and HIV uninfected patients. There was a high prevalence of vitamin D deficiency in 
the study population. Vitamin D levels varied with season, with lowest levels of 
vitamin D occurring at the end of winter and highest levels in summer. In addition 
there was a reciprocal relationship between the seasonal variations of vitamin D 
levels with the tuberculosis notifications of the city of Cape Town. Active 
tuberculosis, sampling from April to September and BMI were independent 
determinants of low vitamin D levels. In addition there was a significant weak 











The clinical and demographic characteristics of the HIV uninfected patients were 
generally unequally distributed between the clinical groups. Patients with OIs were 
significantly older than the LTBI or ATB patients, which impacts on their vitamin D 
status since photosynthesis of vitamin D3 in skin decreases with increasing age due 
to the depletion of 7-DHC in the dermis (MacLaughlin and Holick, 1985). In addition 
the distribution of variables in the HIV uninfected OI group was not comparable to 
the other groups. There was high representation of black Africans among the HIV 
infected and uninfected ATB and LTBI groups who are susceptible to low 25(OH)D3 
levels because melanin limits the penetration of UVB needed for synthesis of vitamin 
D3 (Clemens et al., 1982).  
 
The association of vitamin D deficiency with ATB compared to either OI or LTBI was 
stronger in the HIV infected compared to the HIV uninfected patients. HIV infection 
could be increasing the severity of vitamin D deficiency during co-infection with TB 
(Vescini et al., 2011). The effect of HIV was further supported by the association of 
low vitamin D levels with ATB at the 75 nmol/L threshold in the comparison to LTBI 
that was not the case among the HIV uninfected. Furthermore HIV infected ATB 
patients had significantly low mean 25(OH)D3 levels compared to the HIV 
uninfected.  A high prevalence of vitamin D deficiency has been reported in HIV 
infected patients compared to the HIV uninfected (Villamor, 2006). The high rate of 
vitamin D deficiency in the TB/HIV co-infected patients might be due to chronic 
inflammation (Haug et al., 1998a), immune activation (Vanham et al., 1996) and 
inhibition of 1α-hydroxylase by TNF-α through its effects on PTH metabolism 
(Hanevold et al., 1993, Haug et al., 1994, Villamor, 2006).  
 
In contrast, vitamin D levels of HIV infected and uninfected LTBI patients were 
similar, this might be due to the relatively intact immune system of HIV infected LTBI 
shown by their fairly well-preserved median CD4 count compared to that of the HIV-
infected ATB patients. 1,25(OH)2D3 levels have been shown to correlate with CD4 
cell counts (Haug et al., 1994). Higher CD4 counts and suppression of HIV viral load 











this might be due to absence of interaction between HIV infection and vitamin D 
status (Adeyemi et al., 2011).  
 
A number of studies have reported correlations between vitamin D levels with CD4 
cell count(Haug et al., 1994, Haug et al., 1998a, Teichmann et al., 2003). The 
significant weak positive correlation between vitamin D levels and CD4 which was 
noted in the HIV infected patients is in contrast to some studies, which have shown 
no correlation between CD4 and vitamin D levels (Madeddu et al., 2004, O'Brien et 
al., 2001). 
 
Most of the demographic characteristics of OI group were significantly different from 
the LTBI and ATB patient groups since they were not ethnically matched.  
These characteristics are potential confounders, which introduces bias that can 
compromise the results. The OI patients had a wide range of diseases most of which 
have been reported to be associated with depletion of 25(OH)D3 (Schwalfenberg, 
2011). These include cancers, lower respiratory tract infections, liver disease (Putz-
Bankuti et al., 2012), gallstones (Fisher et al., 2009), gastrointestinal tract and 
genitourinary tract infections (Schwalfenberg, 2011, Yamshchikov et al., 2009). In 
addition those with cancer may have spent some time admitted in hospital and 
stayed indoors with less exposure to sunlight. The LTBI group was the best control 
for the study because it was composed of relatively healthy individuals with no other 
clinical diseases or infection. 
 
Since this is a cross-sectional study causality cannot be inferred. It is possible that 
the vitamin D deficiency noted might have increased susceptibility of the patients to 
active tuberculosis since vitamin D insufficiency was associated with latent TB in 
both HIV infected and uninfected individuals in the comparison of latent TB and ATB. 
This might signify that they are in transition to active TB if their vitamin D levels 













An alternative explanation is increased prevalence of vitamin D deficiency in TB 
patients could be caused by people staying indoors with closed windows there by 
increasing transmission of TB or vitamin D deficiency might be as a result of 
tuberculosis. 
 
The determinants of low vitamin D status in this population were active tuberculosis 
as well as low BMI and sampling in winter, which have been reported in other 
studies. In vivo and in vitro studies support the role of vitamin D in immunity against 
tuberculosis and more recently 1,25(OH)2D3 was shown to restrict the growth of 
both HIV and M. tuberculosis in co-infected macrophages (Campbell and Spector, 
2012). There is a well-known inverse relationship between BMI and 25(OH)D3 levels 
(Blum et al., 2008). The effect of BMI is related to the fact that individuals with high 
BMI have higher body fat, which increases the sequestration of lipid soluble Vitamin 
D3 and 25(OH)D3 (Wortsman et al., 2000).  
 
 A spectrum for the development of M. tuberculosis infection has been postulated 
(Figure 3.6) (Barry et al., 2009). The inclusion of vitamin D status in the model is 
supported by reports of the association of vitamin D deficiency with active 
tuberculosis (Nnoaham and Clarke, 2008, Wilkinson et al., 2000) and progression of 
latent tuberculosis to active tuberculosis (Gibney et al., 2008, Talat et al., 2010). In 
addition a number of studies have shown that low vitamin D levels lead to HIV 
disease progression (Mehta et al., 2010, Viard et al., 2011) with increased viral load 
during the course of HIV infection (Cervero et al., 2012). In addition low 25(OH)D3 
levels associated with active tuberculosis result in poor treatment outcomes (Sato et 
al., 2012).  
 
The effect of season is related to the fact that April to September includes the winter 
months when there is less sunshine, which is needed for the cutaneous synthesis of 
vitamin D. Western Cape, South Africa has a Mediterranean climate composed of 
four seasons autumn starting from mid-February to April, winter May to July, Spring 













Figure 3.6 Spectrum of tuberculosis infection with vitamin D  
(Barry et al., 2009) 
 
The seasonal variation of Vitamin D levels which was observed is corroborated by a 
study carried out by Pettifor et al, that demonstrated that in Cape Town low levels of 
vitamin D were made during winter between April and September and increased 
synthesis occurred in summer between October and March (Pettifor et al., 1996).  
Seasonal variation of vitamin D levels has also been shown previously in a number of 
countries (Webb et al., 1988, Sherman et al., 1990) 
 
Seasonal variation of vitamin D levels was linked to the seasonal variation in the 
tuberculosis notifications of the City of Cape Town. Increase in tuberculosis 
notifications in the second quarter of every year coincided with the decrease in 
vitamin D levels in winter. It is possible that tuberculosis is reactivated during winter 
due to decreased levels of vitamin D. Most patients seek medical attention when 
they become symptomatic usually from July at the end of winter and the beginning 
of spring. The results show that seasonal variation of 25(OH)D3 levels and the new 
tuberculosis notifications in Cape Town might be causally related.  
 
However, the City of Cape Town tuberculosis notifications data is ecological since 
they are for the whole city and are not only for the participants who had their 











Similar results of seasonal variation of TB notifications that have been linked to 
vitamin D deficiency have previously been reported elsewhere (Luquero et al., 2008, 
Mabaera et al., 2009, Schaaf et al., 1996).  
 
The seasonal variation in tuberculosis notifications has been ascribed to seasonal 
variation of vitamin D bioavailability (Sita-Lumsden et al., 2007), winter conditions 
associated with overcrowding and poor ventilation (Atun et al., 2005), viral 
infections in winter (Luquero et al., 2008) and increase in CD4+ cells and decrease in 
CD8+ cells during summer (Paglieroni and Holland, 1994, Rios et al., 2000). The 
possibilities of random errors in the City of Cape Town TB notification data are 
negligible as the data was consistent over an 8-year period. 
 
There are conflicting reports on the season where TB notification peaks occur in 
summer (Douglas et al., 1996, Leung et al., 2005). This might be due to differences in 
methods of diagnosis, healthcare systems, notification policies and seasons between 
countries. Santos and colleagues advocate for the application of chronobiological 
approaches during the development of TB control and treatment health policies 
(Santos et al., 2012).   This study supports the advocacy for supplementation with 
vitamin D especially during the winter seasons, which could play a role in reducing 
tuberculosis cases. 
 
The study was done in Black Nguni Africans from an urban township and therefore 
the results can only be inferred to this group. The vitamin D results can possibly be 
confounded by lifestyle, diet and sun exposure; information that was not provided in 
the study. The OI group was heterogeneous which increases the effects of potential 
confounders that could affect the estimates. 
 
There is a need for a longitudinal study, which monitors diet, exposure to sunlight 
and vitamin D levels in patients with latent TB and no TB infection, up until the time 
a diagnosis of active tuberculosis is made. This will allow the determination of the 
vitamin D concentration threshold at which reactivation or development of active 











The genetics of the study participants in terms of VDR, DBP and CYP27B1 
polymorphism should also be determined in order to investigate their role in 
modulation of the immune system by 1,25(OH)2D3. 
 
The data on the seasonal variation of vitamin D levels and TB notifications in Cape 
Town is important as it can be used in the generation of local public health policies 
on prevention, control and treatment of tuberculosis. This can be achieved by 
increasing case finding and health promotion activities during the peak seasons. 
These results support the need for a clinical trial of adjunctive vitamin D therapy or 

















Chapter 4: Effect of Smoking on Vitamin D Status 
 
4.1 Literature review 
Tobacco smoking is a common recreational drug, which is inhaled through the 
respiratory tract. Cigarette smoke contains up to 4800 constituents most of which 
have detrimental effects on health. The substances include poly-aromatic 
hydrocarbons, aromatic amines, N-nitrosamines, trace metals (Cadmium, nickel, 
arsenic, polonium 210), and hydroxylquinones and their effects range from being 
carcinogenic, toxigenic and ciliotoxic. Smoking causes a number of deleterious 
effects on health which include defects on bone metabolism resulting in 
osteoporosis, lung cancer, cardiovascular disease, emphysema, upper and lower 
respiratory infections (Talhout et al., 2011).  
 
There is an increasing amount of evidence supporting the importance of vitamin D in 
the prevention of many chronic diseases and infections that include cardiovascular 
diseases, diabetes mellitus, cancers, autoimmune disorders, chronic obstructive 
pulmonary disease (COPD) and microbial infections. Factors, which affect vitamin D 
sufficiency including latitude, age, exposure to sunlight and diet (Holick, 2007). 
Tobacco smoking has also been implicated as influencing vitamin D status (Brot et 
al., 1999). 
 
4.1.1 Effects of smoking on the immune system 
Cigarette smoke damages the immune system through its effects on immune cells 
and signalling pathways (Figure 4.1). This causes defective function of the immune 
components resulting in increased susceptibility of smokers to microbial infections 
and diseases. There are conflicting results on the effect of smoking on the immune 
system components due to differences in models used (Sopori, 2002). Cigarette 
smoke activates alveolar macrophages and epithelial cells in lungs, which results in 
increased secretion of pro-inflammatory molecules such as reactive oxygen species 











Increased secretion of pro-inflammatory molecules causes inflammation, which 
results in the oxidation of membrane lipids, DNA damage and damage of the 
respiratory epithelium. Cigarette smoke causes the dysfunction of immune cells such 
as alveoli macrophages, natural killer cells, dendritic cells, T cells and B cells. This 
results in the inability of the host to mount an immune response for clearance of 
intracellular pathogens (Stampfli and Anderson, 2009). 
 

















































Figure 2 | Overview of immune defects caused by smoking in the lungs. 
Cigarette smoke has both pro-inflammatory and immunosuppressive effects 
on the immune system. Acute effects of smoke on macrophages and epithe-
lial cells promote inflammation by inducing the recruitment of cells from the 
microcirculation to the lungs. At the same time, cigarette smoke impairs 
innate defence mechanisms that are mediated by macrophages, epithelial 
cells, dendritic cells (DCs) and natural killer (NK) cells, thereby increasing the 
risk, severity and duration of infection. The transition to a more severe expres-
sion of smoking-associated disease is marked by the impaired ability of 
macrophages to kill bacteria or viruses, the loss of the ability to remove dead 
cells, the degradation and chemical modification of the extracellular matrix, 
the increasing retention of oligoclonally expanded CD8+ T cells and the 
induction of interleukin-17 (IL-17)-secreting effector T cells. After long-term 
exposure to cigarette smoke, lymphoid aggregates with T cells and B cell 
zones may form at the site, supporting the production of pathogenic auto-
antibodies and driving autoimmune disease. Loss of mucosal defences can 
lead to bacterial colonization (as occurs in around 30% of long-term smokers 
with chronic obstructive pulmonary disease (COPD)). Concurrently somatic 
mutations in the epithelium and alteration of macrophage phenotype 
promote inflammation and the development of cancer (carcinoma in situ) 
that has a high chance of metastatic spread. CTL, cytotoxic T lymphocyte; 
TAM, tumour-associated macrophage; T
H
17, T helper 17; T
Reg
, regulatory T.
Interestingly, there is also direct evidence 
that CD1-restricted NKT cells mediate 
inflammation. One study45 has recently 
described an essential role for CD1d-
dependent NKT cell-directed macrophage 
activation in the development of life-long 
inflammatory changes following viral 
infection in the lungs. The impact of ciga-
rette smoke was not assessed in this study. 
Also, only low numbers of NKT cells were 
observed in airway biopsies, bronchoalveolar 
lavage and induced sputum from subjects 
with COPD and healthy controls. No signifi-
cant differences were observed among the 
two groups of subjects46, suggesting that NKT 
cell defects are probably linked to recurrent 
infections rather than to underlying  
inflammation in smoke-induced diseases.
Dendritic cells. In the lungs, dendritic cells 
(DCs), which are the most potent antigen-
presenting cells and are indispensable for 
the initiation of T cell-mediated immune 
responses47, are probably highly susceptible 
to smoke-induced effects because of their 
anatomical position (in the lumen and 
directly beneath the epithelium of the lung)48. 
Although it is known that the DC-directed 
chemokine CX
3
CL1 is upregulated in emphy-
sema48, there are only a few studies on the 
effects of smoking on lung DCs in humans 
and animal models49. Clinical studies suggest 
that the number of mature DCs is reduced 
in the large airways of patients with COPD 
who smoke50. Following smoking cessation, 
the numbers of mature DCs increase and 
are similar to non-smoking healthy controls. 
By contrast, the number of immature DCs 
is increased in the small airways of patients 
with COPD compared with individuals who 
have never smoked and individuals who 
smoke but do not have COPD48. These data 
indicate the smoking may affect DC numbers 
and maturity state. Studies in animal models 
have reported both decreased and increased 
numbers of DCs, depending on the type of 
smoke exposure system.
The reasons for these conflicting data 
are currently not well understood and may 
relate to differences between cohorts and 
experimental systems (as discussed above), 
or the use of different criteria to identify 
DCs and probably the labile size of the DC 
pool, which can expand and contract rap-
idly, especially if patients are treated with 
steroids51. Functional studies suggest that 
cigarette smoke exposure decreases the 
expression of co-stimulatory molecules, 
IL-23 and the T helper 1 (T
H
1) cell-inducing 
cytokine IL-12 by DCs, at least in mouse 
smoke exposure models52–54. In non-human 
primates, this T
H
2 cell-inducing and T
H
1 
cell-suppressing activity of smoke is most 
pronounced when exposure commences 
in utero55. These data are inconsistent 
with the more commonly held view that 






B cells and antibody-mediated autoimmunity. 
Autoimmunity has been proposed as a cause 
of smoke-induced lung disease. B cells are 
abundant in smoke-induced lung disease, 
and their roles, although obscure, are prob-
ably greatly underestimated. Cigarette smoke 
serves as an adjuvant, possibly because it is a 
potent inducer of granulocyte/macrophage 
colony-stimulating factor (GM-CSF) produc-
tion in the lungs, which enhances the ability 
of DCs to present antigen and probably to 
induce T
H
2 type-biased immune responses56. 
Cigarette smoking has also been shown to 
decrease serum levels of all immunoglobulin 
classes, except for IgE10. Similarly, animal 
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Figure 4.1 Effects of smoking in lungs (Stampfli and Anderson, 2009). 
 
4.1.2 Effects of smoking on bone and vitamin D 
Smoking cigarettes results in abnormal bone formation causing osteoporosis as it 
has also been shown to result in abnormal vitamin D metabolism (Brot et al., 1999). 
Smoking in ibits calcium absorption, which is media ed by vitami  D (H pper and 
Seeman, 1994). 
 
The cigarette smoke metabolite benzo-(α)-pyrene (BaP), produced from cigarette 
combustion, accelerates the breakdown of 25(OH) D3 resulting in vitamin D 
deficien y in smokers. BaP enhances the 1,25(OH)2D3 dep nde t induction of 
cytochrome P450 24A1 (CYP24A1) in monocytes and macrophages, which causes the 












Levels of 25(OH)D3 and intact parathyroid hormone (iPTH) have been reported to be 
decreased in smokers compared to non-smokers (Need et al., 2002, Brot et al., 
1999). Effects of smoking on bone metabolism might have an impact on vitamin D 
levels. Calcium is essential in the synthesis of bone, vitamin D is an important 
mediator of bone formation and PTH is a vital hormone, which increases calcium 
levels by bone resorption. Smoking affects all the metabolic processes mediated by 
calcium, vitamin D and PTH. It has been reported to interfere with the PTH-calcium 
axis through inhibition of PTH secretion thereby dysregulating vitamin D metabolism 
and resulting in vitamin D deficiency (Hopper and Seeman, 1994, Need et al., 2002, 
Brot et al., 1999). 
 
Vitamin D and smoking have opposing effects on the immune system. Vitamin D has 
anti-inflammatory effects while cigarette smoke activates the pro-inflammatory 
response (Stampfli and Anderson, 2009).  A number of studies have shown that 
smokers have low 25(OH)D3 levels compared to non-smokers (Brot et al., 1999, 
Need et al., 2002). 
 
4.1.3 Vitamin D, smoking and respiratory disease 
 
Smoking is associated with increased susceptibility to respiratory tract infections 
such as tuberculosis, pneumonia and influenza (Bates et al., 2007, Arcavi and 
Benowitz, 2004). It is a major risk factor for chronic obstructive pulmonary disease 
(COPD), a disease associated with destruction of the lungs and chronic productive 
cough. There is increased prevalence of vitamin D deficiency among patients with 
COPD (Janssens et al., 2011). Smoking has also been associated with increased risk of 
tuberculosis (Bates et al., 2007). This might be related to the effects of smoking on 
the lung epithelium. Smoking damages the lung epithelium and causes the 
dysfunction of alveolar macrophages. It causes defective phagocytic function of 
macrophages. In addition, vitamin D deficiency might be the cause of the increased 
prevalence of active tuberculosis in smokers since cigarette smoke affects vitamin D 











Vitamin D is very important for the maintenance of an effective innate immune 
system against pathogens in the lungs  
(Hansdottir et al., 2008). 
 
The Western Cape has the highest number of smokers in South Africa, 44.7% of men 
and 27% of women are smokers (Health, 2012). In view of the effects of smoking on 
vitamin D metabolism, bone and the immune response, I also investigated the 
interaction between smoking and vitamin D status in Cape Town, South Africa. 
 
4.2 Results 
4.2.1 Demographic and clinical characteristics of study participants 
Among the 370 individuals in the active tuberculosis (ATB) and latent tuberculosis 
infection (LTBI) groups 274 with smoking information w re included in the analysis 
and their characteristics are presented in Table 4.1. There were 59 (21.5%) current 
smokers, 39 (14.2%) ex-smokers and 176 (64.2%) individuals who had never smoked.  
Significant differences were observed for median age (p=0.003), median BMI 
(p=<0.001), and median education (p=0.001) between the groups. Ex-smokers were 
significantly older than current smoked (p=0.008) or never smokers (p=0.008). Low 
BMI was associated with ex-smokers in the comparison with never smoked 
(p=0.005). Current smoking was associated with low BMI in contrast to never 
smokers (p <0.001). 
 
There was a higher representation than expected of active tuberculosis (TB) amongst 
ex-smokers (p=0.004); HIV infection among never-smoked (p=0.01); sampling of ex-
smokers between April to September (p=0.03) and a greater number of males 
amongst current smokers (p<0.001). Active TB was associated with being an ex-
smoker in the comparison with either never smoked (p=0.001) or current smokers 
(p=0.025). HIV infection was associated with never smoked in the comparison with 











Male sex was associated with current smokers in the comparison with never smoked 
(p <0.001), likewise male sex was associated with ex-smokers in the contrast with 
never smokers (p=0.02). Sampling from April to September was associated with ex-
smokers in the comparison with current smokers (p=0.01). No significant differences 
were observed in the distribution of median CD4 count, median smoking years, 























Median age, years 
(IQR) 
31.8 
(24.6 to 41.3) 
 
32.1 
(26.3 to 39.7) 
 
26.6  











(18.6 to 22.9) 
 
20.2 
(17.7 to 24.0) 
 
22.6 







Education, (IQR) 10 
(8 to 11) 
10 
(7 to 11) 
11.0  
(9 to 12) 
0.001 
Median CD4 (IQR) 
In  HIV infected 
340 
(193 to 447) 
160 







smoking (IQR)  
10 
(4.5 to 20 
10.5 
(6.5 to 18.8) 
 0.925 
Tuberculosis n (%)     





                      LTBI 25 (42.4) 8 (17.1)  87 (49.4)  
HIV status n (%)     
                     Yes 14 (23.7) 16 (41) 80 (45.5) 0.013 
0.003* 
                      No 45 (35.3) 23(59) 96 (54.5)  
Sex, n (%)     






                   Females  8(13.67) 16(41) 118(67)  
Ethnic group n (%)     
                Black 56 (94.9) 38(97.4) 175 (99.4) 0.075 
              ‘Coloured’ 3 (5.1) 1 (2.6) 1(0.6)  
Sampling n (%)     




                Oct - Mar 45 (76.3) 20 (51.3) 109 (62.3)  
Years of smoking 
n(%) 
    
                 1-10 21 (52.5) 10 (50)  0.86 
                >10 19 (47.5) 10 (50)   
Cigarettes per day 
n(%)  
    
                 1-4 22 (50) 10 (52.6)  0.85 
                >4 22 (50) 9 (47.4)   
§ =Current smokers vs. ex-smokers, ‡= Ex-smokers vs. never smoked, *= Current 









































































Figure 4.2 Serum 25(OH)D3 by stratified by smoking status. (A) Divided into 3 groups 
(B) divided into 2 groups (ever smoked composed of current smokers and ex-
smokers). 
 
There was a significant difference between the mean vitamin D levels among the 
different smoking groups (p=0.007) (Table 4.2). Performance of post hoc tests 
showed that low mean vitamin D levels were associated with ex-smokers in the 
comparison between current smokers and ex-smokers (mean difference= 12.6, 95% 
CI: 2.5 to 22.8, p=0.009). Similarly low mean vitamin D levels were also associated 
with being an ex-smoker compared with the never smoked group (mean difference 
=14.1, 95%CI: 2.5 to 25.9, p=0.01) (Figure 4.2A). When the current smokers were 
combined with the ex-smokers to make the ever smoked group, there was no 
significant difference in mean vitamin D levels between this group and the never 
smoked group (mean difference = -4.14, 95% CI: -10.1 to 1.9, p=0.17) (Figure 4.2B).  
 
A high prevalence of vitamin D deficiency was observed in the study population with 
54% classified as vitamin D deficient, 30.7% were vitamin D insufficient and 15.3% 
were vitamin D sufficient. There was no association between vitamin D status at the 
20nmol/L and 75nmol/L thresholds with smoking status. Analysis of the vitamin D 
status at the 50nmol/L threshold revealed that vitamin D deficiency was associated 



























<20 nmol/L,  
n (%) 
3 (5.1) 6 (15.4) 16 (9.1) 0.22 
<50 nmol/L,  
n (%) 
31 (52.5) 29 (74.4) 88 (50) 0.02 
<75 nmol/L,  
n (%) 


















50.5 (24.7) 0.007 
 
Further analysis at the 50 nmol/L threshold demonstrated that vitamin D deficiency 
was associated with being an ex-smoker when compared with current smokers (odds 
ratio (OR)= 0.16, 95% confidence interval (CI): 0.03 to 0.92, p=0.03).  In contrast, the 
comparison between having never smoked and ex-smokers also showed that vitamin 
D deficiency was associated with being an ex-smoker (OR= 2.9, 95% CI: 1.3 to 6.3, 
p=0.006). There was no association with vitamin D deficiency in the comparison 























Table 4.3 Post hoc analysis of vitamin D deficiency and mean vitamin D levels of 
smoking groups (n=274). 
 





  (n=59) 
Ex-smokers 
    (n=39) 
Never smokers 




      vs. 
       Ex    
smokers 
    Ex-
smokers 





    vs.   
Never 
smoked 
<50 nmol/L, n          
       (%) 
31 (52.5) 29 (74.4) 88 (50) 







(n=176)    










50.5 (24.7) 0.009 0.01 1 
 
4.2.3 Analysis of risk factors of vitamin D status 
Univariate analysis of the possible categorical determinants of vitamin D status 
indicated that low vitamin D status was associated with active tuberculosis (p=0.01), 
male sex (p=0.04), sampling between April and September inclusive (p <0.001), and 
smoking status of being an ex-smoker (p=0.007). For the continuous correlates 
vitamin D status significantly correlated with age (p<0.001) and BMI (p<0.001), 
(Table 4.4). 
 
Multivariate analysis indicated that low vitamin D status was independently 
associated with active tuberculosis (p=0.001), month of sampling (p=0.001) and BMI 
(p=0.02) (Table 4.4). In addition multivariate analysis showed that low BMI was 
independently associated with being an ex-smoker (p=0.02), active tuberculosis (p 
















Table  4.4 Correlates of vitamin D status: univariate and multivariate analysis 
(n=274). 
 
 Univariate analysis Multivariate analysis 
Categorical 
correlates 
Mean serum 25(OH) 
D, nmol/L (s.d) 
p-value β (95% CI) p-value 
TB status       






-17.6 (-27.8 to 7.3) 
 
0.001 
                 Latent 62.6 (23.0)  Ref  
     
HIV infection               






                        No 50.4 (22.2)    
     
Sex                                    




5.4 (-5.5 to 16.4) 
 
0.33 
                Female 51.9 (23.6)  Ref  
     
Month of 
sampling 













            Oct - Mar 55.5 (24.0)  Ref  
     
 Smoking status                       
               Current  






5.0 (-15.6 to 25.6) 
 
0.63 
        Ex-smokers 37.90 (21.52)  -3.4 (-24.2 to 17.3) 0.75 
                 Never    
              Smoked 
50.52 (24.71)  Ref  
     
Continuous 
correlates 
Spearman’s r (95% CI) p-value β (95% CI) p-value 
Age, years -0.33 (-0.83 to -0.31) <0.001 -0.15 (-0.4.3 to 0.14) 0.31 


























Table  4.5 Correlates of BMI: univariate and multivariate analysis (n=274) 
 
 Univariate analysis Multivariate analysis 
Categorical 
correlates 
Mean BMI, kg/m2 
(s.d) 
p-value β (95% CI) p-value 
TB status       






1.6 (0.06 to 3.2) 
 
0.04 
                 Latent 24.3 (4.6)  Ref  
     
HIV infection               






                        No 50.4 (22.2)    
     
Sex                                




-4.0 (-5.9 to -2.1) 
 
<0.001 
                Female 24.6 (5.0)  Ref  
     
Month of 
sampling 












            Oct - Mar 22.9 (5.0)    
     
 Smoking status                       
              Current     






-1.4 (-7.3 to 4.5) 
 
0.63 
        Ex-smokers 21.4 (4.7)  -3.5 (-6.5 to -0.6) 0.02 
                  Never   
              Smoked 
23.6 (4.9)  Ref  
     
Continuous 
correlates 
Spearman’s r (95% CI) p-value β (95% CI) p-value 
Age, years -0.072 (- 0.078 to 3.24) 0.25   

















This analysis showed that low mean vitamin D levels and vitamin D deficiency were 
associated with ex-smokers in the univariate analysis, but in the multivariate analysis 
smoking was not independently associated with low vitamin D status. Just like the 
earlier analysis in in chapter 3 active tuberculosis, sampling from April to September 
and BMI were independently associated with low vitamin D levels among the study 
participants.  
 
Low BMI was independently associated with active tuberculosis, male sex and being 
an ex-smoker. Association of smoking with low BMI is a common feature in 
individuals who smoke worldwide (Molarius et al., 1997). Active tuberculosis was 
associated with participants who were ex-smokers. A large number of 
epidemiological studies show that smoking is a major risk factor for active 
tuberculosis and increases the risk of progression from latent tuberculosis infection 
to active disease among current smokers and ex-smokers compared to those that 
have never smoked (Bates et al., 2007). The increased susceptibility to TB is mainly 
dependent on the number of years spend smoking (Lin HH et al., 2009, Bates et al., 
2007).  
 
The biological mechanism by which smoking increases respiratory infections is by 
supressing the innate and adaptive immune responses resulting in decreased 
secretion of pro-inflammatory cytokines, immunoglobulins, mechanical disruption of 
cilia function, defective function of alveoli macrophages, natural killer cells, and 
dendritic cells in response to infection (Arcavi and Benowitz, 2004, Stampfli and 
Anderson, 2009). In this study active tuberculosis was associated with being an ex-
smoker. This might be explained by the fact that ex-smokers were significantly older 
than current smokers and as smokers get older many are usually compelled by 














A significantly large number of participants that have never smoked were infected 
with HIV. This was contrary to a number of reports that found smokers to be at 
increased risk of HIV infection than never smokers even though there is no plausible 
biological evidence of mechanism that support the high risk (Furber et al., 2007).  
Male sex was also associated with being a current smoker in comparison with ex-
smokers or never smoked. This is in line with studies elsewhere in which generally 
there is higher prevalence of smokers among males compared to females (Bolego et 
al., 2002).  
 
Smoking was not an independent determinant of low 25(OH)D3 levels. The 
association of vitamin D deficiency levels with ex-smokers in the univariate analysis 
might be due to confounding results. There are conflicting results on the effect of 
smoking on vitamin D status between smokers and non-smokers with some studies 
reporting lower levels in smokers (Hermann et al., 2000, Brot et al., 1999, Lorentzon 
et al., 2007, Szulc et al., 2002) while others report no significant difference in results 
between smokers and non-smokers (Arunabh et al., 2003, Need et al., 2002, Scragg 
et al., 1992) . The variation of results might be due to the use of different methods of 
vitamin D measurement. Electrochemiluminiscence methods result in higher vitamin 
D levels in smokers than in non-smokers due to interference by smoke molecules in 
samples (Grimnes et al., 2010). In addition, the conflicting results might be due to 
heterogeneity among the different populations as they vary in genetics, amount of 
smoking and nutrition (Sopori, 2002). 
 
In this study, ex-smokers were more susceptible to vitamin D deficiency, while other 
studies observed this in current smokers. This could be caused by the older age of 
the ex-smokers in this study, which makes them more susceptible to vitamin D 
deficiency. Similarly, a decrease in vitamin D levels in ex-smokers after stopping for 
at least a month has been reported in men (Supervia et al., 2006). This could be due 
to the irreversible effects of smoking on the vitamin D –PTH system resulting in 
maintenance of low PTH and vitamin D levels (Need et al., 2002, Brot et al., 1999, 
Supervia et al., 2006). After cessation of cigarette smoking some of its pathological 











and elevation of inflammatory molecules like CRP, TNF-α, IL-6, fibrinogen and white 
blood cell count which makes the high susceptibility to cancer and respiratory tract 
infections persist in ex-smokers even after stopping smoking (Wannamethee et al., 
2005, Helmersson et al., 2005, Bermudez et al., 2002, Costenbader and Karlson, 
2006). In this case it might have resulted in ex-smokers still being at high risk of 
vitamin D deficiency as systemic inflammation can result in inhibition of PTH by the 
pro-inflammatory mediators such as TNF-α (Haug et al., 1994, Haug et al., 1998b). 
 
Low vitamin D levels were also associated with male sex whereas other studies have 
reported association between low vitamin D levels with female sex (Hyppönen and 
Power, 2007, Levis et al., 2005, Meddeb et al., 2005). The difference can be 
explained by the fact that smoking was associated with male sex while on the other 
hand smoking has been associated with vitamin D deficiency. Cigarette smoking is 
suggested to be a possible determinant of sex differences for the prevalence of 
active tuberculosis (Watkins and Plant, 2006). 
 
The limitations of this study were that it was a cross-sectional study and therefore 
causality cannot be assigned. The self-reporting of smoking status could have 
possibly introduced bias owing to effects of social desirability from the participants 
and may underestimate the p evalence of smoking, particularly among active 
tuberculosis patients. Information on the brands of cigarettes and method of 
smoking was not obtained this is important for accessing the degree of exposure as 
the smoke composition of different brands of cigarettes vary. Ninety-six participants 
were not included in this analysis as smoking information was absent. Participants 
with smoking data had significantly lower BMI, were mostly males, HIV infected and 
were sampled during summer (October to March). They also had higher vitamin D 
levels, which can affect the generalizability of the results.  
 
Smoking was not an independent determinant of vitamin D status. The effect of 












Active tuberculosis, sampling from April to September and low BMI were maintained 
as potential risk factors of low vitamin D levels in this population setting. Cigarette 
smoking was eliminated as a potential confounder of the association between 
vitamin D deficiency with active tuberculosis. Therefore since active tuberculosis and 
sampling during winter have also been reported globally as potential risk factors of 











Chapter 5: Immunophenotyping Of Mϕ-1 and Mϕ-2   
 
5.1 Literature review 
5.1.1 The mononuclear phagocyte system 
The mononuclear phagocyte system that was postulated in 1972 consists of 
committed monocyte myeloid precursors, monocytes, tissue macrophages and 
dendritic cells. The mononuclear phagocytes are classified according to their 
morphology, function, haemopoietic origin and kinetics (van Furth et al., 1972). The 
study of the biology of cells in mononuclear phagocyte system is important for 
understanding susceptibility and control to infectious diseases and inflammatory 
responses. 
 
Macrophages are generated from haemopoietic stem cells in the bone marrow, 
which proliferate and differentiate to monocytes that leave BM into peripheral 
blood circulation. Monocytes can spend up to 4 days in the peripheral blood 
circulation before they move into inflammatory sites in response to chemokines. On 
stimulation with various cytokines, chemokines and tissue factors monocytes attach 
through selectin and integrin adhesion molecules to blood vessel wall endothelium 
and extravasate into tissues where they mature into tissue macrophages (Penna et 
al., 2002). The monocytes continuously enter tissues even in the absence of 
inflammation where they differentiate into macrophages and those that do not 
migrate into tissues undergo apoptosis (Mangan and Wahl, 1991). 
 
Apart from the extravasation of monocytes, tissue macrophages are also replenished 
by local proliferation of tissue macrophages due to the effects of cytokines such as 
monocyte-colony stimulating factor (M-CSF), IL-3 and IL-4 independent of the bone 












Monocytes mature into specific types of macrophages depending on their tissue 
localization: alveolar macrophages in lungs, Kupffer cells in liver, Langerhans cells in 
skin, osteoclasts in bone, microglial cells in brain, peritoneal macrophages in 
abdominal cavity, synovial A cells in joint synovial fluid and mesengial cells in kidneys 
(Gordon and Taylor, 2005). In addition tissue macrophages are found as both fixed 
and free: free macrophages are found in pleural, synovial, alveolar spaces and 
peritoneal while the fixed ones are found in liver Kupffer cells, bone osteoclasts, 
splenic macrophages and brain microglia. Macrophages are located at strategic 
positions in tissues where they encounter invading pathogens or host components, 
which need to be phagocytosed.  
 
Osteoclasts develop from peripheral blood when they are exposed to a 
microenvironments composed of M-CSF and receptor activator of nuclear factor-
kappaβ ligand (RANKL) from stromal cells (Husheem et al., 2005). Also, peritoneal 
macrophages are generated in abdominal tissues in the presence of M-CSF (Xu et al., 
2007) and alveolar macrophages are generated from monocytes in presents of 
granulocyte-macrophage colony stimulating factor (GM-CSF) and surfactant protein 
A and D (SP-A) and (SP-D) (Guth et al., 2009). Furthermore, microglia cells are 
generated from monocytes in the presents of GM-CSF and IL-3 (Kloss et al., 1997).  
 
5.1.2 Roles for macrophages in immunity 
Macrophages have many different functions that are dependent on their ability to 
change their phenotype and properties depending on the microenvironment 
(Gordon and Taylor, 2005, Stout and Suttles, 2004). They are very important 
mediators of many biological processes such as immunity against infection and 
malignancy, healing and clearance of cellular debris (Gordon, 2003).  
 
Despite the ability of macrophages to efficiently detect and phagocytose microbes, 
some facultative intracellular pathogens are able to use them to avoid detection and 












Infection of macrophages with M. tuberculosis results in inhibition of fusion of the 
phagosome and lysosome allowing their survival inside the cells. In addition HIV uses 
host macrophages as a reservoir of infection and also use them to gain accessibility 
to the central nervous system tissues. 
 
The typical macrophages receptors CD11b an integrin mediates cell-to-cell 
interaction and phagocytosis of iC3b opsonized pathogens or cells while CD33 a 
sialoadhesin and CD15, mediate cell-cell interaction and signalling. In addition they 
express CD14 which is involved in recognition and antimicrobial response against 
lipopolysaccharide binding protein opsonized microbial components (Schumann et 
al., 1996) and CD16 a low affinity Fc receptor involved in recognition, phagocytosis 
of antibody opsonized molecules and antibody dependent cell cytotoxicity (ADCC) 
(Keler et al., 2000 ). Macrophages phagocytose microbes or antigens, process them 
and present them to T cells via their major histocompatibility complex (MHC) Class II 
molecules. They are able to influence the type of T cell and B cell response to be 
stimulated by secretion of different cytokines e.g. IL-12 and IL-10, which stimulate 
activation of Th1 CD4 T lymphocytes and Th2 CD4 T lymphocytes respectively 
(Verreck et al., 2004).  
 
5.1.3 Macrophage polarization and activation 
Macrophage classification in the mononuclear phagocyte system is complex due to 
the fact that the cells continuously change depending on their microenvironment 
resulting in changes in their functional pattern characteristics. There are many 
different types of macrophage activation states, which are a continuum from pro-
inflammatory to anti-inflammatory cells with no clear separation (Mantovani et al., 
2004). The three main types of macrophage polarised states, are innate activation, 
classical activation and alternative activation (Gordon, 2003). However another 
proposal is that macrophages should be classified as classical activated 
macrophages, wound healing macrophages and regulatory macrophages (Mosser 












The high plasticity and heterogeneity of macrophages means they readily respond to 
environmental signals in their milieu. The significance of this in vivo is that there is a 
spectrum of macrophage activation continuum which is important for the regulation 
of the immune response as the ability of the cells to respond to the changes in 
cytokines, microbes and host debris materials allows the cells not to be over 
stimulated. It allows the activation of the cells to secrete pro-inflammatory and 
antimicrobial molecules in the presence of pathogens and the return to the steady 
state after the clearance or prevent over stimulation by production of anti-
inflammatory molecules IL-4, IL-10 and 1,25(OH)2D3, which change the phenotype of 
the cells towards alternative activation. It seems the macrophages are able to 
respond to all cytokines and molecules in their milieu by being able to be refractory 
to others and being stimulated by others depending on the concentration such that 
under steady state all the different phenotypes might be present with the levels 
being skewed when the balance is disturbed (Mantovani et al., 2004, Gordon, 2003). 
 
5.1.3.1 Innate activation 
The stimulation of macrophage Toll like receptors (TLR) by microbial molecules such 
as lipopolysaccharide (LPS) results in the innate activation of the cells. The innate 
activated cells have high surface expression of co-stimulatory molecules such as HLA-
DR, CD86 that allow them to effectively stimulate CD4+ T cells. The innate activated 
macrophages secrete pro-inflammatory cytokines like interferon α and β, which 
stimulate expression of inducible nitric oxide synthase (iNOS) and production of 
reactive oxygen species (ROS) and nitric oxide (NO). They are efficient phagocytes 
due to increased expression of scavenger receptors and mannose receptors (Nau et 
al., 2002, Gordon, 2003). 
 
 5.1.3.2 Classical activation 
Stimulation of macrophages with Interferon-γ in the presence or absence of LPS 
results in a pro-inflammatory type of macrophages named classical activated 











The M1 macrophages secrete high levels of pro-inflammatory cytokines and 
chemokines: IL-12, IL-6, IL-1β, TNF-α, IP-10, macrophage inhibitory peptide-1α (MIP-
1α), macrophage chemotactic protein-1 (MCP-1) and low levels of IL-10 (Mantovani 
et al., 2004, Mosser, 2003). They have increased expression of MHC-II, CD86, CD14, 
CCR5 and down regulation of mannose receptors (Mosser, 2003, Mantovani et al., 
2004). M1 macrophages have increased antimicrobial activity and are highly 
effective in killing of intracellular pathogens and tumour resistance. In general M1 
macrophages are associated with type 1 inflammation, delayed type hypersensitivity 
(DTH), and Th1 immune response (Mantovani et al., 2002).  
 
5.1.3.3 Alternative activation 
Alternatively activated macrophages are generated by stimulation of macrophages 
with a variety of stimulatory molecules like IL-4, IL-13, IL-10, glucocorticoid and 
1,25(OH)2D3 (Goerdt and Orfanos, 1999). Three subclasses of alternatively activated 
macrophages have been proposed; stimulation of the macrophages with IL-4 or IL-13 
results in generation of M2a macrophages, stimulation with immune complexes and 
agonists of TLR or IL-1R results in generation of M2b macrophages, and M2c 
macrophages are generated on stimulation of the macrophages with IL-10, 
glucocorticoids and 1,25(OH)2D3  (Mantovani et al., 2004, Gordon, 2003) 
 
The alternatively activated M2a macrophages express MHC class II receptors, 
mannose receptors and scavenger receptors, which they use for detection and 
phagocytosis of the materials. The M2a cells are mainly involved in mediation of Th2 
immune responses, type II inflammation, allergy, tissue repair, collagen synthesis 
and encapsulation of parasites.  
 
The M2b and M2c activated macrophages are mainly involved in immune regulation.  













They are characterized with surface expression of co-stimulatory molecules MHC-II 
and CD86 for stimulation of CD4+ T cells. On stimulation, they secrete increased 
levels of IL-10, TGF-β TNF-α, IL-1 and IL-6 and low levels of IL-12 (Mantovani et al., 
2004). 
 
5.1.4 In vitro generation of macrophages 
Human monocytic leukaemia cell lines such as Mono Mac-1, Mac- 6, THP-1, HL-60 
and U937 at different stages of differentiation can be used as macrophage model 
since primary tissue macrophages cannot be readily extracted and proliferated ex 
vivo. Stimulation of these monocytic cell lines with phorbol myristate acetate (PMA) 
or 1,25(OH)2D3 results in their differentiation to macrophages like cells. The 
phenotype of the macrophages varies depending on the durati n and type of 
stimulation (Kohro et al., 2004). These cell lines are established from disordered 
tissues and continuous passaging in the laboratory may also results in alteration of 
their genomic constitutions and characteristics (Odero et al., 2000, Abrink et al., 
1994).  However some of the advantages of cell line use is their high accessibility, 
ease of standardization and unlimited expansion. 
 
Monocyte derived macrophage  (MDM) reflect better the characteristics of tissue 
macrophages. They are generated from monocytes in vitro by stimulation with M-
CSF, GM-CSF, Vitamin D, IL-3 or adherence (Daigneault et al., 2010, Geissler et al., 
1989). The phenotypic characteristics, effector functions and morphology of the 
monocyte-derived macrophages generated in presence of these cytokines are 
different. GM-CSF and M-CSF concentrations ranging from 5 ng/ml to 100 ng/ml 
have been used for the generation of monocyte-derived macrophages in the 
literature. There is no defined standard concentration of the cytokines, used for the 
generation of the MDMs by researchers, which results in researchers generating 
cells with different phenotypes and morphology from use of the same cytokines, 












M-CSF is a disulphide linked homodimeric growth factor that acts on monocytes, 
macrophages and dendritic cells via the MCSFR receptor (CD115) (Sherr et al., 1985). 
It controls the differentiation, proliferation, and maturation of blood cells in the 
mononuclear phagocytic lineage from pluripotent stem cells residing in the bone 
marrow and the differentiation of monocytes to macrophages (Irvine et al., 2008). 
M-CSF is the only primary macrophage growth factor, which is detectable in 
peripheral blood under steady-state conditions (Bartocci et al., 1987). 
 
In vivo levels of M-CSF are present in normal serum around 30ng/ml (Irvine et al., 
2008) and favours an M2 polarized phenotype during human to macrophage 
differentiation (Verreck et al., 2004, Martinez et al., 2009).  M-CSF is continuously 
secreted by cells that include fibroblasts, macrophages, endothelial cells and 
osteoblasts. Monocytes generated via adherence only are also differentiated by M-
CSF as the adherence of the cells to plastic induces the monocytes to produce 
autocrine M-CSF and TNF (Komuro et al., 2005). 
 
GM-CSF is a haemopoietic growth factor and pro-inflammatory cytokine that is 
involved in inflammation, activation, proliferation, differentiation and recruitment of 
macrophages and granulocytes (Hamilton, 2002). It activates the effector functions 
of mononuclear phagocytes and granulocytes. It is produced by a variety of immune 
cells, which include T cells, B cells, macrophages, fibroblasts, mast cells and 
endothelial cells in response to various stimuli. GM-CSF enhances oxidative 
metabolism, antibody dependent cell cytotoxicity (ADCC), microbial phagocytosis, 
superoxide production and tumoricidal activity of the macrophages (Cannistra et al., 
1988). GM-CSF in particular is important in the development of alveolar 
macrophages as its deficiency results in defective alveolar function and alveoli 
proteinosis (Stanley et al., 1994) and deficiency of M-CSF results in reduced 
monocytes and macrophages in the body (Schonlau et al., 2003). GM-CSF is a pro-
inflammatory cytokine that is not detectable in circulation and is found locally at 












In general monocyte derived macrophages generated in the presence of GM-CSF are 
pro-inflammatory secreting large amounts of IL-12, TNF-α, IL-1, IL-6 , IL-23 and low 
levels of IL-10. The M-CSF generated macrophages are anti-inflammatory secreting 
high levels of IL-10 and IL-4 while inhibiting IL-12 and IL-6 secretion (Verreck et al., 
2004, Verreck et al., 2006). GM-CSF generated macrophages have the M1 or M1 like 
phenotype (Mϕ-1) while the M-CSF generated macrophages are said to have an M2 
like phenotype (Mϕ-2) (Hamilton, 2008, Fleetwood et al., 2009, Verreck et al., 2004). 
 
The two MDM populations have distinct morphological characteristics. Mϕ-1 are 
round with a centrally or eccentrically placed nucleus and Mϕ-2 have a fusiform or 
spindle shaped structure. Both Mϕ-1 and Mϕ-2 have been reported to have surface 
expression of CD11b, CD11c, CD14, CD4, CCR5, CXCR4, Fcγ receptors and HLADR 
(Young et al., 1990, Metcalf et al., 1986).  In addition Mϕ-1 express CD71, HLADQ 
and which are not expressed by Mϕ-2. Furthermore Mϕ-2 secrete large amounts of 
hydrogen peroxide and express integrin receptor αυβ5 whereas Mϕ-1 express αvβ3 
integrin and secrete less hydrogen peroxide due to their high catalase expression (De 
Nichilo and Burns, 1993, Akagawa, 2002, Komuro et al., 2001). 
 
In terms of susceptibility to infectious diseases Mϕ-2 are more susceptible to HIV 
infection and resistant to M. tuberculosis infection while Mϕ-1 are resistant to HIV 
infection and more susceptible to M. tuberculosis infection (Akagawa, 2002, 
Matsuda et al., 1995). It is thought that HIV replication is inhibited post 
transcriptionally since both Mϕ-1 and Mϕ-2 express the same amount viral DNA 
(Matsuda et al., 1995). Also Mϕ-2 macrophages express the natural resistance 
associated macrophage protein 1 (NRAMP1) gene while Mϕ-1 do not express it. The 
NRAMP1 gene is associated with increased resistance to M. tuberculosis infection in 
humans (Bellamy et al., 1998). Moreover Mϕ-2 suppresses IFN-γ production by 
lymphocytes in response to purified protein derivative (PPD) while Mϕ-1 does not 













Gene expression studies by Brocheriou and colleagues demonstrated that Mϕ-2 had 
low expression of CD163L and increased expression of stabilin-1 (STAB1) mediator of 
tissue repair and modelling, selenoprotein-1 (SEPP1) an anti-oxidant selenoprotein 
and a disintegrin and metalloproteinase domain-like protein decysin-1 (ADAMDEC1) 
that are anti-inflammatory. The Mϕ-1 had increased expression of pro-inflammatory 
genes CD163 molecule like-1 (CD163L), pro-platelet basic protein (PPBP) a 
chemokine and activator of neutrophils and arachidonate 5-lipoxygenase-activating 
protein (ALOX5AP) that encodes a 5-lipooxygenase involved in leukotriene synthesis 
(Brochériou et al., 2011). Stimulation of Mϕ-1 with M-CSF results in decreased 
secretion of anti-inflammatory cytokines with the phenotype moving towards the 
anti-inflammatory (Fleetwood et al., 2007). The macrophages can also be 
differentiated by their surface marker expression.  
 
All this data show that the GM-CSF and M-CSF differentiated macrophages differ in 
their characteristics and the level of polarization. The Mϕ-1 have a pro-inflammatory 
phenotype while the Mϕ-2 macrophages have an anti-inflammatory phenotype. 
Therefore we sought to identify the phenotype and cell surface markers that are 
differentially expressed by macrophages generated from use of GM-CSF (Mϕ-1) and 




5.2.1 Morphological characteristics of Mϕ-1 and Mϕ-2 
Mϕ-1 and Mϕ-2 were generated in parallel from peripheral blood CD14+ monocytes 
derived from same donor in the presence of GM-CSF and M-CSF respectively. After 6 
days of differentiation Mϕ-1 were homogenously large round cells with an 
eccentrally placed nucleus “fried egg” morphology (Figure 5.1A). In contrast the Mϕ-
2 where mainly composed of irregularly round cells with a few spindle or fibroblastic 
cells (Figure 5.1B). 











             





5.2.2 Analysis of MDM by flow cytometry 
5.2.2.1 Gating strategy 
To identify macrophages, forward scatter (FSC) vs. side scatter (SSC) was used to 
determine the distribution of the monocyte-derived macrophages (MDM) based on 
size and intracellular granularity. The first macrophage gate was set in a FSC vs. SSC 
dot plot and applied to a SSC vs. CD11b dot plot to set the macrophage gate around 
the CD11b positive cells as shown in Figure 5.2. These CD11b positive monocyte 
derived macrophages (MDMs) where analysed for various surface receptor 
expression. 
 
Figure 5.2. The gating strategy: macrophages were identified by staining for CD11b.  
First gate was set in a FSC vs. SSC dot plot (A) and applied to a CD11b vs. SSC dot plot 
(B) to set the macrophage gate around the CD11b positive cells (C). 
 











Figure 5.3A shows the forward scatter vs side scatter density plots of Mϕ-1 and Mϕ-
2. The subpopulation consisting of cells with high FSC and SSC gate G1 are the 
monocyte derived macrophages. The percentage of CD11b positive cells on gating of 
this population did not differ between the Mϕ-1 and Mϕ-2 (99.3±0.5% and 99.3± 
0.94 %, respectively) (Table 5.1). The dot plots show results of a representative 
donor shown in Figure 5.3 B to F.  
 
Representative histograms for CD11b, TLR2, CD33, CD14, CD16, CD15, HLADR and 
DC-SIGN of the Mϕ-1 and Mϕ-2 are shown in Figure 5.4.  
             
  
Figure 5.3 Flow cytometry dot plots of Mϕ-1 and Mϕ-2 from a representative donor. 
Cells were stained with labelled monoclonal antibodies (A) FSC vs. SSC (B) CD33 vs. 



























 99.33 (0.5) 99.25 (0.94) -16.43 to 16.27 
CD33 
 95.54 (7.4) 95.00 (4.2) -18.45 to 17.37 
DC-SIGN 
 0.41 (0.2) 0.033 (0.05) -16.73 to 15.97 
CD15 
 62.58 (20.1) 73.83 (22.49) -8.777 to 31.28 
CD1a 
 0.41 (0.1) 0.28(0.24) -23.26 to 22.99 
HLA-DR 
 98.62 (2.0) 92.82 (4.52) -22.15 to 10.55 
CCR5 
 98.23 (2.2) 96.88 (3.82) -17.70 to 15.00 
CD4 
 49.60 (20.6) 27.60 (24.0) -38.35 to -5.652 
TLR2 
 25.73 (19.5) 10.65 (6.92) -31.43 to 1.277 
CD14 
 55.30 (32.6) 27.88 (19.82) -43.77 to -11.07 
CD16 
 38.90 (12.6) 17.47 (11.03) -37.78 to -5.082 
 
5.2.2.2 Expression of T cell co-stimulatory and antigen presenting molecules on 
MDMs. 
Mϕ-1 and Mϕ-2 had similar number of cells expressing HLA-DR and CD1a, on 
assessment by flow cytometry. Both Mϕ-1 and Mϕ-2 had large number of cells 
expressing of HLA-DR 98.6% and 92.8% respectively and a negligible number of cells 



















Figure 5.4 Expression of cell surface receptors on Mϕ-1 and Mϕ-2. The unshaded 
histograms show cells stained with specific antibody and the shaded histograms 
show negative controls. 
 
 
 5.2.2.3 Expression of adhesion molecules on MDM 
Both Mϕ-1 and Mϕ-2 have high expression of CD33 and CD11b and neither of them 
expressed DC-SIGN Table 5.1 and Figure 5.5. Expression of CD15 was increased in 













 5.2.2.4 Expression of pathogen pattern recognition receptors and innate immunity 
receptors on monocyte derived macrophages. 
Mϕ-1 had higher percentage of cells expressing TLR2 (25.7% ±19.5 vs. 10.65±6.9), 
CD14 (55.3±32.6 vs. 27.9±19.8) and CD16 (38.9±12.6 vs.17.5±11) than Mϕ-2 
respectively as shown in Figure 5.4 and Table 5.1. Mϕ-1 had significantly increased 
expression of CD14 and CD16 than in Mϕ-2 (p<0.0001 and p<0.01 respectively Figure 
5.5). 
 
5.2.2.5 Expression of HIV entry receptors CD4 and CCR5 on MDM 
There was similarly increased number of cells expressing CCR5 in both Mϕ-1 and Mϕ-
2 populations (98.2% ±2.2 and 96.9 % ± 3.8 respectively Table 5.1). Mϕ-1 had higher 
expression of CD4 receptor than Mϕ-2 (49.6% ± 20.6 and 27.6% ± 24 respectively 











































































Figure 5.5 Quantitative comparison of phenotypic characteristics of Mϕ-1 and Mϕ-2 
















In the present experiments, the phenotype of monocyte-derived macrophages 
(MDM) was determined by flow cytometry. Growth factors GM-CSF and M-CSF were 
used for the differentiation of monocytes into macrophages resulting in generation 
of Mϕ-1 and Mϕ-2 respectively. The same flow cytometer and instrument settings 
were used for all the analysis to allow semi-quantitative comparisons of surface 
receptors between donors. Effects of GM-CSF and M-CSF were compared directly in 
MDM from the same donor in order to eliminate donor variation. The Mϕ-1 and Mϕ-
2 expressed the typical macrophage markers Mac-1 receptor (CD11b) and sialic acid 
binding Ig-like lectins-3 (CD33) and Mϕ-1 had significantly increased expression of 
CD4, CD14 and CD16 receptors compared to Mϕ-2.  
Review of literature shows that variable concentrations of GM-CSF and M-CSF are 
used for the generation of macrophages, which results in differences in the surface 
receptor expression between studies. Our experiments were optimized to use 5 
ng/ml GM-CSF and 20 ng/ml M-CSF. The Mϕ-1 were homogenously round with 
eccentrically places nucleus (fried egg) morphology, which is in line with results from 
other studies (Hassan et al., 1994, Verreck et al., 2006). The Mϕ-2 were round with 
very few numbers of spindle /fibroblastic cells which deviated from heterogeneous 
and fibroblastic cells reported in other studies (Bender et al., 2004, Young et al., 
1990, Matsuda et al., 1995). The high concentrations of M-CSF above 20 ng/ml used 
in other studies account for the heterogeneous and fibroblastic morphology of the 
cells. M-CSF concentration of 20 ng/ml was used in the current experiments as it is 
physiologically relevant and within the steady state concentration exposed to 
monocytes and macrophages in vivo (Irvine et al., 2008).  
Both Mϕ-1 and Mϕ-2 had similarly high expression of the adhesion receptors CD11b, 
CD33, and CD15, which has been reported by others (Akagawa, 2002, Finnin et al., 
1999, Verreck et al., 2006, Xu et al., 2007). The cells showed the typical absence of 













In line with other studies both Mϕ-1 and Mϕ-2 had increased expression of HLA-DR, 
which regulates antigen-presenting functions to T cells (Verreck et al., 2006). In 
previous studies GM-CSF has been reported to increase the HLA-DR expression 
(Dimri et al., 1994, Eischen et al., 1991) while in contrast M-CSF has been found to 
either increase or have no effect on HLA-DR expression (Becker et al., 1987, 
Erickson-Miller et al., 1990). The absence of CD1a and CD83 co-stimulatory and 
mediators of antigen presentation makes macrophages weak in co-stimulation and 
antigen presentation compared to DCs. CD1a and CD83 are typical dendritic cell 
markers hence their absence confirms that macrophages were generated and not 
DCs (Tkachenko et al., 2005, Verreck et al., 2006). 
The increased expression of CD14 and CD16 receptors by Mϕ-1 supports their role as 
the main cells involved in antimicrobial response against invading pathogens. These 
receptor molecules are potent mediators of the innate immune response against 
microbial pathogens. Indeed other researchers have shown that GM-CSF generated 
macrophages express high levels of CD14 and CD16 (Verreck et al., 2004, Fleetwood 
et al., 2007, Becker et al., 1987, Erickson-Miller et al., 1990, Finnin et al., 1999, 
Brochériou et al., 2011). The levels of expression of TLR2 were also higher in Mϕ-1 
though non-significantly. This is because the generated macrophages were not 
stimulated, TLR2 is down regulated in unstimulated macrophages and upregulated 
on stimulation with microbial molecules (Henning et al., 2008).   
 
The cells that were generated from monocytes with GM-CSF or M-CSF were 
macrophages as they expressed the typical macrophage markers: CD11b, CD33, 
CD14 and HLA-DR on their cell surfaces. The cells did not express any of the dendritic 
cells markers like CD1a, CD209, and CD83. However, the notable exception was 
expression of CD14, CD16 and CD4, which were significantly increased on Mϕ-1 
compared to Mϕ-2. Differences in cytokine expression and phenotype of Mϕ-1 and 
Mϕ-2 have been described elsewhere (Verreck et al., 2004), In line with this the Mϕ-
1 expressed cell surface molecules associated with M1 pro-inflammatory 
macrophage phenotype due to the high expression of the innate antimicrobial 











The overall analyses of the difference in receptor expression of the two-macrophage 














Chapter 6: Macrophage Phenotype Dictates Cellular Ability to Control 
M. tuberculosis And HIV-1 Replication In Response To Vitamin D 
 
 
6.1 Literature review 
6.1.1 Vitamin D and monocyte/macrophage biology 
Macrophages are responsive to immunomodulatory molecules and their function is 
dependent on their phenotype, which is influenced by their microenvironment. 
1,25(OH)2D3 modulates the immunological activities of cells of the mononuclear 
phagocyte system by enhancing their antimicrobial responses (Martineau et al., 
2008). Macrophages and monocytes are able to synthesize 1,25(OH)2D3 from 25-
dihydroxycholecalciferol (25(OH)D3) through expression of the CYP27B1 enzyme. 
The 1,25(OH)2D3 produced, down regulates the expression of co-stimulatory 
molecules CD80, CD86, CD40 and that of CD4, MHC-II, toll like receptor-2 (TLR-2), 
TLR4 and TLR9 on monocytes(Clavreul et al., 1998, Dickie et al., 2010, Xu et al., 
1993). On the other hand, it increases the expression of CD14 and CXCR4 (Biswas et 
al., 1998) on monocytes.  
  
In the presence of microbial molecules such as LPS, 25(OH)2D3 and 1,25(OH)2D3 
have been shown to suppress the secretion of IL-6 and TNF-α through the inhibition 
of p38 activation by mitogen activated protein kinase phosphatase 1 (Zhang et al., 
2012). In addition, 1,25(OH)2D3 also upregulates the expression of macrophage 
specific antigens and lysosomal enzyme acid phosphatase and it enhances oxidative 
functions, chemotaxis and immunoglobulin- and complement-mediated phagocytic 
function of monocytes and macrophages (Stoffels et al., 2006, Abu-Amer and Bar-
Shavit, 1993, Xu et al., 1993). IL-4, on the other hand, antagonises the effects of 
1,25(OH)2D3 on monocytes and macrophages (Xu et al., 1993). 
 
Activation of macrophages by interferon gamma (IFN-γ) or through TLR induction 











In turn this is involved in synthesis of 1,25(OH)2D3 from 25(OH)D3, which induces 
the synthesis of the antimicrobial peptides, cathelicidin and β defensins, that restrict 
the growth of intracellular pathogens such as Mycobacterium tuberculosis 
(Martineau et al., 2007b, Fabri et al., 2011, Wang et al., 2004).  
 
1,25(OH)2D3 synthesis in macrophages is not tightly regulated as it is dependent on 
the availability of the substrate 25(OH)D3.  1,25(OH)2D3 induces the expression of 
the truncated splice variant of CYP24 by macrophages that is not able to degrade 
1,25(OH)2D3.  It only binds it, preventing its degradation, and thereby increasing 
availability of 1,25(OH)2D3 for cell functions (Ren et al., 2005).  This is in contrast to 
the renal production of 1,25(OH)2D3, which is controlled by negative feedback on 
CYP27B1 (Adams and Gacad, 1985). 
 
6.1.2 Vitamin D signalling and HIV-1 long terminal repeat (LTR)  
 
The HIV-1 LTR is a sequence of nucleotides in the HIV-1 genome that have binding 
sites for molecules that control HIV-1 replication. It is responsive to different types 
of molecules; some of which stimulate and others inhibit HIV-1 replication.  In vivo 
and in vitro HIV-1 and M. tuberculosis co-infection has been shown to stimulate the 
secretion of molecules that stimulate signalling pathways that result in modulation 
of the HIV-1 LTR. 
 
The HIV-1 long terminal repeat (LTR) has three parts: U3, R and U5 as shown in 
Figure 6.1. The U3 area has the promoter, enhancer and regulatory sequences, while 
the R region contains the transactivator response element (TAR) (Stevens et al., 
2006). The LTR sequences interact with host transcriptional factors, chromatin 
remodelling factors and viral proteins to induce or inhibit expression of viral RNA and 
proteins.  
 
The processes that are under LTR control include viral replication, expression of viral 











HIV-1 has two LTR; 5’-LTR and 3’-LTR, which have identical sequences and structural 
organisation but different functions. The 5’-LTR is involved in induction of HIV-1 
transcription while the 3’-LTR is important for termination of transcription, cleavage 




Figure 6.1 Structure of the HIV-1 5’-LTR of HIV-1 subtype B (Stevens et al., 2006) 
 
Interaction of host transcriptional factors and viral proteins with the HIV-1 5’-LTR 
stimulates transcription of viral DNA by RNA polymerase II (pol II). The LTR contains 
binding sites for specific proteins like; nuclear factor kappa beta (NF-κβ), 
CCAAT/enhancer binding proteins (C/EBP), nuclear factor of activated T cells (NFAT), 
activator protein (AP-1) and activating transcriptional factor (ATF) in the U3 and U5 
regions. The number and arrangement of these binding sites varies between HIV-1 
subtypes (Stevens et al., 2006).  
 
Initiation of viral transcription is induced in the core promoter that contains three 
specific protein-1 (sp-1) binding sites, TATA box and initiator element (Kilareski et al., 
2009).  The initiator element interacts with a number of host molecules that can 
either stimulate or inhibit basal HIV-1 transcription. In the enhancer region, there 
are two binding sites for proteins of the Rel family and NF-κβ. Binding of the NF-κβ 
to the HIV-1 enhancer region increases HIV-1 replication and expression of HIV-1 











HIV-1 subtype C has three, subtype B has two and subtype E has one NF-κβ binding 
sites. These are the principal binding sites of NF-κβ, whose p65 subunit is a strong 
inducer of HIV-1 transcription (Natoli et al., 2005). More NF-κβ binding sites in 
subtype C results in its higher level of basal and TNF-α induced transcriptional 
activity (Montano et al., 2000).  
   
NF-κβ binding sites also bind nuclear factor of activated T cells (NFAT), resulting is 
stimulation of transcription in T lymphocytes. NFAT-5 is important in induction of 
basal transcription and HIV-1 replication in monocytes and monocyte derived 
macrophages (Bates et al., 2008). The regulatory and TAR also contains the binding 
sites for transcriptional factors that target the mitogen activated protein kinase 
(MAPK) signal transduction pathways such as activating protein (AP-1).  
 
1,25(OH)2D3 has been shown to down regulate NF-κβ mediated signalling by 
inhibiting its translocation to the nucleus in a number of cells types, including 
monocytes and macrophages (Cohen-Lahav et al., 2006, Dong et al., 2003). 
Consequently, this results in the suppression of the expression of gene products that 
are under its control. NF-κβ is composed of two subunits; p50 and p65, which under 
normal conditions stay in the cytoplasm bound to inhibitory kappa beta (Iκβ). 
Activation of cells results in phosphorylation and break down of Iκβ resulting in 
release of NF-κβ, which migrates to the nucleus where it modulates target genes. 
1,25(OH)2D3 modulates NF-κβ functions by increasing the levels of Iκβ and by 
inhibition of Iκβ phosphorylation. It also prevents the binding of NF-κβ to the 
promoters of its target genes (D'Ambrosio et al., 1998, Harant et al., 1998, Cohen-
Lahav et al., 2006).  
 
6.1.3 Effects of vitamin D on HIV-1 and M. tuberculosis 
There are conflicting reports on the effects of vitamin D molecules 25(OH)D3 and 
1,25(OH)2D3 on HIV-1 replication. Previous studies have mainly been carried out in 











Studies that report increased HIV-1 replication by 1,25(OH)2D3 were primarily 
performed in cell lines (including HL-60, U937, THP-1, A3.5 and U1 cells) after pre-
treatment of the cells prior to HIV-1  infection. HIV-1 replication in these 
experiments was determined by the measurement of p24 levels (Kitano et al., 1990, 
Pauza et al., 1993, Skolnik et al., 1991) and HIV-1 proviral DNA reverse transcriptase 
activity (Biswas et al., 1998). However, addition of 1,25(OH)2D3 to cells post-
infection with HIV-1, results in inhibition of HIV-1 replication (Pauza et al., 1993). In 
cells with constitutively low viral expression due to integration of proviral DNA into 
their genome (chronically HIV-1 infected cells such as U937 and J-HL-60), 
1,25(OH)2D3 increases HIV-1 replication (Locardi et al., 1990, Kitano et al., 1990). In 
contrast, 1,25(OH)D3 suppressed HIV-1 replication in chronically HIV-1 infected U1 
cells and the addition of exogenous TNF-α increased HIV-1 replication (Goletti et al., 
1995).  
 
The effect of 1,25(OH)2D3 on primary monocyte derived macrophages (MDM) has 
also produced variable results. Pre-treatment of MDM with 1,25(OH)2D3 has been 
shown to increase HIV-1 replication (Skolnik et al., 1991, Kizaki et al., 1993) and the 
addition of 1,25(OH)2D3 post-infection with HIV-1, results in inhibition of HIV-1 
replication (Kizaki et al., 1993). The effect of 1,25(OH)2D3 on HIV-1 in MDM was 
found to vary between donors, as pre-treatment with 1,25(OH)2D3 resulted in 
inhibition of HIV-1 replication in most of the donors, but in a few, it resulted in 
increased HIV-1 replication which was, however, less than that seen in myeloid cell 
lines (Pauza et al., 1993). In addition, the binding of 1,25(OH)2D3 to VDR in HeLa, 
Cos-1 and U937 cell lines has been shown to transactivate HIV-1 LTR in combination 
with its co-activators, which stimulate HIV-1 replication (Nevado et al., 2007). 
However, more recently, Campbell and Spector demonstrated that 1,25(OH)2D3 is 
able to inhibit both HIV-1 and M. tuberculosis replication by autophagy even during 
co-infection (Campbell and Spector, 2012). 
 
A number of in vitro studies have shown that 1,25(OH)2D3 and 25(OH)D3 are able to 











Several mechanisms are used to inhibit growth of M. tuberculosis in the presence of 
vitamin D, for instance, the induction of the synthesis of antimicrobial peptides 
cathelicidin and  defensins in phagocytes that lyse the bacilli by the formation of 
pores in their cell wall and membranes (Martineau et al., 2007b, Liu et al., 2006).  
Other mechanisms include the induction of autophagy, increased synthesis of ROS, 
RNI, and inhibition of secretion of MMP that are involved in tissue destruction (Sly et 
al., 2001, Yuk et al., 2009, Coussens et al., 2009). Further, vitamin D has been shown 
to inhibit coronin, thereby enhancing the maturation and fusion of the phagosome 
containing M. tuberculosis together with the lysosomes and results in its degradation 
in macrophages (Anand and Kaul, 2003). 
 
 In cognisance of the inconclusive results of the effect of vitamin D on HIV-1 
replication and in order to examine the safety of vitamin D supplementation in HIV-1 
infected individuals in primary monocyte derived macrophages, I next investigated 
the effect of pre-treatment of macrophages with 25(OH)D3 and 1,25(OH)2D3 on HIV-
1 replication. Additional factors, including macrophage phenotype and co-infection 
with M. tuberculosis, were also investigated. 
 
6.2 Results 
6.2.1 The effect of vitamin D on HIV-1 replication 
To determine the effect of vitamin D pre-treatment on HIV-1 replication in 
phenotypically distinct macrophages, supernatant p24 concentrations were 
measured 144 hrs and 240 hrs after HIV-1 infection of both Mϕ-1 and Mϕ-2.  
 
Two-way repeated measure ANOVA was used for analysis of the results. There was a 
significant effect of 25(OH)D3 and 1,25(OH)2D3 after 144hrs which, inhibited HIV-1 
replication in Mϕ-1 (p=0.01). Macrophage phenotype had no effect on HIV-1 
replication (p=0.73) nor was there an interaction between macrophage phenotype 












In order to determine where the effect of vitamin D molecules was located, 
additional post-hoc pairwise ANOVA comparisons with Bonferroni correction of 
multiple comparison were used within each macrophage phenotype. Vitamin D 
significantly inhibited HIV-1 growth in Mϕ-1 (p=0.0009), with a greater significance of 
the effect seen with 1,25(OH)2D3 than 25(OH)D3 (p<0.001 and p<0.05, respectively) 
pre-treatment. Conversely, there was no significant effect of either vitamin D 









































Figure 6.2. The effect of 1,25(OH)2D3 on HIV-1 replication after (A) 144 hrs and (B) 
240 hrs of infection. Bars represent median and error bars IQR (n=12); repeated 
measures 1way ANOVA with Bonferroni post-hoc correction, * = p<0.05, ** = P<0.01, 












After 240 hrs there was a significant difference in inhibition of HIV replication after 
treatment with vitamin D molecules in Mϕ-1 (p = 0.0388) and 1,25(OH)2D3 
significantly restricted HIV replication (p <0.05). In Mϕ-2 there was significant 
inhibition of HIV replication in the presence of vitamin D molecules (p = 0.0087) and 
25(OH)D3 significantly restricted HIV replication (p <0.01) (Figure 6.2B). 
 
6.2.2 The effect of vitamin D on HIV-1 replication during co-infection with M. 
tuberculosis. 
As previous studies have shown, co-infection with M. tuberculosis enhances HIV-1 
replication.  The effect of vitamin D molecules on HIV-1 replication in macrophages 
co-infected with M. tuberculosis was therefore assessed.  The effect of vitamin D 
molecules on HIV-1 replication was evaluated by two way repeated measure ANOVA 
after 72 hrs of HIV-1 and M. tuberculosis co-infection of macrophages. The vitamin D 
molecules restricted HIV-1 replication in Mϕ-1 (p=0.01). On the other hand, co-
infection with M. tuberculosis had no effect on HIV-1 replication (p=0.54). There was 
no interaction of vitamin D molecules and co-infection with M. tuberculosis, to 
influence HIV-1 replication (p=0.51). Further pair-wise multiple comparisons 
revealed a significant difference in the growth of HIV-1 in Mϕ-1 macrophages co-
infected with M. tuberculosis (p=0.006). Both 25(OH)D3 and 1,25(OH)2D3, 
significantly restricted HIV-1 replication during co-infection with M. tuberculosis 
(p<0.05 in both cases) (Figure 6.3A). 
 
In the Mϕ-2, HIV-1 replication was not influenced by vitamin D molecules, nor by co-
infection with M. tuberculosis (p=0.16 and p=0.58 respectively). There was also no 
interaction between these two independent variables to influence HIV-1 replication 
(p=0.38). One-way ANOVA showed that there was no significant difference in the 
HIV-1 p24 levels for the macrophages co-infected with M. tuberculosis in the 




























































































Figure 6.3. Effect of 25(OH)D3 and 1,25(OH)2D3 on HIV-1 replication 72 hrs after 
coinfection with or without M. tuberculosis. (A) Mϕ-1 and (B) Mϕ-2 Median is plotted 
with IQR (n=12). One way ANOVA with Bonferroni post-hoc correction, * = p<0.05, 
** = p<0.001. 
 
 
6.2.3 The effect of vitamin D on Uptake of M. tuberculosis 
1,25(OH)2D3 has previously been shown to enhance phagocytosis by macrophages.  I 
therefore studied the effect of vitamin D molecules on uptake of M. tuberculosis 
after 4 hrs of infection and used two way repeated measure ANOVA for analysis of 
the results. 1,25(OH)2D3 and 25(OH)D3, did not have an effect on the phagocytosis 











Also, the macrophage phenotype had no effect on the uptake of M. tuberculosis in 
the presence of vitamin D in HIV-1-infected and HIV-1-uninfected macrophages 
(p=0.99 and p=0.81 respectively). In addition, co-infection with HIV-1 did not 
influence the phagocytosis of M. tuberculosis by Mϕ-1 and Mϕ-2 (p=0.92 and 0.61 















































Figure 6.4. The effect of vitamin D molecules on the uptake of M. tuberculosis in (A) 
Mϕ-1 and (B) Mϕ-2 grown for 168 hrs in either the presence or absence of HIV-1 
infection . Mean is plotted with SD (n=6).  
 
 
6.2.4 The effect of vitamin D on the growth of M. tuberculosis. 
The growth of M. tuberculosis in the presence of vitamin D and HIV-1 co-infection 












M. tuberculosis growth was significantly suppressed in HIV-1 infected Mϕ-1 after 168 
hrs in the presence of 25(OH)D3 and 1,25(OH)2D3 compared to the controls (p <0.05 
in both cases). In addition 1,25(OH)2D3 also restricted the growth of M. tuberculosis 
in HIV-1 uninfected Mϕ-1 (p <0.05). 
 








































Figure 6.5. Growth of M. tuberculosis over 168 hrs in the presence or absence of 
vitamin D and or HIV-1 in (A) Mϕ-1 and (B) Mϕ-2. Bars represent mean ± SD (n=6).  
* = p<0.05, ** = P<0.01, *** = p<0.001. 
 
At the 24 hrs and 96 hrs time points neither vitamin D molecules nor co-infection 
with HIV-1 had significant effect on the growth of M. tuberculosis in both Mϕ-1 and 








































































Figure 6.6. The effect of vitmain D on intracelluar M. tuberculosis (MTB) growth at  
24 hrs (A-B) and 96 hrs (C-D) post- M. tuberculosis infection of Mϕ-1 (A,C) and Mϕ-2 
(B,D) in the presence (HIV+MTB) or absence (MTB) of HIV-1 infection 168 hrs pre- M. 
tuberculosis infection. Bars represent mean ± SD (n=6). 
 
 
Two-way repeated measure ANOVA was used to determine the effect of vitamin D 
molecules and co-infection with HIV-1 on the growth of M. tuberculosis at the 168 
hrs time point in Mϕ-1. The analysis revealed a significant effect of vitamin D on the 
growth of M. tuberculosis (p=0.001) during mono-infection. Co-infection with HIV 
had no effect on M. tuberculosis growth (p=0.99) and there was no interaction 
between vitamin D molecules and co-infection on the growth of M. tuberculosis 
(p=0.93, Figure 6.7A).  
 
Post hoc analysis showed that there was a significant difference in the growth of M. 
tuberculosis in HIV-1 uninfected Mϕ-1 (p=0.0521) and HIV-1 infected Mϕ-1 











In the HIV-1 uninfected Mϕ-1 only, 1,25(OH)2D3 significantly inhibited the growth of 
M. tuberculosis (p<0.05). Whereas in HIV-1-infected Mϕ-1, both 25(OH)D3 and 
1,25(OH)2D3 significantly restricted the growth of M. tuberculosis (p<0.05 in both 
cases).  Vitamin D molecules or co-infection with HIV-1 had no significant effect on 










































Figure 6.7. The effect of vitamin D on intracellular M. tuberculosis (MTB) after       
168 hrs in (A) Mϕ-1 and (B) Mϕ-2 in the presence or absence of HIV-1 co-infection 
(HIV+MTB). Error bars represent mean ± SD (n=6). (* = p<0.05). 
 
 
6.2.5 The effect of macrophage phenotype on M. tuberculosis growth 
 
The effect of macrophage phenotype and vitamin D molecules on the growth of M. 











There was no effect of macrophage phenotype on M. tuberculosis growth in HIV-1 
infected (p=0.82) and uninfected  (p=0.41) macrophages. Finally, there was no 
interaction between macrophage phenotype and vitamin D molecules in HIV-1 
infected (p=0.27) and uninfected (p=0.55) macrophages. 
 
6.3 Discussion 
The safety of vitamin D supplementation has been a question of interest as 
inconclusive results on the effect of vitamin D on HIV-1 replication have been 
reported by various studies. Here, I investigated the effect of vitamin D 
supplementation during HIV-1, MTB and HIV-1/MTB co-infection using pro-
inflammatory (Mϕ-1) and anti-inflammatory (Mϕ-2) macrophages generated from 
primary human monocytes.  
 
I found that vitamin D molecules, 25(OH)D3 and 1,25(OH)2D3, were effective in 
suppressing HIV-1 replication in pro-inflammatory macrophages infected with HIV-1 
only and during co-infection with M. tuberculosis. In addition, 25(OH)D3 and 
1,25(OH)2D3, significantly restricted the growth of M. tuberculosis in HIV-1 infected 
and HIV-1 uninfected pro-inflammatory macrophages. 25(OH)D3 only inhibited HIV 
replication while  both 25(OH)D3 and 1,25(OH)2D3, had no effect on HIV-1 
replication and M. tuberculosis growth during co-infection in Mϕ-2. 
 
For the past fifty years there have been no new tuberculosis drugs on the market, 
although a number of drugs are currently in development.  In recent years, the 
prevalence of multidrug resistant and extensively drug resistance tuberculosis has 
been on the rise, due to a number of factors; including social and economic factors, 
high prevalence of HIV-1, non-adherence to treatment and inaccessibility to 
consistent medical care (Cox et al., 2010). This has necessitated the need to explore 













Vitamin D is one of the immunotherapeutic agents that has been shown to enhance 
the host innate immune response against M. tuberculosis (Martineau et al., 2007a). 
Vitamin D also has anti-inflammatory functions which help resolve pathology better 
than normal treatment alone (Coussens et al., 2012). 
 
The finding that pre-treatment of MDM with vitamin D molecules 25(OH)D3 and 
1,25(OH)D3 results in restriction of HIV-1 is contrary to  other studies which showed 
that pre-treatment stimulates HIV-1 replication (Skolnik et al., 1991, Kizaki et al., 
1993, Kitano et al., 1990).  In line with what was reported by Pauza et al., in 
monocyte-derived macrophages, there was a variation of the effect of the vitamin D 
molecules among the donors. Most of the donors inhibited HIV-1 replication, but a 
few of them failed to inhibit HIV-1 replication in the anti-inflammatory Mϕ-2 (Pauza 
et al., 1993). The ability of 1,25(OH)2D3 to suppress growth of HIV-1 has also been 
reported in monocyte derived macrophages during co-infection with M. tuberculosis 
(Campbell and Spector, 2012). This study also found no effect of co-infection on HIV-
1 replication in response to Vitamin D. In contrast, many studies using cell lines like 
Cos-1, U937, U1, HeLa and A3.5 have reported increased HIV-1 replication in the 
presence of 1,25(OH)2D3 (Nevado et al., 2007, Biswas et al., 1998, Skolnik et al., 
1991, Pauza et al., 1993).  
 
The variation in results may relate to the use of different HIV-1 strains with different 
receptor tropism, differences in time points where the measurement of virus 
concentration was performed, the use of different cell lines, some of which produce 
cytokines that activate HIV-1 replication, the use of different concentrations of 
vitamin D molecules, the purity of isolated cells (if T cells are present or not), the 
maturation state and the period that cells are treated with vitamin D molecules pre- 















The mechanisms by which vitamin D is able to inhibit HIV-1 replication is not not yet 
fully understood. Since vitamin D has been shown to inhibit TNF-α secretion 
(Martineau et al., 2007b), the suppression of HIV-1 replication by vitamin D might be 
through its inhibition of the TNF-α and NF-κβ signaling pathways that activate HIV-1 
replication through binding of NF-κβ to the HIV-1 LTR (Lee et al., 2005, Cohen-Lahav 
et al., 2006). Indeed, 1,25(OH)2D3, has been shown to inhibit Respiratory Syncytial 
Virus (RSV) replication through suppression of the NF-κβ pathway, by increasing the 
levels of Iκβ and its stability in RSV-infected cells (Hansdottir et al., 2010). Moreover, 
1,25(OH)2D3 has also been shown to inhibit HIV-1 replication by mediating enhanced 
autophagy, which results in the killing of HIV-1 (Campbell and Spector, 2012). 
 
Despite the in vitro studies that report increased HIV-1 replication in the presence of 
vitamin D, there are no in vivo studies that support the result. A number of in vivo 
studies, where vitamin D has been provided to HIV-1-infected individuals, resulted in 
no adverse effects, and had no effect on viral load and CD4+ cell counts (Arpadi et 
al., 2012, Arpadi et al., 2009, Kakalia et al., 2011, Havens et al., 2012). Moreover, 
some supplementation studies even show increased CD4+ cell count and better 
survival in HIV-1-infected individuals with higher vitamin D levels (Mehta et al., 2010, 
Mehta et al., 2011). 
 
In the current study, 100 nM 25(OH)D3 and 100 nM 1,25(OH)2D3 significantly 
restricted M. tuberculosis growth in HIV-1 infected pro-inflammatory Mϕ-1, whereas 
only 1,25(OH)2D3 treatment significantly restricted the growth of M. tuberculosis in 
HIV-1-uninfected Mϕ-1. This is in line with a number of studies that have 
demonstrated that vitamin D inhibits the growth of M. tuberculosis (Liu et al., 2006, 
Martineau et al., 2007b). Vitamin D has been demonstrated to restrict the growth of 
M. tuberculosis through a number of mechanisms which include; direct lysis by pore-
forming antimicrobial peptides cathelicidin and β-defensins, autophagy, which is 
enhanced by cathelicidin, enhanced fusion of M. tuberculosis phagosomes with 
lysosomes, increased production of ROI and RNI and also by inhibition of the 
synthesis of coronin (Yuk et al., 2009, Fabri et al., 2011, Anand and Kaul, 2003, Liu et 











In addition, vitamin D has been shown to restrict growth of M. tuberculosis by 
increasing the production of ROS and in the mouse model has been shown to induce 
production of RNI (Yang et al., 2009, Thoma-Uszynski et al., 2001).  
 
Furthermore TLR2/1 stimulation by M. tuberculosis, results in secretion of IL-15, 
which induces IL-32 and subsequently activates the vitamin D dependent 
antimicrobial pathway, which restricts M. tuberculosis growth (Marcos Munoz et al., 
2012, Krutzik et al., 2008). IL-32 has previously been shown to inhibit growth of M. 
tuberculosis in macrophages (Bai et al., 2010) . The hypoxic conditions, such as those 
encountered in the granuloma during latent tuberculosis, have also been shown to 
activate the production of cathelicidin and β-defensins via the vitamin D 
antimicrobial pathway that result in suppression of M. tuberculosis growth (Nickel et 
al., 2012).   
 
The mechanism by which 25(OH)D3 and 1,25(OH)2D3 restrict the growth of both 
HIV-1 and M. tuberculosis during co-infection is not yet fully understood but the 
antimicrobial peptides cathelicidin and defensins as well as autophagy induced by M. 
tuberculosis infection might also inhibit HIV-1 replication during co-infection 
(Campbell and Spector, 2012, Yuk et al., 2009). Both cathelicidin and β-defensins 
have been shown to inhibit HIV-1 replication (Bergmana et al., 2007, Seidel et al., 
2010). In addition IL-32, which is also secreted in response to M. tuberculosis by the 
macrophages, has also been shown to restrict HIV-1 replication (Nold et al., 2008, 
Marcos Munoz et al., 2012).  All these pathways might be working synergistically to 
inhibit the growth of both HIV-1 and M. tuberculosis in macrophages. 
 
Vitamin D molecules did not have an effect on the phagocytosis of M. tuberculosis by 
pro-inflammatory and anti-inflammatory macrophages. A previous study by Chandra 
et al., found that 1,25(OH)2D3 increases phagocytosis of M. tuberculosis by 
macrophages with a low phagocytic index but not for those with a high phagocytic 
index (Chandra et al., 2004). Macrophage phenotype had no significant effect on the 











The similar growth of HIV-1 in pro-inflammatory Mϕ-1 and anti-inflammatory Mϕ-2 
might be due to the anti-inflammatory effects of vitamin D on the pro-inflammatory 
macrophages making them more like the anti-inflammatory macrophages. The pro-
inflammatory Mϕ-1 were more effective in significantly restricting the growth of HIV-
1 and M. tuberculosis compared to the anti-inflammatory Mϕ-2 when treated with 
vitamin D. This has clinical relevance in vivo, since alveolar macrophages have a pro-
inflammatory phenotype due to their exposure to high levels of GM-CSF in lung 
tissue as detected in the mouse model (Trapnell and Whitsett, 2002).  In healthy 
donors, GM-CSF levels are detectable and are increased on exposure to microbes 
(Akagawa et al., 2006, Aggarwal et al., 2000, Chen et al., 2001, Gomez and Prince, 
2008).  
 
Even though 25(OH)D3 and 1,25(OH)2D3 down modulate pro-inflammatory 
cytokines like TNF-α, IL-12, IL-6 and IL-1β which play a role in immunity to HIV-1 and 
M. tuberculosis, they are able to enhance the ability of the innate immune response 
to control pathogens. In the presence of the vitamin D molecules, the immune 
system stimulates the antimicrobial pathways that are effective in the elimination of 
HIV-1 and M. tuberculosis. Also, the modulation of the pro-inflammatory immune 
response prevents tissue damage by allowing clearance of the pathogens in 
competent tissue. In vivo supplementation of vitamin D has predominant anti-
inflammatory effects, which benefit the host during infection (Coussens et al., 2012). 
 
Primary monocyte derived macrophages give a better reflection of the interaction of 
HIV-1 and M. tuberculosis in macrophages in vivo in the presence of vitamin D 
molecules compared to myeloid and osteoblastic cell lines. This is because cell lines 
do not accurately mimic the behavior of tissue macrophages and might produce 
different amounts and types of cytokines that might stimulate HIV-1 replication as 
they are derived from malignant cells. For example increased activation of NF-κβ, 
which also induce HIV-1 replication is found in many malignant cells where it is a 
major activator of cancer cell proliferation and survival as it activates many pro-











The limitation of the macrophage model is the absence of other cells, as 
macrophages in the host interact with other immune cells. There is therefore a need 
for further investigations in a model where T lymphocytes are included in the model 
in order to better mimic the situation in the lungs. 
 
Bronchoalveolar lavage fluid from HIV infected persons have low levels of 25(OH)D3 
than those from HIV uninfected persons (Anandaiah et al., 2012). Therefore 
increased vitamin D levels might result in effective inhibition of both HIV-1 and M. 
tuberculosis growth in lungs of HIV-1 infected individuals. M. tuberculosis strains 
such as CDC1551 have been shown to increase HIV-1 replication through enhanced 
production of NF-κβ through the effects of the Rv0652 protein, which stimulates the 
secretion of pro-inflammatory cytokines and activates NF-κβ signalling (Kim et al., 
2012). Vitamin D supplementation might inhibit HIV-1 replication by down regulating 
the expression of NF-κβ in HIV-1-infected individuals infected with this strain thereby 
ameliorating disease outcome. There is also a need for the evaluation of the effect of 
vitamin D together with tuberculosis drugs on the growth of multidrug resistant and 
extremely drug resistant strains of M. tuberculosis in HIV-1-infected and HIV-1-
uninfected infection models. This is because vitamin D induces the production of 
pore-forming antimicrobial peptides such as cathelicidin and defensins, increased 
production of ROS and RNI and inhibition of coronin damages the bacilli and can 
possibly enhance the ability of anti-tuberculosis drugs to kill the drug resistant 
bacteria (Martineau et al., 2007b, Sly et al., 2001, Anand and Kaul, 2003, Rathored et 
al., 2012). Further investigations to determine the effects of 25(OH)D3 and 
1,25(OH)2D3 on different strains of M. tuberculosis are also needed. 
 
In conclusion, 25(OH)D3 and 1,25(OH)2D3 inhibited HIV-1 and M. tuberculosis 
growth in Mϕ-1 and 25(OH)D3 inhibited HIV replication in Mϕ-2, taken together with 
the currently available in vivo data, this supports the use of vitamin D by HIV-1-
infected individuals for the prevention of activation of tuberculosis and as a adjunct 
therapy against M. tuberculosis. Moreover it will improve bone health and reduce 
HIV-1 disease progression. There is need for further supplementation studies in HIV-











evaluate its safety in vivo. Also, more in vitro studies need to be done to investigate 
the mechanism by which vitamin D inhibits HIV-1 replication in the presence or 
















Chapter 7: The Influence of Macrophage Phenotype On The Differential 
Growth of M. Tuberculosis Strains and HIV-1 Replication During Co-
infection 
 
7.1 Literature review 
Tuberculosis is often the first AIDS defining illness that manifests in HIV infected 
individuals in sub-Saharan Africa (Munyati et al., 2005). Clinical progression in 
tuberculosis patients who are HIV infected is more rapid on first exposure or 
reactivation with short subclinical stage. Some patients who are HIV infected excrete 
the bacilli while they are not yet symptomatic (Wood et al., 2007). There are many 
factors that affect disease outcome during M. tuberculosis and HIV co-infection such 
as host variability, HIV subtype and M. tuberculosis strain variation.  
 
HIV and M. tuberculosis (HIV/TB) co-infection results in progressive disease as both 
pathogens accelerate the natural history of each other. In most cases individuals are 
exposed to M. tuberculosis infection first followed by infection with HIV later on in 
life. M. tuberculosis infection in HIV infected individuals is associated with increased 
HIV replication shown by high viral loads in co-infected individuals (Whalen et al., 
1995) and on the other hand HIV infection is thought to increase the growth of M. 
tuberculosis and its pathogenesis as shown by high mycobacterial sepsis in HIV 
infected individuals (Shafer et al., 1989). The impact of M. tuberculosis strain 
variation in HIV infected individuals is not yet fully evaluated. 
 
The successful sequencing of the M. tuberculosis genome enhanced the study of M. 
tuberculosis evolution and distinction of the strains (Cole et al., 1998). During its 
evolution M. tuberculosis lost horizontal gene transfer capabilities (Alland et al., 
2003) and genetic variation occurs as a result of single nucleotide polymorphisms 
(SNPs) and large sequence polymorphism (LSPs), mutations in its DNA interspersed 
with repeats and tandem repeats, through deletions, duplications, inversions and 











It used gene duplication to diversify and acquire virulent genes like the early 
secretory antigen target-6 (ESAT-6) gene clusters, proline-glutamic acid (PE) and 
proline-proline-glutamic acid (PPE) genes (Nair et al., 2011, Gey van Pittius et al., 
2006). 
 
7.1.1 Clinical outcomes associated with M. tuberculosis strain variation. 
Mycobacterium tuberculosis strains have differences in transmissibility, virulence, 
and immunogenicity that are determined by their genetics and environment. It is a 
diverse species and immune responses of the host to specific strains might influence 
the clinical outcome of the disease. Different M. tuberculosis strains activate 
different immunomodulatory pathways in the host with different cytokine networks 
and immune mediators being secreted (Nicol and Wilkinson, 2008).  
 
M. tuberculosis strain variation can interact with host genotype and environment to 
influence disease outcome. Genetic variation of M. tuberculosis has been shown to 
result in ability of some strains to cause disease in different populations, rapid 
disease progression to active tuberculosis in recently exposed household contacts 
and ability to stimulate an effective immune response (Gagneux et al., 2006, de Jong 
et al., 2008, Rakotosamimanana et al., 2010).  
 
Different M. tuberculosis strains have unique virulence characteristics that influence 
disease outcome. The lineage 2, East Asian strains are associated with disease 
outbreaks, treatment failure, high virulence, multidrug resistance, co-infection with 
HIV, extra-pulmonary disease, suppressed pro-inflammatory immune responses and 
increased expression of macrophage deactivating cytokines IL-4 and IL-13 (Reed et 
al., 2004, Caws et al., 2006, Middelkoop et al., 2009, Manca et al., 2004). The 
virulence of Beijing strains is attributed to phenolic glycolipid (PGL) that modulates 
the pro-inflammatory response to M. tuberculosis (Hanekom et al., 2011, Ordway et 
al., 2007) although it is not the only determinant of virulence of Beijing strains 












On the other hand the virulence of the CDC1551 strain of lineage 4 is ascribed to its 
ability to stimulate a strong pro-inflammatory response by comparison to the HN878 
strain of lineage 2, which suppress the pro-inflammatory response (Manca et al., 
2005, Manca et al., 2001, Coscolla and Gagneux, 2010). In another study, CDC1551 
was shown to induce a more pro-inflammatory response than the laboratory 
reference strain H37Rv and the Erdman strain even though the Edman strain is more 
virulent than the H37Rv and CDC1551 strain (Manca et al., 1999). In addition 
Portevin and colleagues showed that lineage 1, 5 and 6 were associated with a 
higher pro-inflammatory cytokine response compared to lineages 2, 3 and 4 
(Portevin et al., 2011). Similarly clinical strains from lineage 2 have been shown to 
induce low pro-inflammatory cytokines IL-12p40 and TNF than lineage 4 clinical 
strains (Sarkar et al., 2012)and H37Rv also infection of macrophages with these 
strains was associated with high necrosis and low apoptosis (Sohn et al., 2009, 
Tanveer et al., 2009).  
 
Moreover M. tuberculosis strains have been shown to have differences in tissues 
they preferentially infect and ability to spread to other organs that is dependent on 
their virulence characteristics (Click et al., 2012). In a study in Vietnam the Euro 
American lineage 4 was associated with pulmonary tuberculosis rather than extra 
pulmonary tuberculosis in particular meningeal tuberculosis (Caws et al., 2008) 
whereas Lineage 3 CAS/ East African Indian and Indo-Oceanic of lineage 1 have been 
associated with extra pulmonary tuberculosis (Lari et al., 2009, Click et al., 2012). 
Therefore infection with different M. tuberculosis strains can potentially have a 
differential effect on the outcome of disease in HIV infected persons. HIV might 
modulate the host cells especially those co-infected in such a way that M. 
tuberculosis strains can induce differential HIV replication or differentially increase 













 7.1.2 Immunopathogenesis of HIV and M. tuberculosis co-infection 
Tuberculosis is the leading opportunistic infection during the course of HIV infection 
at any CD4 count and co-infection is associated with high mortality rates. The risk of 
tuberculosis increases as the degree of immunosuppression increases (Glynn et al., 
2008). Even after initiation of HAART and CD4 count recovery HIV infected 
individuals still have a higher risk of tuberculosis compared to HIV uninfected 
individuals (Badri et al., 2002). This might be related to immune dysfunction of T 
cells and other components of the immune system caused by HIV (Lawn et al., 2005). 
In HIV uninfected persons active tuberculosis results in formation of granulomas and 
progresses slowly where as in the HIV infected persons it forms diffuse lung 
infiltrates that occur fast and disease is progressive (Escombe et al., 2008). The 
impact of the interaction between HIV and tuberculosis on tuberculosis 
infectiousness is not fully understood. There are conflicting results varying between 
increased or decreased infectiousness of HIV infected individuals, however a 
systematic review concluded that HIV had no effect on transmissibility of M. 
tuberculosis (Cruciani et al., 2001).  
 
The effect of HIV-1 subtypes and M. tuberculosis strain variation on the immune 
response to the HIV and M. tuberculosis during co-infection is not well defined. 
Different M. tuberculosis strains have been shown to stimulate host immune system 
differentially and stimulate the secretion of molecules that might have different 
effects on host immune system during HIV TB co-infection. There is need for more 
research to determine the effects of HIV subtypes and M. tuberculosis strain 
variation on the immune response to HIV and M. tuberculosis during co-infection. 
 
7.1.2.1 The impact of the HIV-1 subtype on HIV/TB co-infection 
There are increasing numbers of HIV-1 subtypes and circulating recombinant forms 
(CRF) that impact on the control of HIV infection by the immune system. Each HIV 
replication cycle results in generation of new HIV quasi species due to mutations 












HIV strains and subtypes induce variable modulation of host immune response 
because of differences in gene sequences, which produce different proteins. These 
protein products stimulate the immune system in unique ways with activation of 
different transduction pathways that allow them to evade the host immune system 
(Nowak, 1992). HIV subtype D has been reported to be more virulent and results in 
high rate of disease progression and mortality compared to subtype A (Kiwanuka et 
al., 2008, Baeten et al., 2007). In addition subtype C, D and G were found to cause 
faster disease progression with development of AIDS within 5 years compared to 
subtype A and B (Kanki et al., 1999). This might be related to subtype D high 
efficiency in shifting to producing CXCR4 tropic virions, syncytium formation and high 
rate of HIV replication (Tscherning et al., 1998, Kaleebu et al., 2001). In terms of 
transmission HIV-1 subtype C is highly transmissible as it causes increased vaginal 
shedding compared the other HIV-1 subtypes (John-Stewart et al., 2005).  
 
Some HIV subtypes might be more responsive to molecules that are stimulated or 
released in response to different M. tuberculosis strains that can differentially 
stimulate HIV replication. This is because HIV-1 subtypes LTR respond to different 
molecules for example HIV-1 subtype E inhibits the transcription of the TNF gene in 
infected cells (Ranjbar et al., 2006) therefore it is less responsive to TNF-α activation 
and T cell activation in absence of tat compared to subtype B LTR (Montano et al., 
1998, Lemieux et al., 2004, Verhoef et al., 1999). In addition HIV-1 subtype C is more 
transcriptionally active than subtype B and E, as its LTR is more responsive to NFκβ 
p65 (Montano et al., 1997, Montano et al., 1998).  
 
7.1.2.2 The effects of HIV on tuberculosis 
HIV infection has an impact on the natural history and progression of tuberculosis 
infection during co-infection. The presence of HIV results in defective granuloma 
formation as the granulomas during HIV infection lack the typical caseous necrosis 
instead they are composed of diffuse pulmonary infiltrates or lesions and necrosis 











This results in poor control of M. tuberculosis growth and increased occurrence of 
disseminated miliary tuberculosis and subclinical active tuberculosis in HIV infected 
individuals due to reduced CD4+ T lymphocytes (Mtei et al., 2005, Patel et al., 2011). 
 
HIV increases the risk of progression from latent tuberculosis to active tuberculosis 
and also causes rapid progression to active TB after exposure to new tuberculosis 
infection or relapse of disease in previously treated patients (Corbett et al., 2003). 
This is related to the pathogenicity of HIV involving the depletion and dysfunction of 
CD4+ T cells (Antonucci et al., 1995). HIV impairs the activation of T cells and 
immune responses to M. tuberculosis resulting in abnormal IFN-γ secretion 
(Sutherland et al., 2006). In addition it reduces the number of macrophages and 
impairs their antimicrobial activities such as phagocytosis, maturation of the 
phagosome, intracellular killing (ROS), and cytokine secretion (Kedzierska and 
Crowe, 2002). 
 
HIV infection also causes increased destruction of M. tuberculosis specific memory T 
lymphocytes (Wilkinson et al., 2009). The depletion and dysregulation of CD4+ T 
lymphocytes due to HIV infection decreases the effectiveness of the protective 
immune response against M. tuberculosis. During primary HIV infection there is 
increased depletion of memo y PPD specific IFN-γ secreting T cells as well as early 
secretory antigenic target-6 (ESAT-6) specific T cells which affect immunity to 
tuberculosis (Geldmacher et al., 2008). In addition HIV proteins cause dysfunction of 
monocytes, monocyte derived macrophages and dendritic cells maturation and 
antimicrobial functions including the ability to respond to M. tuberculosis TLR 
ligands, phagocytosis, maturation of the phagosome, intracellular killing (ROS), and 
cytokine secretion and killing (Kedzierska and Crowe, 2002, Kalsdorf et al., 2009, 
Collini et al., 2010). Furthermore HIV/TB co-infection is associated with increased 
occurrence of drug resistant M. tuberculosis infection in HIV infected patients (Wells 
et al., 2007). This might be caused by increased M. tuberculosis growth, 
malabsorption of drugs during HIV infection and the drug interactions of HAART and 











7.1.2.3 The effects of M. tuberculosis on HIV 
M. tuberculosis infection increases the viral replication in HIV infected individuals 
(Toossi, 2003). The lungs of individuals with active tuberculosis have high viral mRNA 
showing increased levels of HIV replication and transcription (Nakata et al., 1997). In 
addition M. tuberculosis increases HIV replication in CD4+ T lymphocytes, monocyte 
derived macrophages and ex vivo in alveolar macrophages (Goletti et al., 2004, 
Hoshino et al., 2002, Zhang et al., 1995, Mancino et al., 1997). Infection with M. 
tuberculosis and HIV stimulates secretion of TNF-α that is involved in the restriction 
of M. tuberculosis growth whilst at the same time stimulates HIV replication 
(Kedzierska et al., 2003). 
 
Co-infection of dendritic cells with M. tuberculosis and HIV results in the suppression 
of the pro-inflammatory cytokine and up regulation of anti-inflammatory cytokine 
secretion causing defective activation of T cells by DC and allowing immune escape 
of HIV (Jiao et al., 2002). M. tuberculosis stimulates the secretion of MIP-1α, MIP-1β 
and RANTES by macrophages that compete with HIV for CCR5 binding sites thereby 
inhibiting HIV infection (Kinter et al., 1996, Saukkonen et al., 2002). The 
manipulation of the cytokine networks by M. tuberculosis towards those that have 
an effect on HIV replication can result in increased disease progression during 
HIV/TB co-infection (Manca et al., 1999, Reed et al., 2004). In vitro studies, using 
PBMC have shown that different strains of M. tuberculosis induce differential HIV 
replication, with CDC1551 inducing increased HIV replication of HIV-1 subtypes B, C 
and E compared to HN878, which was attributed to increased generation of NF-κβ by 
the pro-inflammatory cytokines TNF, IL-6, and MCP-1 produced in response to 
CDC1551 strain (Ranjbar et al., 2009b). However the impact for interaction of M. 
tuberculosis strains with HIV during co-infection of physiologically relevant 
macrophage phenotypes is unknown. 
 
The mechanism and impact of interaction between M. tuberculosis strains and host 
pathogen interactions during HIV/TB co-infection are not yet fully understood. There 
is great need to investigate the mechanisms and sites at which HIV and M. 











In light of the study by Ranjbar et al 2009 which demonstrated differential 
stimulation of HIV replication by M. tuberculosis strains, there is need to examine 
the effect further at single cell level. Therefore this study investigates the hypothesis 
that different M. tuberculosis strains differentially stimulate of HIV replication in pro-
inflammatory and anti-inflammatory macrophages. This study further examines the 
impact of HIV on the growth of M. tuberculosis strains to determine if the infecting 
strain affects outcome of infection during co-infection with HIV.  
 
7.2 Results 
7.2.1 Comparison of growth kinetics of M. tuberculosis strains 
Three M. tuberculosis strains; H37Rv, LAM3 and HN878 were cultured in 
Middlebrook 7H9 liquid media supplemented with albumin-dextrose-catalase  
 (ADC).  The cultures were set up in triplicate for each strain, starting with a 1:100 
inoculum dilution of the cultures at an OD of 0.01nm.  Figure 7.1 shows the growth 
kinetics of the strains over 19 days. The growth curves of all the strains showed the 
typical sigmoid growth curve with the lag phase, exponential phase, stationary phase 
and death phase. All the strains had a short lag phase of 2 days before entering the 
exponential phase on the 3rd day. The exponential phase of the LAM3 strain was 
longer, as it went up to day 13, whereas that of H37Rv and LAM3 only went up to 
day 9 and 10 respectively. For all the curves, after the exponential phase, the typical 
horizontal line of the stationary phase was very short as the bacteria quickly entered 
































Figure 7.1 Growth kinetics of M. tuberculosis strains H37Rv, LAM3 and HN878 in 
Middlebrook 7H9 broth supplemented with ADC in triplicates. Errors bars represent 
mean ± SD. 
 
 
7.2.2 The effects of M. tuberculosis strain on HIV replication 
In order to determine if HIV-1 p24 levels depend on M. tuberculosis strain variation 
and macrophage phenotype, GM-CSF macrophages (Mφ-1) and M-CSF macrophages 
(Mφ-2) were generated from monocytes matured from PBMC of 5 donors (Verreck 
et al., 2004). The macrophages were infected with HIV-1 BAL at a MOI 1:3 for seven 
days followed by infection with M. tuberculosis strains H37Rv, LAM3 and HN878 at a 
MOI 1:1. HIV-1 p24 levels were measured at 4 hours, 24 hours, 96 hours and 168 
hours post M. tuberculosis infection. The results of the p24 measurements are 



















































































Figure 7.2 The effect of M. tuberculosis strain variation on HIV-1 p24 levels at 
specific time points (A) 4 hrs, (B) 24 hrs, (C) 96 hrs and (D) 168 hrs. Errors bars 
represent median and IQR (n=5).  
 
A two-way analysis of variance (ANOVA) was conducted to evaluate the effects of 
infection with M. tuberculosis strains H37Rv, LAM3 and HN878 on p24 levels in Mϕ-1 
and Mϕ-2 macrophages. M. tuberculosis strain variation had no effect on HIV 
replication. This was shown by no significant differences of p24 concentrations in 
response to infection with H37Rv, LAM3 or HN878 after 4 hrs (p=0.90), 24 hrs 
(p=0.94), 96 hrs (p=0.79) and 168 hrs (p=0.92) of infection. However, HIV-1 
replication was significantly increased in Mϕ-2 compared to Mϕ-1, revealing an 
effect of macrophage phenotype, after 4 hrs (p=0.002), 24hrs (p=0.05), 96 hrs 
(p=0.03) and 168 hrs (p=0.01) (Figure 7.3). There was no interaction between 
macrophage phenotype and M. tuberculosis strain variation to influence HIV 
replication in Mϕ-1 and Mϕ-2 after 4 hrs (p=0.58), 24 hrs (p=0.94), 96 hrs (p=0.88) 




















































































Figure 7.3 Comparison of HIV replication in Mϕ-1 and Mϕ-2 at specific time points (A) 
4 hrs, (B) 24 hrs, (C) 96 hrs and (D) 168 hrs. Errors bars represent median and IQR, 
(n=5).  
 
Post hoc pairwise comparisons with Bonferroni correction for multiple comparisons 
were performed to determine where the differences of macrophage phenotype 
were located. HIV replication was significantly increased in Mϕ-2 after 4 hrs of co-
infection with H37Rv and LAM3 (p<0.05 in both cases). Likewise, after 24 hrs, HIV 
replication was significantly increased in Mϕ-2 infected with HIV only (p<0.05) and 
those that were co-infected with H37Rv and HN878 (p <0.05 and p<001 
respectively). HIV replication during co-infection with H37Rv remained significantly 
increased in Mϕ-2 macrophages compared to Mϕ-1 after 96 hours and 168 hours of 



















































































































































































Figure 7.4 Effect of M. tuberculosis strains on HIV replication in Mϕ-1 and Mϕ-1 
macrophages at specific time points (A) 4 hrs, (B) 24 hrs, (C) 96 hrs and (D) 168 hrs. 
Errors bars represent median and IQR (n=5). (* = p <0.05). 
 
Figure 7.5 shows the growth curve of HIV-1 in Mϕ-1 and Mϕ-2. There was a steep 
increase in p24 within the first 24 hours followed by a steady increase up to 168 hrs for 
Mϕ-1. For Mϕ-2, there was a steep increase of p24 levels in the first 24 hrs followed by a 
steady decrease that was greater in the HIV/LAM3 co-infected macrophages by 168 hrs.  
Overall HIV-p24 levels were not affected by M. tuberculosis strain type, but they 
were influenced by the macrophage phenotype, where increased HIV replication 


















































Figure 7.5 The growths curve of HIV in macrophages (A) represents Mϕ-1 and (B) Mϕ-2. 
Errors bars represent median and IQR (n=5). 
 
 
7.2.3 The effect of HIV on M. tuberculosis strains growth. 
7.2.3.1 M. tuberculosis strain uptake 
The uptake of M. tuberculosis strains was determined by the number of CFU 
phagocytosed after 4 hrs of infection and the results were analysed by two way 
repeated measure ANOVA. Macrophage phenotype had no effect on the uptake of 
M. tuberculosis strains in HIV infected and HIV uninfected macrophages (p=0.49 and 
p=0.42 respectively). Instead M. tuberculosis strain variation had a significant effect, 
there was significant differences in the number of H37Rv, LAM3 and HN878 CFU 












However there was no interaction between macrophage phenotype and M. 
tuberculosis strain variation to influence uptake of M. tuberculosis in HIV infected 
and HIV uninfected macrophages (p=0.90 and p=0.70 respectively). In addition the 
uptake of M. tuberculosis strains in Mϕ-1 and Mϕ-2 was independent of HIV infection 
(p=0.88 and p=0.69 respectively). 
 
Post hoc pairwise analysis showed that there was a significant increased uptake of 
LAM3 strain compared to HN878 strain in HIV-uninfected Mϕ-1 (p<0.05) (Figure 
7.6A). There was a trend towards increased uptake of the LAM3 strain compared to 
HN878 strain in HIV-infected Mϕ-1 and in both HIV-infected and uninfected Mϕ-2, 

























































Figure 7.6 Two-way ANOVA of uptake of M. tuberculosis strains (A) HIV uninfected 
(B) HIV infected. Errors bars represent median and IQR (n=5), (* = p<0.05). 
 
 7.2.3.2 The effect of HIV on M. tuberculosis strain growth 
To examine the effect of HIV infection and macrophage phenotype on growth of M. 
tuberculosis strains, two-way repeated measure ANOVA was used for analysis of the 
results. There was no significant difference in the growth of the M. tuberculosis 
strains between Mϕ-1 and Mϕ-2 after 24 hrs (p=0.99), 96 hrs (p=1) and 168 hrs 
























































































Figure 7.7 Variation in growth of the M. tuberculosis strains H37Rv, LAM3 and 
HN878 in Mϕ-1 and Mϕ -2 after (A) 4 hrs, (B) 24 hrs (C) 96hrs and (D) 168hrs of 
culture, (n=5). Errors bars represent median and IQR (n=5).  
 
The effect of HIV infection on growth of M. tuberculosis strains was analysed. There 
was no significant difference in the growth of H37Rv, LAM3 and HN878 strains in the 
comparison of HIV infected and HIV uninfected Mϕ-1 after 24 hrs (p=0.92), 96 hrs 
(p=0.80) and 168 hrs (p=0.59) of infection (Figure 7.8 A-C). However M. tuberculosis 
strain variation had a significant effect on differences in M. tuberculosis CFU as there 
was a significantly increased growth of HN878 strain compared to LAM3 strain in 
both HIV uninfected (p< 0.05) and HIV infected (p<0.01) Mϕ-1 after 168 hrs of 
infection (Figure 7.8C). 
 
Similar to Mϕ-1 there was no significant difference in the growth of H37Rv, LAM3 
and HN878 strains in the comparison between HIV uninfected and HIV infected  
Mϕ-2 after 24 hrs (p=0.92), 96 hrs (p=0.41) and 168 hrs (p=0.56) of infection (Figure 
7.9A-C). There was significantly increased growth of H37Rv strain compared to LAM3 
strain (p<0.05) and compared to HN878 (p<0.008) in HIV infected Mϕ-2 after 96 hrs 











In addition, after 168 hrs of infection in HIV uninfected Mϕ-2, HN878 strain growth 
was significantly greater than that of LAM3 (p <0.01), whereas in the HIV infected 































































Figure 7.8 The growth of M. tuberculosis strains in Mϕ-1 stratified by HIV infection status after (A) 24 hrs, (B) 96 hrs and (C) 168 hrs. Errors bars 




















































Figure 7.9 The growth of M. tuberculosis strains in Mϕ-2 stratified by HIV infection status after (A) 24 hrs, (B) 96 hrs and (C) 168 hrs. Errors bars 











Figure 7.10 A and B shows the growth of H37RV, LAM3 and HN878 strains in Mϕ-1 
and Mϕ-2 respectively. During the course of infection M. tuberculosis growth 
increases in the first 96 hrs and then starts to decrease steadily with a significant 
decrease in CFU for LAM3 in Mϕ-1 and Mϕ-2 after 168 hrs. 
 













































Figure 7.10 Growth curve of M. tuberculosis strains in (A) Mϕ-1 and (B) Mϕ-2. Errors 















The M. tuberculosis strains, H37Rv, LAM3 and HN878, with varying virulence had 
similar growth curves during in-vitro liquid culture, showing that the strains have 
comparable inherent capacities to replicate. My study found that these M. 
tuberculosis strains had no differential effect on HIV replication during co-infection 
of Mϕ-1 and Mϕ-2. On the other hand, neither HIV infection nor macrophage 
phenotype influenced the growth of the 3 strains. Nevertheless, there was 
significantly increased HIV replication in Mϕ-2 compared to Mϕ-1 macrophages and 
different M. tuberculosis strains had significantly different growth rates.  
 
Increased HIV replication in lungs and other organ systems has been reported during 
co-infection with M. tuberculosis, (Nakata et al., 1997, Toossi et al., 2001, Matthews 
et al., 2012). Despite that in vivo infection with M. tuberculosis results in increased 
HIV viral load and progression to AIDS (Whalen et al., 1995), there are conflicting 
results on the in vitro effects of M. tuberculosis on HIV replication. Similar to the 
current results H37Rv had no effect on HIV replication (Meylan et al., 1992). 
However in other studies M. tuberculosis strains H37Rv and CDC1551 increased HIV 
replication in M-CSF MDM (Pathak et al., 2010, Ranjbar et al., 2012), while in other 
cases it inhibited HIV replication (Goletti et al., 2004). Use of unpurified HIV virions 
contaminated with host proteins and membranes from T cells that the virus was 
passaged through during preparation could result in increased HIV replication during 
co-infection in macrophages (Mikovits et al., 1992)  
 
In contrast to the current results M. tuberculosis strain variation induced differential 
HIV replication in PBMC with the CDC1551 strain stimulating the highest HIV 
replication compared to the HN878 strain (Ranjbar et al., 2009b). The difference in 
results may be due to the use of different models of infection since differentiation of 
monocytes to macrophages is accompanied by the increased expression of the 
inhibitory 16kDa isoform of CCAAT enhancer binding protein β (C/EBPβ), a 
transcriptional factor that inhibits activation of HIV replication (Weiden et al., 2000, 













In fact, macrophages require cross-linking of their surface co-stimulatory molecules 
B7, CD40 and intercellular adhesion molecule -1 (ICAM-1) through contact with 
lymphocytes or neutrophils. This contact stimulates HIV replication through 
inhibition of the inhibitory 16kDa isoform of C/EBPβ and increases the expression of 
the 37kDa isoform of C/EBPβ that activates HIV replication by stimulation of NF-kβ 
signalling (Hoshino et al., 2002, Hoshino et al., 2007). Therefore, in the PBMC model 
used by Ranjbar et al., (2009) HIV replication was differentially stimulated by M. 
tuberculosis strains, possibly because of the contact of the lymphocytes with the 
mononuclear phagocytes that phagocytosed M. tuberculosis.  
 
M. tuberculosis strain variation had a significant effect on the phagocytosis of M. 
tuberculosis however HIV infection had no effect on uptake of M. tuberculosis. 
Similar results have been reported elsewhere, phagocytosis of the H37Rv strain and 
M. avium has been shown to be the same in HIV-infected and uninfected 
macrophages (Meylan et al., 1992, Elssner et al., 2004). The increased phagocytosis 
of LAM3 compared to HN878 in HIV uninfected Mϕ-1 might be related to the 
mannosylation of lipoarabinomannan (ManLAM) since M. tuberculosis strains 
without ManLAM have decreased phagocytosis due to their inability to use the 
mannose receptor for entry into macrophages (Torrelles et al., 2008).  
 
The absence of effect of HIV on M. tuberculosis growth has also been observed by 
others (Kalsdorf et al., 2009, Meylan et al., 1992), although some in vitro studies 
have shown increased growth of M. tuberculosis during co-infection with HIV 
(Pathak et al., 2010, Imperiali et al., 2001). The different M. tuberculosis strains had 
different growth rates during the co-infection model. Previous studies have shown 
that different M. tuberculosis strain growth rates in macrophages and whole blood 
vary differentially depending on strain and virulence (Theus et al., 2006, Wong et al., 
2007, Cheon et al., 2002, Janulionis et al., 2005). The increased growth of HN878 
strain compared to LAM3 strain in both Mϕ-1 and Mϕ-2 after 168 hrs of infection 
might be due to the virulence of HN878 strain or ability of the macrophages to 
restrict growth of LAM3. However this conclusion is limited, because viability of the 













The decrease in LAM3 growth after 168 hrs might be caused by necrosis of LAM3 
infected macrophages since LAM3 strains have been associated with increased 
apoptosis of polymorphonuclear cells (Romero et al., 2012). Also continuous 
passaging of M. tuberculosis is associated with adaptation to in vitro growth and loss 
of some virulence factors (Domenech and Reed, 2009). In this study the LAM3 strain 
was passaged twice while the laboratory strains H37Rv and HN878 had been 
passaged a number of times. Variable growth rates of clinical M. tuberculosis strains 
compared to laboratory strains have been reported elsewhere (Li et al., 2002).  
 
Macrophage phenotype had no influence on growth of M. tuberculosis strains. 
Similarly, the growth of BCG was similar in Mϕ-1 and Mϕ-2 (Vogt and Nathan, 2011). 
However according to Akagawa, et al., Mϕ-2 are more effective in inhibition of M. 
tuberculosis growth than Mφ-1, due to expression of the natural resistance-
associated macrophage protein 1 (NRAMP1) in Mϕ-2, but not in Mϕ-1 (Akagawa et 
al., 2006). In addition, in the mouse model Andrade, et al., report a significant 
decrease in H37Rv growth in pro-inflammatory macrophages (M1) compared to anti-
inflammatory macrophages (M2) after 6 days of culture (Andrade et al., 2012). 
 
Activation of macrophages into a pro-inflammatory phenotype by IFN-γ and GM-CSF 
is important in the restriction of the growth of M. tuberculosis as they secrete pro-
inflammatory cytokines (Herbst et al., 2011, Fabri et al., 2011, Denis and Ghadirian, 
1990). Mϕ-2 are like alternatively activated macrophages and they secrete anti-
inflammatory cytokines and are less microbicidal. The absence of effect of 
macrophage phenotype on M. tuberculosis growth might due to high plasticity of 
macrophages as infection of Mϕ-2 with HIV skews their phenotype towards Mϕ-1 
(Chihara et al., 2012) and virulent strains of M. tuberculosis modulate Mϕ-1 towards 
Mϕ-2 with reduced bactericidal activity (Ordway et al., 2007, Andrade et al., 2012). 
 
The observed increased HIV replication in Mϕ-2 compared to Mϕ-1 has been 
corroborated by other studies in the absence of infection with M. tuberculosis 













This is the first study to show that there is increased HIV replication in Mϕ-2 
compared to Mϕ-1 during co-infection with M. tuberculosis. The increased HIV 
replication in Mϕ-2 compared to Mϕ-1 might be due to increased expression of 
stimulatory 37kDa isoform of C/EBPβ and Hck in Mϕ-2 after HIV infection. Mϕ-2 have 
higher affinity for nef than Mϕ-1 and Hck binds nef which induces signal transduction 
pathways that increase NF-κβ signalling and HIV replication in Mϕ-2 (Chihara et al., 
2012, Komuro et al., 2003, Saksela et al., 1995). There is a need to elucidate the 
mechanism by which M. tuberculosis increases HIV replication during co-infection, as 
the above studies were carried out in the presence of HIV only.   
 
The clinical implication of the increased HIV replication in Mϕ-2 is large.  Monocytes 
in various tissues differentiate into macrophages in the presence of M-CSF and other 
immune-modulatory molecules. For example; osteoclasts develop in the presence of 
M-CSF and RANKL, while peritoneal macrophages develop in the presence of M-CSF 
(Asagiri and Takayanagi, 2007, Akagawa, 2002, Xu et al., 2007). Therefore, increased 
HIV replication might occur in macrophages for long periods of time in tissues, some 
of which are immunologically protected since macrophages are long-lived cells. 
Further studies are needed in different types of tissue macrophages ex vivo and in 
vitro to verify this. 
 
There is a great need for more investigations on the nature and mechanisms of the 
interaction between the host and co-infection with HIV and M. tuberculosis to 
identify genetic, immunological and molecular biomarkers that result in outcome of 
disease. The understanding of the pathogenesis and mechanisms by which the 














Chapter 8: General Conclusion 
 
The challenges of HIV/TB co-infection require development of novel interventions 
that are able to reduce the impact of TB on HIV infected individuals. Most suggested 
interventions include development of new drugs and that of pre and post TB 
vaccines. The development of novel immunotherapeutic interventions can also 
possibly improve the ability of HIV infected patients to resist active disease. Vitamin 
D is one of the immunotherapeutic agents, which can enhance the innate immune 
response against M. tuberculosis while at the same time modulating the pro-
inflammatory immune response. 
 
This study focused on the determination of the vitamin D status of Capetonians, with 
the particular aim of evaluating the relationship with active tuberculosis. In the 
absence of any studies of vitamin D and tuberculosis in this population, the cross-
sectional design of the study allowed for the relatively fast collection of preliminary 
data. This provided a snapshot of the prevalence of vitamin D deficiency and related 
characteristics, and how they relate to ATB and LTBI status. 
 
The results indicate for the first time the association of vitamin D deficiency with 
tuberculosis in HIV infected patients. Vitamin D deficiency might be one of the 
drivers which increases prevalence of TB among HIV infected patients. Active 
tuberculosis occurs throughout the course of HIV infection independent of CD4 
count, which might reflect that other factors like vitamin D deficiency might play a 
role in increased susceptibility of HIV infected individuals to tuberculosis. The study 
provided the in vivo data of seasonal variation of vitamin D levels in Cape Town, 
South Africa that were reciprocal to the TB notifications. The predisposition of HIV 
infected individuals to development of active tuberculosis is influenced by both 















The study of these factors that influence susceptibility of HIV infected individuals to 
tuberculosis could be useful in understanding immune response for development of 
vaccines as well as in biomarker discovery for identification of individuals with risk of 
developing active disease.  
 
There is need for longitudinal studies, which includes individuals who do not have 
latent TB (TST and IGRA negative) to determine if there is a trend of decrease in 
vitamin D levels towards deficiency in the patients with active TB. The low vitamin D 
levels might result in suboptimal immunity to TB resulting in progression to active 
tuberculosis. Therefore a longitudinal study, which follows up on patients to 
determine the risk of development of TB in patients with vitamin D deficiency is 
needed to determine the mechanisms and role of vitamin D in immunity to 
tuberculosis. 
 
There were no detelerious effects of vitamin D during infection of Mϕ-1 and Mϕ-2 
with HIV and M. tuberculosis. In Mϕ-1 25(OH)D3 and 1,25(OH)2D3 inhibited HIV 
replication while 1,25(OH)2D3 inhibited Mtb growth during mono-infection. During 
co-infection 25(OH)D3 and 1,25(OH)2D3 restricted HIV replication and M. 
tuberculosis growth. In Mϕ-2 only 25(OH)D3 inhibited HIV replication after 240 hrs of 
mono-infection and vitamin D molecules had no significant effect on HIV replication 
and M. tuberculosis growth during co-infection. These findings support that vitamin 
D supplementation can be a safe, cheap and effective way to enhance immunity 
against M. tuberculosis and HIV during co-infection. There is need for clinical trials to 
determine the dose and efficacy of vitamin D supplementation in HIV infected 
persons. Apart from the potential benefit of enhanced treatment of tuberculosis and 
prevention of latent TB activation, vitamin D supplementation in HIV infected 
persons can improve their bone health, as they are known to have low bone mineral 
density due to effects of HIV.  
 
M. tuberculosis strains and HIV had no effect on each other’s growth during co-
infection in pro-inflammatory and anti-inflammatory macrophages. M. tuberculosis 













The three M. tuberculosis strains had different growth rates, which were 
independent of the macrophage phenotype or HIV co-infection. The study of the co-
existence of HIV and M. tuberculosis strains in the macrophage is important for 
understanding the interaction of these pathogens with the host. HIV might modulate 
the cells in such a way that different strains of M. tuberculosis grow differentially 
which can have an impact on outcome of M. tuberculosis infection. The study of the 
impact of HIV on the growth of M. tuberculosis strains can shed light on the role of 
HIV in the rapid progression from latent tuberculosis to active tuberculosis in HIV 
infected persons since there is heterogeneity in rate of progression. More studies 
are needed to investigate the cytokine and gene expression changes during co-
infection, which can allow identification of targets for treatment and biomarkers for 
diagnosis. 
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